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ABSTRACT 
Hypertension affects 1 in 3 adults and is the single greatest risk factor for 
premature death. Salt-sensitive hypertension occurs in approximately 50% of 
hypertensive patients and results in a 3-fold increase in the risk of adverse cardiovascular 
events. However, the pathophysiology of salt-sensitive hypertension remains to be fully 
elucidated. There has been increased interest in the interaction between the sympathetic 
nervous system and the kidney and how that interaction mediates sodium excretion to 
drive the development of salt-sensitivity. Previous studies show that sympathetic over-
activity increases expression of the sodium chloride cotransporter (NCC) resulting in 
increased NCC-mediated sodium reabsorption, and the development of salt-sensitive 
hypertension. In this thesis, I show the effect of increased norepinephrine (NE) and high 
salt intake in salt-resistant vs. salt-sensitive rat phenotypes on blood pressure regulation, 
NCC activity, and the adrenoreceptor-mediated regulatory kinase network signal 
transduction pathway. A high salt diet 1) exacerbates NE-induced hypertension in salt-
resistant Sprague-Dawley (SD) rats and 2) results in hypertension in Dahl salt-sensitive 
(DSS) rats. In contrast to salt-resistant phenotypes (SD & Dahl salt-resistant), dietary 
sodium-evoked suppression of NCC expression and activity is prevented in salt-sensitive 
		 viii 
rats (SD-NE infusion & DSS) - I show that this occurs through a failure of a high salt 
intake to suppress renal OxSR1, SPAK, and WNK1 (NCC regulatory proteins). I 
demonstrate that α1-adrenoreceptors are responsible for mediating the salt-sensitive 
component of hypertension and restore dietary sodium-evoked suppression of the NCC 
via a predominant OxSR1 pathway. Chronic β-adrenoreceptor antagonism significantly 
reduces blood pressure in NE-mediated hypertension. How the body senses salt remains 
unknown, but my data show that selective removal of the afferent renal nerves prevents 
dietary sodium-evoked suppression of NCC expression and activity resulting in salt-
sensitive hypertension, suggesting that the afferent renal nerves play an important role as 
a sodium-sensing mechanism. Overall, these data demonstrate that attenuated afferent 
renal nerve feedback drives renal efferent nerve release of NE to prevent the 
downregulation of the NCC via an α1-adrenergic receptor-gated WNK1-OxSR1 signal 
transduction pathway to evoke the development of salt-sensitive hypertension. 
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CHAPTER ONE: Introduction 	
Cardiovascular disease is the leading global cause of death, accounting for over 
17 million deaths a year, a number expected to increase to 24 million by 2030 (American 
Heart Association Heart & Stroke Statistics Update (AHA-HS) 2016). According to the 
American Heart Association, every 90 seconds, a person dies from cardiovascular disease 
in America. Approximately 80 million U.S. adults and over 1 billion people worldwide 
have been diagnosed with high blood pressure, making high blood pressure one of the 
leading causes of cardiovascular disease (AHA-HS 2016). Clinically, a patient is 
diagnosed with high blood pressure, also known as hypertension, when blood pressure 
readings are consistently 140/90 mmHg or higher. Hypertension is a significant public 
health burden costing the U.S. around $48 billion a year and is considered to be the single 
greatest risk factor for premature death via increased mortality risk from stroke, 
myocardial infarction, kidney failure, and congestive heart failure. Despite the fact that 
anti-hypertensive therapies can decrease the risk of stroke by 30%, congestive heart 
failure by 45%, coronary heart disease by 15% and overall mortality by 10%, only half of 
those undergoing treatment have their hypertension adequately controlled (AHA-HS 
2016). About 95% of hypertensive patients have essential hypertension which is a 
heterogeneous type of hypertension where the cause is unknown, making it difficult to 
adequately treat (Carretero and Oparil, 2000). The limitations in our understanding of the 
pathophysiology of hypertension coupled with its high economic burden have created a 
need to develop more efficacious and specific anti-hypertensive therapies. 
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Overview of Blood Pressure Regulation 
The regulation of blood pressure is a very complex physiological process that is 
dependent upon the coordinated actions of the cardiovascular, neural, renal, and 
endocrine systems. These systems modulate cardiac output, fluid volume, and total 
peripheral vascular resistance, all of which are key determinants of mean arterial pressure 
(MAP) or blood pressure. Changes in cardiac output and/or arterial blood pressure are 
mediated, in part, by the autonomic nervous system. Global neural control of arterial 
blood pressure occurs through the sympathetic nervous system (SNS), while the 
parasympathetic nervous system contributes primarily to the regulation of cardiac 
function(Guyton et al., 1972). Traditional theories of blood pressure regulation propose 
short-term changes in blood pressure are mediated by the SNS and the renin-angiotensin-
aldosterone system (RAAS), while the kidney is responsible for long-term regulation of 
blood pressure (Guyton et al., 1972). More recently, the SNS has been shown to play a 
pivotal role in the long-term regulation of blood pressure because it is an important 
stimulus for the release of renin, an enzyme that mediates extracellular volume via the 
RAAS, through the renal sympathetic nerves (Chopra et al., 2011). Abnormal activation 
of the RAAS has been shown to contribute to the development of hypertension due to its 
important role in the maintenance of fluid homeostasis (Guyton et al., 1972). Angiotensin 
II (AngII) and aldosterone are both vasoconstricting hormones in the RAAS that can 
cause increases in blood pressure by influencing renal sodium and water retention. The 
importance of the RAAS system in blood pressure regulation is evidenced by the 
numerous anti-hypertensive therapies that target an aspect of the RAAS (e.g. angiotensin 
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converting enzyme inhibitors, angiotensin receptor blockers, etc.)(Guyton et al., 1988; 
Guyton, 1989; Gonzalez-Villalobos et al., 2013). The kidney is crucial in the regulation 
of blood pressure because of its role in the maintenance of fluid homeostasis. Classic 
studies demonstrated that changes in systemic blood pressure are correlated with changes 
in renal sodium excretion (Guyton et al., 1972; Guyton, 1991). While the kidney and SNS 
are the primary regulators of blood pressure, vasoactive hormones like nitric oxide, 
endothelin (Emoto and Yanagisawa, 1995), atrial natriuretic peptide (ANP) (Luchner and 
Schunkert, 2004), and vasopressin (Nielsen et al., 1995), all have the ability to influence 
the vasculature and therefore blood pressure. These vasoactive hormones have a variety 
of effects on the kidney, SNS and vasculature, further illustrating the complexity of blood 
pressure regulation and the importance in maintaining blood pressure and fluid 
homeostasis (Figure 1). 
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Figure 1: Schematic of blood pressure regulation. Blood pressure regulation primarily influenced by 
regulation of sodium excretion by the kidney, activity of the central and sympathetic nervous systems and 
contractility of the vasculature. Adapted from Coffman. Nature Medicine (2011) 17, 1402-1409. 
Salt-Sensitivity 
Several studies have shown a direct correlation between blood pressure and 
dietary salt intake (Weinberger et al., 2001; He and MacGregor, 2003). In certain 
patients, systemic blood pressure is susceptible to changes in dietary salt intake. Whether 
normotensive or hypertensive, people with variations in blood pressure following 
increased dietary salt intake are considered salt-sensitive. More specifically, salt-sensitive 
hypertension occurs in approximately 50% of hypertensive patients and results in a 3-fold 
increase in the risk of adverse cardiovascular events (Weinberger et al., 2001). Currently, 
there is no efficient clinical test designed to determine if one is salt-sensitive or not. The 
only clinical test used to determine salt-sensitivity is the Bonfils method where the 
patient spends three weeks undergoing dietary manipulation of salt balance to determine 
if changes in sodium intake correlate to changes in blood pressure (Weinberger et al., 
2001). In recent years, genetic markers and humoral factors have been investigated in the 
context of salt-sensitivity. However, the mechanisms by which these different factors 
affect the blood pressure response to salt remained to be fully elucidated. 
 
Pressure-Natriuresis 
It is well established that multiple factors contribute, in an integrated fashion, to 
the pathophysiology of salt-sensitive hypertension and current evidence points to the 
kidney playing a pivotal role in the long-term control of blood pressure through its 
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essential role in regulating sodium homeostasis (Kobori et al., 2003; Gonzalez-Villalobos 
et al., 2013). In the 1970s, Arthur Guyton suggested that the kidney governs the level of 
blood pressure by regulating extracellular fluid volume, arguing that sodium homeostasis 
is maintained by matching urinary excretion of salt and water with dietary sodium intake 
(Guyton et al., 1972). This theory suggests that when blood pressure increases, renal 
perfusion pressure will increase with a consequent increase of sodium and water 
excretion, called pressure-natriuresis (Guyton et al., 1972) (Figure 2). This hypothesis 
predicts that modification of the pressure-natriuresis response is required to sustain a 
chronic elevation in blood pressure, establishing a new set point for blood pressure by 
shifting the equilibrium point for salt and water excretion (Guyton et al., 1972). In a salt-
resistant individual, increased sodium intake correlates to increased renal sodium 
excretion without any change in MAP, which is illustrated as a steep (almost vertical) 
line in a pressure-natriuresis figure (Figure 2). However, in salt-sensitive individuals, 
increased sodium intake correlates to increased renal sodium excretion as well as 
increased MAP, which is depicted as a line shifted to the right with a less steep slope 
(Figure 2). The importance of the kidney in blood pressure regulation has been 
showcased in various cross-transplantation studies between salt-sensitive and salt-
resistant animal phenotypes. If a kidney from a Dahl salt-sensitive (DSS) rat is 
transplanted into a normotensive Dahl salt-resistant (DSR) rat, salt-induced increases in 
blood pressure will be observed (Dahl et al., 1974; Dahl and Heine, 1975). Conversely, if 
a DSS rat receives a transplant from a normotensive animal the development of salt-
induced hypertension is attenuated (Dahl et al., 1974; Dahl and Heine, 1975). More 
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recently kidney transplants have been performed in humans where treatment-resistant 
hypertension can be alleviated after a successful kidney transplantation (Curtis et al., 
1983). These data show the crucial and critical role the kidney plays in long-term blood 
pressure regulation. 
 
Figure 2: Effect of salt-sensitivity vs. salt-resistance of blood pressure on the chronic pressure-natriuresis curves. 
The curves represent the relationship between salt intake and blood pressure. In salt-resistance, changes in 
salt balance correspond to little change in arterial blood pressure, showing a relatively steep slope. Salt-
sensitive individuals, changes in salt balance correspond with increases in arterial blood pressure, showing 
a shift of the pressure-natriuresis curve to the right and a shallower slope. Adapted from Van Vliet & 
Montani. Intl J Obesity (2008) 32, S35-S47. 
The Kidney 
The kidney is responsible for controlling water and ionic balance by regulating 
water, sodium, potassium, and calcium, homeostasis. The major components of the 
kidney are the cortex, medulla, and renal pelvis (Figure 3). Blood vessels and the ureter 
connect with the kidney as well as sympathetic nerves (Taal et al., 2012). The kidney is 
comprised of nephrons, which are the basic units of the kidney. Each kidney has about 1 
million nephrons, a number that declines with age (Taal et al., 2012). The nephron 
consists of the glomerulus and the tubules that lead to the collecting duct. The various 
segments that make up the tubules of the nephrons are: the proximal tubule, loop of 
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Henle, distal convoluted tubule, and the collecting tubule (Figure 4)(Taal et al., 2012). 
The urinary filtrate is formed in the glomerulus and passes into the tubules where its 
content and volume are altered by reabsorption or secretion of sodium and water. The 
bulk of sodium reabsorption occurs in the proximal tubule, while the fine-tuning of 
sodium reabsorption occurs in the DCT (Taal et al., 2012). The primary hormones that 
act on the kidney are vasopressin and aldosterone (Taal et al., 2012). Vasopressin 
stimulates water reabsorption, while aldosterone promotes sodium reabsorption. The 
kidney releases renin, which aids in the formation of AngII, a potent vasoconstrictor, 
allowing AngII to act directly on the proximal tubule to promote sodium retention (Taal 
et al., 2012). 
 
Figure 3: Diagram of the kidney. Cross-section of the right kidney showing major blood vessels and key 
structural features. Adapted from human body: cross section of right kidney. Art. Britannica Online for 
Kids. Web. 3 Dec. 2015.  
 
The proximal tubule (Figure 4) is the portion of the nephron, which leads from 
Bowman’s capsule to the loop of Henle, and is responsible for absorbing 65% of the 
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sodium that comes through the nephron as well as regulating the pH of the filtrate (Taal 
et al., 2012). In the early part of the proximal tubule, the sodium gradient drives the 
cotransport of sodium with bicarbonate, amino acids, glucose, and/or other organic 
molecules (Taal et al., 2012). The Na+/H+ exchanger (NHE3) takes advantage of the 
established sodium gradient to drive sodium reabsorption from the filtrate and H+ 
secretion into the filtrate with the secretion of H+ equivalent to the reabsorption of 
bicarbonate (HCO3-). As the filtrate reaches the late proximal tubule, most organic 
molecules and bicarbonate have already been removed and sodium ions are reabsorbed 
primarily with chloride ions(Taal et al., 2012). 
 
Figure 4: Diagram of a nephron. Internal structure of a nephron.  
 
The loop of Henle (Figure 4) leads from the proximal tubule to the distal 
convoluted tubule and is made up of a thin and thick segment. This portion of the 
nephron is responsible for 25% of the sodium reabsorption (Taal et al., 2012). The thin 
descending segment is permeable to water, but not to sodium, so water is able to 
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passively leave the tubule (Taal et al., 2012). However, the thin ascending segment is 
permeable to sodium, but not to water. The filtrate loses water in the descending segment, 
a higher concentration of sodium and chloride ions are present in the lumen of the thin 
ascending limb, and both ions diffuse out (Taal et al., 2012). The thick ascending limb is 
composed of large cells that are able to generate enough energy for active transport. The 
key transporter in the thick ascending limb is the sodium potassium chloride 
cotransporter-2 (NKCC2), which uses the sodium gradient for the cotransport of one 
sodium, one potassium, and two chloride ions (Taal et al., 2012). The potassium ions are 
able to re-enter the tubule via the renal outer medullary potassium (ROMK) channel, 
leaving the tubular lumen positively charged driving the paracellular transport of 
positively charged ions like, sodium, potassium, calcium, magnesium, and/or ammonium 
(Taal et al., 2012). The NKCC2 is an important sodium transporter with multiple 
transmembrane domains and can be inhibited by furosemide (loop diuretic)(Taal et al., 
2012). Additionally, vasopressin stimulates the activity of NKCC2 by increasing NKCC2 
trafficking to the membrane and phosphorylates specific serine/threonine kinases, 
increasing its activity. Increased NKCC2 activity occurs with concomitant increases in 
water reabsorption via aquaporin-2 (Ares et al., 2011; Rieg et al., 2013). 
The distal convoluted tubule (DCT) (Figure 4) is responsible for about 5% of the 
filtered sodium (Taal et al., 2012). The primary sodium transporter along this segment of 
the nephron is the thiazide-sensitive sodium chloride cotransporter (NCC). As the filtrate 
in the lumen of the DCT is negatively charged, it drives paracellular movement of 
negatively charged chloride ions (Taal et al., 2012). Sodium reabsorption in the DCT is 
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mediated by aldosterone, which increases sodium reabsorption(Taal et al., 2012). The 
sodium reabsorption is mediated by a group of kinases called WNK (with-no-lysine) 
kinases, the different isoforms as well as their effect on the NCC will be discussed in the 
NCC section of this introduction.  
The collecting duct (Figure 4) is responsible for 2-5% of sodium reabsorption and 
the epithelial sodium channel (ENaC) is the primary sodium transporter in this segment 
of the nephron (Taal et al., 2012). Sodium enters the principal cells via ENaC, leaving the 
lumen negatively charged driving paracellular movement of chloride ions (Taal et al., 
2012). ENaC’s function and regulation will be discussed further in the ENaC section of 
this introduction. 
 
Sympathetic Nervous System and Hypertension 
Recently, interest has grown in examining how interactions between the SNS and 
the kidney affect the regulation of sodium reabsorption and the impact of this interaction 
on long-term blood pressure regulation. The SNS contributes to the regulation of blood 
pressure by modifying cardiac output, peripheral vascular resistance, and renal function. 
Activation of the SNS to the kidney increases sodium reabsorption, renin release, and 
renal vascular resistance (DiBona and Kopp, 1997). All of these actions play a role in the 
long-term changes in blood pressure by shifting the pressure-natriuresis curve to the right 
(DiBona and Kopp, 1997). Increased dietary salt intake in salt-resistant phenotypes 
results in the suppression of neural, humoral, and renal sodium-retaining mechanisms to 
facilitate sodium homeostasis and normotension (Lohmeier et al., 1999; Brooks et al., 
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2005; Osborn et al., 2008). In contrast, increased activity of the SNS is thought to play a 
key role in the pathogenesis of salt-sensitive hypertension by triggering an increase in 
renal sodium and water retention, resulting in the re-setting of the pressure-natriuresis 
mechanism to a new higher set-point blood pressure (DiBona, 2003, 2004; Rodriguez-
Iturbe and Vaziri, 2007). In this re-setting of the set-point of the pressure-natriuresis 
relationship, as predicted by Guyton’s model, the relationship between arterial pressure 
and renal sodium excretion is shifted to the right in patients with salt-sensitive 
hypertension and the slope is less steep that that of a salt-resistant individual (Hall et al., 
1999) (Figure 2).  
Recent interest has grown in understanding the role the SNS, specifically the role 
of the renal sympathetic nerves, in the development and pathogenesis of salt-sensitive 
hypertension. Further, numerous studies have examined the role of the renal sympathetic 
nerves by performing renal denervations to assess the role of the renal nerves in a variety 
of animal models. Renal denervation involves the removal of both the efferent and 
afferent renal nerves, without distinguishing between the contributions of the efferent and 
afferent renal nerves (Figure 5). The efferent and afferent renal nerves interact with one 
another where increased efferent renal sympathetic nerve activity, increases afferent renal 
sympathetic nerve activity and through a renorenal negative feedback loop, decreases 
efferent renal sympathetic nerve activity (DiBona and Kopp, 1997) (Figure 5). Ideally, 
efferent renal sympathetic nerve activity remains at a low level in order to facilitate renal 
sodium excretion. Afferent renal sympathetic nerve fibers express TRPV1 receptors that 
release substance P, a neuropeptide associated with inflammation and pain (DiBona, 
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2013). When the TRPV1 receptor agonist, capsaicin, is administered decreases in efferent 
renal sympathetic nerve activity are observed (Ditting et al., 2012). The effects of 
decreasing efferent renal nerve activity on the kidney are decreases in RAAS activity, 
renal vasoconstriction and glomerular filtration followed by decreases in renal tubular 
sodium reabsorption, shifting the pressure-natriuresis curve back to the left (DiBona and 
Kopp, 1997). The effect of decreasing afferent renal nerve activity results in decreased 
total peripheral resistance, cardiac output, and sodium reabsorption (DiBona and Kopp, 
1997). 
 
Figure 5: Representative image of afferent vs. efferent renal nerve actions on the kidney. In a salt-resistant 
phenotypes, afferent nerve stimulation by increased salt intake for example, triggers decreased efferent 
nerve activity, reducing NE release at the level of the kidney, allowing for an increase in sodium excretion. 
Adapted from Ameta et al. Heart India (2014) 2, 3-10. 
 
Many human and animal studies support the role of the SNS in hypertension, 
including the recent Symplicity HTN-1 and HTN-2 renal denervation trials (Bakris et al., 
2015; Kario et al., 2015) and the clinical efficacy of sympatholytics in hypertensive 
patients (Khan and McAlister, 2006). Catheter-based renal denervation has been shown 
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to result in substantial reductions in renal tissue norepinephrine (NE) content in animal 
studies and decreases in renal NE spillover in human studies (DiBona, 2013). The 
efficacy and safety of renal denervation was demonstrated in treatment-resistant 
hypertensive patients in an initial proof of concept study, Symplicity HTN-1 (Esler et al., 
2012) and subsequently verified in a randomized clinical trial, Symplicity HTN-2 (Bakris 
et al., 2015). Symplicity HTN-2 demonstrated a significantly sustained decrease in blood 
pressure following catheter-based renal denervation (Esler et al., 2012). However, when a 
larger, randomized clinical trial was conducted (Symplicity HTN-3), no significant 
differences in blood pressure were observed following catheter-based renal denervation 
(Bakris et al., 2015; Kario et al., 2015). Of particular relevance, and highlighted by the 
recent human trials (Esler et al., 2012; Krum et al., 2014; Bakris et al., 2015; Kario et al., 
2015), the renal sympathetic nerves, which release NE locally at the level of the kidney, 
play an important role in the handling of water and sodium and the regulation of systemic 
arterial blood pressure (Guyton, 1991; DiBona, 2003, 2004; May et al., 2010). Animal 
studies have demonstrated that when NE is infused into the renal artery, mimicking 
increased renal sympathetic nerve release of NE, it decreases urinary sodium excretion 
and can result in salt-sensitive hypertension (Lohmeier et al., 1984). Chronic activation of 
the renal SNS, which increases renal NE content, results in sodium and water retention 
via multiple mechanisms including increased renin release, decreased renal blood flow 
and increased tubular sodium reabsorption (DiBona, 2005; Guild et al., 2012). Of 
relevance to our studies, chronic exposure of the kidney to increased levels of NE has 
been shown to upregulate the expression of various renal epithelial transport systems 
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(Sonalker et al., 2008), which play an important role in mediating sodium homeostasis. 
All of the aforementioned studies highlight the importance the SNS plays in the 
pathogenesis of salt-sensitive hypertension. 
 	
Renal Sodium Transporters 
Epithelial Sodium Channel (ENaC) 
ENaC aids in the movement of sodium ions across epithelial cells, a critically 
important cellular process. In the kidney, our organ of interest, ENaC is located at the 
apical membrane of polarized epithelial cells in the collecting tubules and the DCT. 
ENaC is composed of α-, β-, and γ-subunits (Figure 6) with 1:1:1 subunit stoichiometry 
(Canessa et al., 1994). Each subunit contains two membrane-spanning domains that are 
separated by a large glycosylated extracellular region and short N- and C-terminal 
cytoplasmic tails (Canessa et al., 1994; Snyder, 2002). The α-subunit is critical in the 
formation of the ion-permeating pore of ENaC, while the β-and γ-subunits are required 
for maximal channel activity (Sun et al., 2011). ENaC is highly selective for sodium ions, 
which enter the cell passively moving down its electrochemical gradient. Despite the fact 
that ENaC accounts for a small percentage of distal renal sodium reabsorption, its 
location along the nephron gives it a key role in regulating extracellular fluid volume, 
electrolyte balance, and long-term blood pressure (Sun et al., 2011). 
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Figure 6: Structural features of the epithelial sodium channel (ENaC). ENaC is made up of single α, β, and γ 
subunits, each with two membrane-spanning domains. Adapted from Bhalla & Hallows. J Am Soc Nephrol 
(2008) 19(10), 1845-1854. 
 
ENaC Regulation 
ENaC plays a key role in mediating apical entry of sodium ions in the 
aldosterone-sensitive distal nephron (Bhalla et al., 2006). Aldosterone is a key hormone 
regulating sodium transport in the collecting ducts through its genomic effects on the 
mineralocorticoid receptor (Alvarez de la Rosa et al., 2000). One of the primary 
regulators of ENaC is SGK1 (serum- and glucocorticoid-induced kinase-1; Figure 7), an 
aldosterone-sensitive kinase (Bhalla et al., 2006). However, in order for SGK1 to activate 
ENaC, it needs to be phosphorylated. There are two primary kinases that phosphorylate 
SGK1: mTOR (mammalian target of rapamycin) and PDK1 (PI3K-dependent kinase-1) 
(Alvarez de la Rosa et al., 2000; Lu et al., 2010). Once activated SGK1 can stimulate 
ENaC function through effects Nedd4-2 (neural precursor cell expressed developmentally 
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downregulated protein 4), post-translational Nedd4-2-independent effects on SGK1 and 
the transcription of gene products like αENaC. The C-terminal tails of ENaC interact 
with Nedd4-2 resulting in decreased ENaC surface expression through ubiquitination 
(Staub et al., 1996). SGK1 interacts with Nedd4-2 via phosphorylation (Debonneville et 
al., 2001; Snyder, 2002), indirectly enhancing cell-surface expression of ENaC (Alvarez 
de la Rosa et al., 1999; Alvarez de la Rosa et al., 2003). Studies have demonstrated that 
SGK1 can directly phosphorylate the αENaC subunit, directly activating the channel 
(Diakov and Korbmacher, 2004). SGK1 acts as a mediator of aldosterone-sensitive 
αENaC transcription via inhibition of a transcriptional repressive element resulting in 
increased ENaC activity and sodium reabsorption. The importance of SGK1 as a 
regulator of ENaC has been shown in SGK1 knock-out mice, where sodium retention is 
impaired. SGK1 influences salt balance and consequently blood pressure by affecting 
sodium intake and renal sodium reabsorption. In two different SGK1 knock-out models, 
there is a failure to appropriately respond to salt restriction (Wulff et al., 2002; Fejes-Toth 
et al., 2008), suggesting a mild form of aldosterone resistance (Berger et al., 1998). 
GILZ1 (glucocorticoid-induced leucine zipper protein 1) is a small chaperone 
protein found to stimulate ENaC surface expression by disrupting MAPK signaling 
(Muller et al., 2003; Soundararajan et al., 2005), the Raf-MEK-ERK1/2 MAPK pathway 
inhibits ENaC. GILZ1 interacts and inhibits Raf-1, leading to ENaC activation. Together, 
SGK1 and GILZ1 form an ENaC regulatory complex, which can cooperatively inhibit 
Nedd4-2 and Raf-1 to synergistically stimulate ENaC surface expression and activity 
(Muller et al., 2003; Soundararajan et al., 2005; Soundararajan et al., 2009). 
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Figure 7: Model for the regulation of sodium reabsorption via epithelial sodium channel (ENaC). Aldosterone 
binds to mineralocorticoid receptors (MR) and stimulates the expression of α-ENaC, SGK1, and ROMK. 
α-ENaC associates with β and γ-subunits to form a fully active ENaC. SGK1 increases sodium 
reabsorption by activating the Na+/K+ ATPase, increasing membrane expression of ENaC via 
phosphorylation and inhibition of Nedd4-2. Adapted from Hummler & Vallon. J Am Soc Nephrol (2005) 
16(11), 3160-3166. 
 
ENaC in Disease 
A few gain-of-function polymorphisms or mutations within the cytoplasmic 
domain have been discovered to increase ENaC activity. A seminal study from Shimkets 
et al. (1994) discovered a mutation in ENaC, a mutation that causes Liddle Syndrome, a 
disorder characterized by hypertension and hypokalemia (Shimkets et al., 1994). This 
finding triggered numerous studies examining the mechanisms and regulation of ENaC, 
demonstrating its role in sodium homeostasis and blood pressure regulation (Shimkets et 
al., 1994). In Liddle syndrome, the mutations are primarily found on the cytoplasmic C-
terminal end of the β- and γ-subunits (Hansson et al., 1995), preventing ENaC from being 
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ubiquitinated by Nedd4-2 (neural precursor cell-expressed, developmentally 
downregulated 4-2). Nedd4-2-dependent ubiquitination of ENaC tags the channel for 
internalization and degradation (Staub et al., 1996; Staub et al., 2000). This mutation 
results in a constitutively hyperactive ENaC resulting in increased sodium reabsorption 
(Staub et al., 1996; Staub et al., 2000). One notable characteristic of Liddle syndrome is 
that most patients are resistant to anti-hypertensive therapies (Warnock, 2001). In Liddle 
syndrome, increased sodium reabsorption leads to volume expansion, with increased 
mean circulatory filling pressure and concomitant increases in blood pressure (Bubien, 
2010). As a result, sodium excretion increases due to pressure-natriuresis establishing a 
new steady state of sodium balance because of this elevation in blood pressure (Bubien, 
2010). 
ENaC and Salt-sensitivity 
The role of ENaC in salt-sensitive hypertension has been evidenced in DSS rats, 
which show significantly increased mRNA expression of α-, β-, and γ-ENaC subunits, as 
well as SGK1 (serum and glucocorticoid-regulated kinase 1) mRNA expression (Aoi et 
al., 2006; Amin et al., 2011). These data suggest aberrant regulation of ENaC and SGK1 
in DSS rats maintained on high salt and that this abnormal expression may contribute to 
the development of salt-sensitivity (Aoi et al., 2006; Amin et al., 2011). Several studies 
conducted in DSS rats have demonstrated that aldosterone activated mineralocorticoid 
receptor increases SGK1 gene transcription in the cortical colleting duct, consequently 
stimulating the activity and expression of the ENaC and NHE3, increasing sodium 
reabsorption (Chen et al., 1999; Kakizoe et al., 2009). The effects of a high salt diet on 
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ENaC were investigated in DSS rats and showed that ENaC activity and α-subunit 
expression is significantly increased in the DSS rats when compared to DSR rats (Husted 
et al., 1996; Naray-Fejes-Toth and Fejes-Toth, 2000). Additionally, in Sprague-Dawley 
rats, ENaC expression is significantly decreased by a high sodium intake, suggesting that 
ENaC plays an important role in the maintenance of sodium homeostasis (Yang et al., 
2008). 
 
Sodium Chloride Cotransporter (NCC) 
The NCC is a thiazide-sensitive transporter that is predominantly found on the 
apical side of the distal convoluted tubule (DCT) in the kidney. The NCC is responsible 
for about 5-7% of the filtered sodium that is reabsorbed along the DCT (Gamba, 2009). 
Despite the fact that the DCT reabsorbs a small percentage of the filtered sodium, small 
disturbances within the DCT can have a significant effect on total body sodium and 
consequently, blood pressure (Ellison et al., 1987; Ellison and Loffing, 2009). Further 
studies have led to the discovery of a complex kinase network that regulates the function 
of the NCC via phosphorylation, trafficking, and lysosomal sorting affecting the influx of 
NaCl across the DCT (Dimke, 2011). 
The NCC belongs to the SLC12 family of electroneutral cation chloride 
cotransporters and is specifically encoded by the SLC12A3 gene (Gamba, 2009). The 
NCC is a membrane glycoprotein with 1,021 amino acid residues with 12 transmembrane 
(TM) regions with a central hydrophobic domain (Mastroianni et al., 1996; Hoover et al., 
2003). An extracellular hydrophilic loop is located between TM7 and TM8 and contains 
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two glycosylation sites necessary for proper function and surface expression of the NCC 
(Mastroianni et al., 1996) (Figure 8). The TM1-7 region of the NCC determines the 
affinity of the chloride ion to the transporter, while TM8-12 play a role in the affinity of 
thiazide diuretics to bind and block the channel (Moreno et al., 2006). All the TM regions 
appear to have an affinity for sodium ions (Moreno et al., 2006). Both the short N-
terminal and long C-terminal domains are located within the cell (Gamba, 2009). The 
amino N-terminal domain of the NCC contains several critical phosphorylation sites, 
Thr46, Thr55, Thr60, Ser72, and Ser91 in humans and Thr44, Thr53, The58, Ser73, 
Ser89 and Ser124 in rats and mice (Dimke, 2011). The individual contribution of each 
phosphorylation site remains unclear, but studies have suggested that Thr60 is critically 
important for the activation of NCC (Lin et al., 2005). The importance of this 
phosphorylation site is showcased by a loss-of-function mutation occurring at Thr60 that 
is the common cause of Gitelman syndrome, a disease characterized by hypokalemia, 
hypomagnesaemia, and hypocalciuria (Simon et al., 1996). Additionally, trafficking of 
the NCC from the subapical vesicles to the membrane plays a key role in the activation of 
the transporter (Hoorn et al., 2011a). Phosphorylated forms of NCC have only been found 
in the plasma membrane, so without proper trafficking, the NCC would be unable to be 
phosphorylated and consequently, activated for sodium transport (Pedersen et al., 2010). 
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Figure 8: Structural features of human sodium chloride cotransporter (NCC). The 12 transmembrane domains 
are illustrated including the hydrophilic loop, several phosphorylation sites, and the binding sites for 
SPAK/OxSR1 on NCC. Adapted from Dimke H. Pflugers Arch – Eur J Physiol (2011) 462:767-777. 
 
The NCC and Genetic Diseases 
The functional relevance of the NCC is showcased in monogenetic diseases that 
affect NCC function. Loss-of-function mutations occurring in SLC12A3 results in the 
development of Gitelman syndrome (Simon et al., 1996). This disease is characterized by 
hypokalemia, hypomagnesemia, metabolic alkalosis, and low arterial blood pressure 
(Simon et al., 1996). Missense mutations account for the majority of the mutations 
present in patients diagnosed with Gitelman syndrome (Simon et al., 1996). Gender and 
the type of mutation determine the phenotype of the disease, with male patients and 
patients with homozygous deep intronic mutations exhibiting a more severe phenotype 
(Lin et al., 2004; Lin et al., 2005). Typically, Gitelman syndrome is a benign disorder, but 
more recent studies have stated that Gitelman syndrome may cause glucose intolerance 
and chronic kidney disease (Lin et al., 2004; Lin et al., 2005). However, patients with a 
(lysine) [46, 50]. The role of the WNK family in the
maintenance of ambient blood pressure has been firmly
established. PHAII patients have defects in either the
WNK1 or WNK4 genes and suffer from increased renal
reabsorption of NaCl and consequently elevated arterial
pressure [24, 48]. Specifically, autosomal dominant muta-
tions in the WNK4 gene or intronic deletions of the WNK1
gene (that massively increase its transcript) are responsible
for PHAII [48].
Thiazide diuretics are known to normalize blood
pressure and correct electrolyte abnormalities when admin-
istered to PHAII patients [10], implicating a prominent role
for N C in this disease. WNK4 has subsequently been
found to inhibit NCC transport by reducing plasma
membrane abundance of the cotransporter in the oocyte
expression system [49, 53]. Recent studies have shown that
WNK4 inhibits NCC activity by diverting the cotransporter
to the lysosomal compartment during forward trafficking.
This likely occurs via a sortilin-dependent mechanism [44,
59] (Fig. 2a). The inhibitory effect of WNK4 occurs
independently of NCC phosphorylation of Thr58 (equiva-
lent to Thr60 in humans), which is important for NCC
activity [21, 22]. Loss-of-function mutations in WNK4
have been the suggested molecular mechanism of PHAII.
Here, mutations in WNK4 increase NCC abundance by
reverting the inhibitory effect on lysosomal shuttling of
NCC (Fig. 2b). One PHAII-causing mutation in WNK4
(Q562E) reduced the inhibitory effect of WNK4 on NCC
activity and trafficking [49, 53]. However, in the same
study, several other PHAII-causing mutations of WNK4
failed to inhibit the activity of the cotransporter [53].
Contrasting these observations is the finding that WNK4
stimulates N-terminal phosphorylation and hence activity of
NCC in the same cellular systems. This occurs via WNK4-
dependent activation of the STE20 family of serine/threonine
kinases, namely the STE20-related proline–alanine-rich ki-
nase (SPAK) and oxidative stress response 1 kinase (OSR1)
[47]. Additionally, angiotensin II increases NCC activity in
the Xenopus ocyte system, but only in the presence of
WNK4. This stimulatory effect of angiotensin II on NCC is
dependent on SPAK activation and coincides with increased
phosphorylation of the cotransporter [40] (Fig. 3a). More-
over, this study could not detect any additional stimulatory
effect of angiotensin II on NCC activity when a PHAII
mutant of WNK4 was expressed, suggesting that the mutated
WNK4 was already in an activated state [40]. The positive
effect of WNK4 on NCC activity may be due to an elevation
of intracellular Ca2+, which is released after angiotensin II
application. San-Cristobal et al., the authors of this study,
highlighted the fact that PHAII mutations in WNK4 are
situated in a negatively charged domain of the WNK4
protein. This part of WNK4 bears some similarity to a Ca2+-
Plasma membrane
Thr46
Thr55 Thr60 Ser73
Ser91
Ser126
SPAK/OSR1 binding 
site RFx[V/I]
-Adducin binding 
region (grey)
Ser811
Fig. 1 Schematic diagram of human NCC, depicting the various
phosphorylation sites within the cotransporter. Please note that Ser126
has not been described in human NCC, but has been identified as Ser124
in rat NCC. In addition, binding sites for the SPAK/OSR1 kinases as
well as the γ-adducin-binding region are indicated in the figure
Pflugers Arch - Eur J Physiol (2011) 462:767–777 769
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heterozygous mutation in the NCC show decreased risk for hypertension and 
cardiovascular diseases and increased bone density (Cruz, 2001). . 
In contrast to Gitelman syndrome, familial hyperkalemic hypertension (FHHt) is 
characterized by hyperkalemia, hypertension, hypercalciuria and metabolic acidosis 
(Hadchouel et al., 2006). FHHt is caused by mutations in the genes encoding WNK1, 
WNK4, Kelch-like 3, or Cullin-3, all of which result in NCC overactivity (Gamba et al., 
1993; Boyden et al., 2012; Louis-Dit-Picard et al., 2012). Intronic deletions in WNK1 
lead to WNK1 overexpression resulting in increased inhibition of WNK4, activating to 
phosphorylate NCC (Moes et al., 2014). Additionally, a missense mutation in the WNK4 
gene results in production of a protein that cannot inhibit SPAK, triggering increased 
activation of the NCC (Boyden et al., 2012). Mutations occurring in the Kelch-like 3 or 
Cullin-3 proteins abolish the ubiquitination of proteins like WNK4 preventing the 
degradation of these regulatory proteins and therefore increasing NCC activity (Shibata et 
al., 2013). One feature of FHHt disorders is that they are all very responsive to treatment 
with thiazide-type diuretics, showcasing NCC activation as a common cause despite the 
variety in genetic mutations (Moes et al., 2014). 
The NCC Signaling Cascade 
Recent studies have helped elucidate the intracellular signaling cascade that 
regulates NCC activity, which consists of a multi-kinase network including WNK (with-
no-lysine), SPAK (STE20/SPS1-related Proline-Alanine-rich kinase), and OxSR1 
(oxidative stress response-1) (Figure 9). Many of these regulatory proteins were 
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identified because mutations in their genes result in genetic diseases that affect sodium 
homeostasis and blood pressure through direct and/or indirect influences on the NCC. 
WNK kinases are considered atypical kinases with pleiotropic effects because 
they are found in different tissue types mediating a variety of physiological processes like 
solute transport, neurotransmission, and cell growth (McCormick and Ellison, 2011). The 
WNKs are serine/threonine kinases that play a key role in the maintenance of blood 
pressure and are primarily located on the distal nephron. WNKs are implicated in the 
direct or indirect regulation of three sodium transporters: the sodium potassium chloride 
cotransporter type 2 (NKCC2), the NCC and the ENaC. WNKs act as molecular switches 
with the ability to modify transporter activity depending on physiological changes, 
playing a significant role in regulating sodium and potassium transport as well as blood 
pressure. 
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Figure 9: Schematic of NCC regulation. Model for the activation of NCC by increasing membrane expression 
and phosphorylation in the DCT. Effects are stimulatory (green arrows) or inhibitory (red breaks). Adapted 
from Vallon V. Kidney Int. 2008; 74(11): 1373-1375. 
 
There are four genes that encode for WNK kinases: WNK1, WNK2, WNK3, and 
WNK4. Each of these isoforms has discrete functions in regulating solute transport in the 
kidney and plays an important role in the maintenance of normotension. The importance 
of these WNK isoforms is demonstrated in the autosomal dominant mutations found in 
the WNK4 gene or intronic deletions in the WNK1 gene responsible for the development 
of psuedohypoaldosteronism type II (PHAII) resulting in hypertension via increased renal 
sodium reabsorption (Vitari et al., 2005). WNKs facilitate transporters actions by 
modulating the translocation of proteins to or from the plasma membrane and by 
modulating transport protein phosphorylation (McCormick and Ellison, 2011). WNK1 
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can inhibit the NCC thereby decreasing NCC activity (McCormick and Ellison, 2011), 
correlating to observations of increased MAP and NCC expression and phosphorylation 
in mice lacking WNK1 (Zambrowicz et al., 2003). The role of the WNK3 remains to be 
fully elucidated, but has been shown to stimulate NCC activity (McCormick and Ellison, 
2011). The stimulatory effect of WNK3 on the NCC is thought to occur by 
phosphorylating and consequently inhibiting WNK4, preventing NCC from being 
shuttled to the lysosomes (Yang et al., 2003). Increases in NCC expression are correlated 
with this effect occurring independently of Thr60 phosphorylation on the NCC (Glover et 
al., 2009). 
WNK4 has the ability to inhibit NCC transport by decreasing NCC expression on 
the membrane (Wilson et al., 2003; Yang et al., 2003). Several studies have demonstrated 
that WNK4 inhibits NCC activity by diverting post-Golgi NCC to lysosomal degradation, 
preventing delivery of the NCC to the plasma membrane (Subramanya and Ellison, 
2010). Changes in NCC activity via WNK4 activity are thought to contribute to renal 
adaptive modulation in response to changes in dietary salt intake, a process crucial for the 
maintenance of sodium balance and blood pressure homeostasis (McCormick and 
Ellison, 2011). Interestingly, WNK4 inhibitory effect is independent of NCC 
phosphorylation on Thr58 (Glover et al., 2009; Glover et al., 2010). Mutations in WNK4 
in the context of PHAII increase NCC abundance by reducing the inhibitory effect of 
WNK4 on NCC activity and trafficking (Wilson et al., 2003; Yang et al., 2003). 
The WNKs use intermediary kinases, SPAK and OxSR1 to mediate 
phosphorylation of various cation transporters in the kidney. Both SPAK and OxSR1 
		 26 
phosphorylate our transporter of interest, the NCC (Richardson et al., 2008). It is unclear 
whether WNKs can phosphorylate sodium transporters directly however, there is 
evidence suggesting that WNK1 and WNK4 phosphorylate SPAK and OxSR1 to 
phosphorylate and activate the NCC (Vitari et al., 2005). Despite the fact that WNK4 has 
inhibitory effects on the NCC, WNK4 also has the ability to stimulate N-terminal 
phosphorylation of the NCC, increasing its activity (Dimke, 2011). Furthermore, NCC 
activity can be increased as a result of increased AngII, but only in the presence of 
WNK4 (McCormick et al., 2008). The stimulatory effect of AngII on NCC activity 
occurs through a SPAK-dependent mechanism coinciding with increased phosphorylation 
of the NCC (San-Cristobal et al., 2008). This same study suggested that PHAII mutations 
have the ability to switch WNK4 into an activated state, stimulating SPAK/OxSR1 to 
phosphorylate NCC, increasing sodium reabsorption across the DCT (San-Cristobal et 
al., 2008). WNK4 has seemingly contradictory effects on NCC function because it can 
act as both a stimulator and inhibitor of the NCC depending upon the conditions within 
the cell. Unless stimulated, WNK4 is primarily inhibitory, shuttling the NCC into 
lysosomes and reducing sodium transport as a result (Subramanya and Ellison, 2010). 
When WNK4 is stimulated (e.g. increased AngII), NCC transport will increase through 
activation of the SPAK/OxSR1 pathway. A recent study examined the contribution of 
WNK1 and WNK4 to the activity of the NCC (Chavez-Canales et al., 2014). This study 
found that WNK1 stimulates NCC expression and activity in a SPAK-dependent manner 
and not through modulation of an inhibitory effect of WNK4, suggesting that WNK1 may 
play a more important role in NCC activation than previously thought (Chavez-Canales 
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2014). Additionally, they concluded that the presence of WNK4 decreases WNK1 and 
WNK3-mediated activation of the NCC (Chavez-Canales 2014).  
While WNK4 can have contradictory effects on the activation of the NCC, 
WNK1, an additional WNK variant, can inhibit WNK4, abolishing WNK4’s ability to 
shuttle NCC into lysosomes (Subramanya and Ellison, 2010). During chloride or 
potassium depleted conditions, WNK1 activates the SPAK/OxSR1 pathway (Anselmo et 
al., 2006). It has been postulated that the WNK1 overexpression observed in PHAII 
increases the activity of the NCC via increased phosphorylation through activation of the 
SPAK/OxSR1 pathway (Vitari et al., 2005). While the exact mechanisms examining the 
influence of WNK4 and WNK1 are not fully elucidated, their influence on renal sodium 
transport and blood pressure are well established. Heterozygous mice with genetic 
ablation of the WNK1 gene show decreases in mean arterial pressure, further 
demonstrating the importance of WNK1 as a key regulator in the maintenance of sodium 
homeostasis and normotension. 
The NCC is predominately activated by the STE20 family of serine/threonine 
kinases, SPAK and OxSR1. Both SPAK and OxSR1 have the ability to phosphorylate 
NCC on Thr46, Thr55, and Thr60 (Richardson et al., 2008). Two isoforms of SPAK have 
been characterized: full-length SPAK (FL-SPAK) and kidney-specific SPAK (KS-SPAK) 
(McCormick et al., 2011). KS-SPAK lacks the kinase domain, but has the ability to 
inhibit FL-SPAK and OxSR1 (McCormick et al., 2011). Two interactions need to occur 
between SPAK and OxSR1 to enable NCC phosphorylation, 1) a docking interaction 
between their C-terminal domains and 2) an interaction between their binding motifs 
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(Vitari et al., 2005; Richardson et al., 2008). For the Ser71 phosphorylation site, studies 
conducted in SPAK-deficient mice show altered Ser71 phosphorylation demonstrating 
that SPAK is required for the phosphorylation at this site (Yang et al., 2010). While, in 
vivo experiments have correlated increases in Ser73 phosphorylation with increased 
SPAK/OxSR1 pathway activation (Filippi et al., 2011). Studies conducted in SPAK-
deficient mice show that NCC phosphorylation is decreased, but not completely 
inhibited, suggesting the involvement of other kinases (Yang et al., 2010). Further, SPAK 
and OxSR1 can interact with both WNK1 and WNK4, but only when the WNKs are 
catalytically active (Yang et al., 2010). While both WNK1 and WNK4 can phosphorylate 
and activate SPAK/OxSR1, WNK1 may be more efficient at phosphorylating 
SPAK/OxSR1 than WNK4 (Vitari et al., 2005). Mutations in SPAK or OxSR1 
phosphorylation sites can alter activation of these kinases. A point mutation at Thr185 to 
alanine in OxSR1 results in embryonic lethality, while mutations in Thr233 in SPAK 
result in hypotension and decreased NCC phosphorylation (Richardson et al., 2008). In 
response to low chloride concentrations, SPAK/OxSR1 phosphorylate and activate the 
NCC at three specific residues: Thr46, Thr55 and Thr60 (Richardson et al., 2008). 
Richardson et al. (2008) demonstrated the importance of the Thr60 phosphorylation site 
during NCC activation. This study showed that a mutation to Thr60 to a non-
phosphorylatable Alanine results in decreased phosphorylation at each of the three 
residues, illustrating an essential role for Thr60 in NCC activation (Richardson et al., 
2008). This mutation at Thr60 significantly blunts NCC activity in response to low 
chloride concentrations (Richardson et al., 2008). The significance of the Thr60 
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phosphorylation site is further demonstrated in the genetic disorder, Gitelman syndrome 
(Maki et al., 2004). 
Regulation of the NCC by Hormones and Other Mechanisms 
A variety of hormones, including aldosterone, angiotensin II, glucocorticoids, 
estrogen, insulin, NE, and vasopressin, have the ability to regulate the NCC 
demonstrating the importance of the NCC in the maintenance of sodium homeostasis 
(Velazquez et al., 1996; Kim et al., 1998; Verlander et al., 1998; Mutig et al., 2010; 
Sohara et al., 2011; van der Lubbe et al., 2011; Chavez-Canales et al., 2014). The first 
hormone discovered to regulate the NCC was aldosterone. Increases in aldosterone, 
through a s.c. infusion or triggered by a low sodium diet, stimulate increases in the NCC 
(Kim et al., 1998; Chiga et al., 2008). Acute increases in aldosterone have been shown to 
only affect the phosphorylation of the NCC, while chronic increases in aldosterone affect 
increases in total NCC expression independent from changes in NCC mRNA levels 
(Abdallah et al., 2001; Masilamani et al., 2002; van der Lubbe et al., 2012). Recently, 
angiotensin II (AngII), a potent vasoconstrictor and sodium-retaining hormone (Mitchell 
et al., 1992), has been shown to alter both the activity and phosphorylation of the NCC 
via actions on the angiotensin type 1 receptor (AT1) (Yang et al., 2008; van der Lubbe et 
al., 2011; van der Lubbe et al., 2013). A series of studies from Ewout J. Hoorn’s lab used 
adrenalectomized rats to distinguish the effects of AngII and aldosterone on the NCC. 
These data demonstrated that aldosterone did not require AngII to activate the NCC, but 
when both hormones were present they had a synergistic effect, dramatically increasing 
NCC abundance (van der Lubbe et al., 2012). Current studies have demonstrated the role 
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of potassium in NCC regulation by showing that increases in dietary potassium inhibits 
the NCC independently of aldosterone (Sorensen et al., 2013; van der Lubbe et al., 2013). 
The dephosphorylation of the NCC as well as a decrease in total NCC occurred after 
increases in potassium intake in mice (Sorensen et al., 2013; van der Lubbe et al., 2013). 
Similarly, when an animal is maintained on a high salt diet, NCC activation and 
expression is suppressed (Chiga et al., 2008). Interestingly, the response of the NCC to 
increased dietary salt intake does not occur as rapidly as the response to an increase in 
dietary potassium intake (Sorensen et al., 2013). Arguably, the effect of a high salt diet 
on the NCC is mediated by aldosterone; however, this effect has not been examined in an 
experimental model where aldosterone is absent (Chiga et al., 2008). Additionally, 
vasopressin has been demonstrated to stimulate NCC activity through a SPAK-dependent 
mechanism (Saritas et al., 2013). 
Drugs Influencing NCC Activity 
In the treatment of hypertension, one of the most commonly prescribed class of 
drugs are thiazide diuretics that act by inhibiting the NCC as well as other sodium-
dependent bicarbonate-chloride cotransporters (Leviel et al., 2010; Melnikov et al., 
2011). Clinically, thiazides, like hydrochlorothiazide (HCTZ), have been used for 
decades to treat specific NCC-related disorders as well as hypertension (Brater, 1998). 
Thiazide diuretics act by inhibiting the NCC, increasing the renal excretion of sodium 
and water (natriuresis) resulting in a lowering of blood pressure (Tamargo et al., 2014). 
Further, thiazides potentially cause vasodilatation via vascular potassium channel 
activation (Pickkers et al., 1998). Long-term use of thiazide diuretics produce 
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hemodynamic changes resulting in a reduction of peripheral vascular resistance and 
blood pressure (Pickkers et al., 1998). A thiazide-based treatment regimen reduces the 
morbidity and mortality associated with hypertension, decreasing the risk of stroke, heart 
failure and coronary heart disease (Tamargo et al., 2014). While thiazide diuretics are 
typically prescribed for the treatment of hypertension, they are also used in sodium-
retaining disorders like heart failure, liver cirrhosis or chronic kidney disease, for 
example (Brater, 1998). In order for the drug to illicit its intended response, it needs to 
get to the DCT, an action mediated by active secretion of thiazide diuretics in the 
proximal tubule through the organic anion transporter and the multidrug resistance-
associated protein 4 (Hasegawa et al., 2007; Vallon et al., 2008). A side of effect of 
taking thiazide diuretics resembles Gitleman syndrome with the addition of hyponatremia 
(Ellison and Loffing, 2009; Ernst and Moser, 2009). 
Interestingly, drugs called calcineurin inhibitors like cyclosporine and tacolimus, 
immunosuppressant drugs, have been known to activate the NCC (Hoorn et al., 2011b). 
While calcineurin inhibitors do not act on the NCC directly, they have the ability to 
influence the WNKs (Melnikov et al., 2011). The side effect profile of calcineurin 
inhibitors resembles a phenotype similar to FHHt (Glover et al., 2010). Furosemide is a 
loop-diuretic that inhibits sodium transport in the thick ascending limb and can increase 
NCC expression (Abdallah et al., 2001). This increase in NCC expression is most likely a 
result of enhanced sodium delivery to the DCT and the activation of the renin-angiotensin 
system (Hoorn et al., 2011b). The researchers posit that the upregulation of NCC 
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compensates for the furosemide effect contributing to the development of loop-diuretic 
resistance. 
 
Current Controversies 
Several recent studies have proposed that excess NE-mediated sympathetic over-
activity evokes increased expression of the NCC, increased NCC-mediated sodium 
retention and the development of salt-sensitive hypertension (Mu et al., 2011; Terker et 
al., 2014). The Sprague-Dawley rat, which remains normotensive and suppresses 
sympathetic outflow and circulating NE levels during high salt intake (Wainford and 
Kapusta, 2012; Kapusta et al., 2013), rapidly and persistently suppresses the expression 
of the NCC in response to increased dietary sodium intake (Yang et al., 2008), a process 
suggested to facilitate sodium homeostasis and normotension. Separate studies have 
demonstrated that chronically elevated levels of NE (via exogenous NE administration), 
result in hypertension in the Sprague-Dawley rat maintained on a normal salt diet, but do 
not cause any change in NCC expression (Sonalker et al., 2008), suggesting there is a yet 
to be determined interaction between dietary salt and circulating NE that impacts the 
regulation and expression of the NCC. Current studies conducted in mice report that 
elevated levels of NE trigger an upregulation of both total and phosphorylated NCC 
levels (Mu et al., 2011) independently of increases in dietary salt intake. However, in 
these studies conducted in both rats and mice the interaction of increased dietary salt 
intake and increased SNS activity, which increases circulating and renal NE levels, as 
occurs in salt-sensitive phenotypes (Terker et al., 2014), on NCC expression or function 
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was not investigated. Additionally, the report of increased levels of phosphorylated NCC 
observed in these studies does not differentiate if these increases are due to increased 
NCC membrane expression or just a general increase in the phosphorylation level of the 
NCC. Recently Mu et al. (2011) suggested a mechanism in which renal β2-adrenergic 
receptor stimulation accelerates tubular sodium reabsorption caused by NCC activation in 
the DCT (Mu et al., 2011). NE infusions in mice caused salt-induced increases in blood 
pressure that was associated with NCC activation mediated by WNK4 downregulation 
(Mu et al., 2011). Since WNK4 is a negative regulator of NCC activity, it can be 
suggested that WNK4 suppression by β2-adrenergic receptor activation, induces 
increased sodium reabsorption through NCC activation in the DCT (Mu et al., 2011). A 
recent study showed that WNK1 has the ability to stimulate NCC activity and expression 
in a SPAK-dependent manner, demonstrating the importance of WNK1 in NCC 
regulation, suggesting an alternative mechanism for the regulation of the NCC in salt-
sensitive hypertension (Chavez-Canales et al., 2014). However, these studies neglected to 
investigate the interaction of the SNS and increased salt on NCC function and expression 
in the development of hypertension as well as the influence of the renal sympathetic 
nerves in the development of NCC dysfunction and salt-sensitive hypertension. 
Additionally, these studies failed to examine the role of the α1-adrenergic receptor as a 
potential activator of the NCC signaling pathway. Meanwhile, Terker et al. (2014) 
demonstrated that adrenergic stimulation results in an enrichment of β1, and not β2-
adrenergic receptors in the DCT, suggesting that β1ARs play a more dominate role in 
NCC activation (Terker et al., 2014). 
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Based on these recent discoveries, we hypothesize that attenuated afferent 
renal nerve feedback drives renal efferent nerve release of norepinephrine to 
prevent the downregulation of the NCC via a predominant α-adrenergic receptor-
gated WNK1-OxSR1 signal transduction pathway to evoke the development of salt-
sensitive hypertension. The following studies are designed to examine the impact of 
excess circulating NE and increased dietary salt intake, both individually and in 
combination, on sodium homeostasis, blood pressure regulation and NCC function and 
expression as well as NCC regulation in salt-resistant and salt-sensitive phenotypes. 
Additionally, these studies will investigate the roles of the α- and β-adrenergic receptors 
and the influence of the afferent renal nerves in the development of NCC dysfunction in 
salt-sensitive hypertension. 
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Illustration 1: Schematic of overall hypothesis of salt-resistance vs. salt-sensitivity in the renal regulation of 
blood pressure. 
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Specific Aims 
Aim 1: To determine that the development of salt-sensitive hypertension is evoked 
by the failure to downregulate renal NCC activity via increased global and renal 
activity of the sympathetic nervous system  
A. Characterize how increased salt intake influences mean arterial pressure and 
NCC function in salt-resistant and salt-sensitive phenotypes 
B. Characterize how excess norepinephrine influences mean arterial pressure and 
NCC function in salt-resistant and salt-sensitive phenotypes 
C. Characterize how excess norepinephrine and increased salt intake together 
influence mean arterial pressure and NCC function in salt-resistant and salt-
sensitive phenotypes 
Aim 2: To determine that the development of salt-sensitive hypertension is evoked 
by the actions of NE on a renal α-adrenergic receptor-gated WNK1-OxSR1 signal 
transduction pathway that drives NCC-mediated sodium reabsorption  
A. Characterize how increased salt intake and excess norepinephrine, both alone 
and together, affect NCC regulatory proteins (OxSR1, SPAK, WNK1) in salt-
resistant and salt-sensitive phenotypes 
B. Characterize the roles of α- and β-adrenergic receptors in the regulation of the 
NCC in chronic studies using salt-resistant and salt-sensitive phenotypes  
Aim 3: To determine that the afferent renal nerves are a critical sympathetic 
nervous system sodium responsive mechanism that mediates the regulation of the 
renal NCC to prevent the development of salt-sensitive hypertension 
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A. Characterize the responsiveness of the afferent renal nerves in salt-resistant 
and salt-sensitive phenotypes 
B. Characterize how afferent renal denervation affects mean arterial pressure and 
NCC function in salt-resistant and salt-sensitive phenotypes 
C. Characterize how afferent renal denervation affects the expression of NCC and 
NCC regulatory proteins in salt-resistant and salt-sensitive phenotypes 
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CHAPTER TWO: General materials and methods 
Animals 
Male Sprague-Dawley, Dahl salt-resistant, and Dahl salt-sensitive rats (Harlan 
Laboratories Inc., Indianapolis, IN, USA; 275-299g bodyweight) were individually 
housed in a temperature (range 68-79oF) and humidity (range 30-70%) controlled 
environment under a 12-h light/dark cycle. Following the completion of surgical 
procedures, rats were randomly assigned to a standard normal salt (NS) rodent diet 
(Teklad Global Diet, Harlan Laboratories, Indianapolis, IN, USA; Teklad Global 18% 
Protein rodent diet #2918, 18% protein, 5% crude fat, 5% fiber, total NaCl content 0.6% 
[102 mEq Na+/kg]) or a high salt (HS) rodent diet (Test Diet, St. Louis, MO, USA; Basal 
diet #5G01, 22% protein, 5.5% crude fat, 5% fiber, modified to contain total NaCl 
content 8% [1,378 mEq Na+/kg]) and tap water ad libitum for a 14-day or 21-day 
experimental period. All protocols were approved by the Boston University School of 
Medicine Institutional Animal Care and Use Committee and all procedures were 
conducted in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals.     
 
Surgical Procedures   
Subcutaneous Osmotic Mini-Pump Implantation: Animals were anesthetized (sodium 
methohexital, 20mg/kg intraperitoneally (i.p.)) and surgically instrumented with an 
osmotic mini-pump (Alzet, osmotic pump model 2ML2, Palo Alto, CA, USA) that was 
placed subcutaneously (s.c.) in the subscapular region. Following s.c. osmotic mini-pump 
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surgical placement all animals were returned to their home cage following administration 
of penicillin (300,000 units/ml, 0.3ml intramuscularly (i.m.)).   
Acute Femoral Vein, Artery, and Bladder Cannulation: Following 14-days or 21-days of 
NS or HS intake, depending on the protocol, animals were anesthetized (sodium 
methohexital, 20mg/kg intraperitoneal (i.p.) supplemented with 10mg/kg intravenous 
(i.v.) as required). Once anesthetized, rats were instrumented with catheters in the left 
femoral artery, left femoral vein, and bladder for the measurement of arterial blood 
pressure, i.v. administration of saline and/or drugs, and renal function, respectively and in 
certain studies an intra-renal catheter was instrumented for local drug infusion in the 
kidney (Kapusta et al., 2013; Wainford et al., 2013; Foss et al., 2015). Rats were then 
placed in a Plexiglas holder and an i.v. infusion of isotonic saline (20µl/min) was 
maintained for a 2-h surgical recovery period prior to experimentation to enable the 
animal to regain full consciousness and for cardiovascular/renal excretory functions to 
stabilize (Kapusta et al., 2013; Wainford et al., 2013; Walsh et al., 2016). Mean arterial 
pressure (MAP) and heart rate (HR) were continuously recorded via the surgically 
implanted femoral artery cannula using computer driven BIOPAC data acquisition 
software (MP150 and AcqKnowledge 3.8.2, BIOPAC Systems, Inc., Goleta, CA, USA) 
connected to an external pressure transducer (P23XL; Viggo Spectramed Inc., Oxnard, 
CA, USA) (Kapusta et al., 2013; Wainford et al., 2013; Walsh et al., 2016). Note that the 
zero level of the pressure transducer corresponded to heart level. 
Telemetry probe implantation: A radiotelemetry device (PA-C40, DSI, MN) was 
implanted into the abdominal aorta via the left femoral artery under ketamine anesthesia 
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(30 mg/kg i.p. ketamine; 3 mg/kg i.p. xylazine). Radiotelemetry data were collected, 
stored, and analyzed using Dataquest A.R.T. 4.2 software (DSI, St. Paul, MN, USA). 
Bilateral Renal Nerve Denervation (RDNX): Animals were anesthetized (sodium 
pentobarbital, 20mg/kg i.p.) and a flank incision was made so that the visceral organs 
were externalized and the left kidney was exposed. A hole was made in the peritoneal 
membrane to expose the renal artery and vein. The fat surrounding the renal artery and 
vein was then gently dissected away from the vessels to expose the renal nerves and were 
stripped of all visible renal nerve bundles. A cotton-tipped swab was soaked 10% phenol 
in ethanol, ensuring the removal of any remaining renal nerve fibers, and was swiped 
multiple times along the renal artery and vein. Once completed, the procedure is repeated 
on the contralateral side. At the end of the procedure, the abdominal muscles and skin 
were closed separately with silk sutures. The sham control was performed by 
externalizing the viscera, visualizing the renal artery and vein, and then closing the 
wound (Foss et al., 2015).  
Selective Afferent Renal Nerve Denervation (Renal-CAP): Animals were anesthetized 
(sodium pentobarbital, 30mg/kg i.p.) and a flank incision was made so that the visceral 
organs were externalized and the left kidney was exposed. A hole was made in the 
peritoneal membrane to expose the renal artery and vein. The fat surrounding the renal 
artery and vein was then gently dissected away from the vessels to expose the renal 
nerves. A cotton-tipped swab was soaked in a capsaicin solution (33mM in 5% ethanol, 
5% tween 80 and 90% isotonic saline) and was swiped multiple times along the renal 
artery and vein and care was taken to avoid any non-renal capsaicin exposure. Once 
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completed, the procedure is repeated on the contralateral side. At the end of the 
procedure, the abdominal muscles and skin were closed separately with silk sutures. The 
sham control was performed by externalizing the viscera, visualizing the renal artery and 
vein, and then closing the wound (Foss et al., 2015).  
 
Experimental Treatment Groups  
 Norepinephrine Studies 
1) Naïve Sprague-Dawley Animals: Naïve Sprague-Dawley animals were randomly 
assigned to receive a NS or HS diet for a 14-day experimental period (N=6/group). 
2) Isotonic Saline Vehicle Infusion: Sprague-Dawley rats underwent implantation of an 
osmotic mini-pump delivering a s.c. infusion of isotonic saline (flow rate 5µl/h) prior to 
random assignment to either a NS or HS diet for a 14-day experimental period 
(N=6/group). 
3) Norepinephrine (NE) Infusion: Sprague-Dawley rats underwent implantation of an 
osmotic mini-pump delivering a s.c. infusion of NE (Sigma, St. Louis, MO, USA; 
cat#A7256) dissolved in isotonic saline (NE: 600ng/min, flow rate 5µl/h) (Sonalker et al., 
2008; Walsh et al., 2016) prior to random assignment to either a NS or HS diet for a 14-
day experimental period (N=6/group). 
4) DMSO/Saline Vehicle Infusion: Sprague-Dawley rats underwent implantation of an 
osmotic mini-pump delivering a s.c. infusion of DMSO/isotonic saline (50:50 solution, 
flow rate 5µl/h) prior to random assignment to either a NS or HS diet for a 14-day 
experimental period (N=6/group). 
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5) NE + Hydrochlorothiazide (HCTZ; NCC antagonist) Infusion: Sprague-Dawley rats 
underwent implantation of an osmotic mini-pump delivering a s.c. infusion of NE (NE: 
600ng/min, flow rate 5µl/h) (Sonalker et al., 2008; Walsh et al., 2016) in combination 
with HCTZ (Sigma, St. Louis, MO, USA; cat#H4759) dissolved in DMSO/isotonic saline 
(50:50 solution; HCTZ: 4mg/kg/day; flow rate 5µl/h) (Ashek et al., 2012; Walsh et al., 
2016) prior to random assignment to either a NS or HS for a 14-day experimental period 
(N=6/group). 
6) NE + Losartan (AT1 antagonist) Infusion: Sprague-Dawley rats underwent 
implantation of an osmotic mini-pump delivering a s.c. infusion of NE (NE: 600ng/min, 
flow rate 5µl/h) (Sonalker et al., 2008; Walsh et al., 2016) in combination with losartan 
(TCI, Tokyo, Japan; cat#L2032) dissolved in DMSO/isotonic saline (50:50 solution; 
losartan: 3mg/kg/day, flow rate 5µl/h) (Martinez and Villalobos-Molina, 2003; Walsh et 
al., 2016) prior to random assignment to either a NS or HS for a 14-day experimental 
period (N=6/group). 
 
 Adrenergic Receptor Studies 
1) Prazosin (α1-adrenergic receptor antagonist) Infusion: Sprague-Dawley rats were 
given prazosin (2.5mg/kg/day, orally; Sigma, St. Louis, MO, USA; cat#P7791) prior to 
random assignment to either a normal (0.6% NaCl) or high salt (8% NaCl) diet for a 14-
day experimental period (N=6/group). 
2) NE + Prazosin (α1-adrenergic receptor antagonist) Infusion: Sprague-Dawley rats 
were given prazosin (2.5mg/kg/d, orally) 3-days prior to implantation of an osmotic mini-
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pump delivering s.c. infusion of NE (600ng/min, flow rate 5µl/hr) (Sonalker et al., 2008; 
Walsh et al., 2016) dissolved in DMSO/isotonic saline (50:50 solution, flow rate 5µl/hr) 
in combination with prazosin (2.5mg/kg/day, orally; Sigma, St. Louis, MO, USA; 
cat#P7791) prior to random assignment to either a normal (0.6% NaCl) or high salt (8% 
NaCl) diet for a 14-day experimental period (N=6/group). 
3) Propranolol (β1/β2-adrenergic receptor antagonist) Infusion: Sprague-Dawley rats 
underwent implantation of an osmotic mini-pump delivering s.c. infusion of propranolol 
(Sigma, St. Louis, MO, USA; cat#P0884) dissolved in DMSO/isotonic saline (50:50 
solution; propranolol 10mg/kg/day, flow rate 5µl/h) (King et al., 2013) prior to random 
assignment to either a normal (0.6% NaCl) or high salt (8% NaCl) diet for a 14-day 
experimental period (N=6/group). 
4) NE + Propranolol (β1/β2-adrenergic receptor antagonist) Infusion: Sprague-Dawley 
were given propranolol (10mg/kg/d, orally) 3-days prior implantation of an osmotic mini-
pump delivering s.c. infusion of NE (600ng/min, flow rate 5µl/hr) (Sonalker et al., 2008; 
Walsh et al., 2016) in combination with propranolol (Sigma, St. Louis, MO, USA; 
cat#P0884) dissolved in DMSO/isotonic saline (50:50 solution; propranolol 
10mg/kg/day, flow rate 5µl/h) (King et al., 2013) prior to random assignment to either a 
normal (0.6% NaCl) or high salt (8% NaCl) diet for a 14-day experimental period 
(N=6/group). 
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 Dahl Rats 
1) Naïve Dahl Salt-Resistant (DSR): Naïve DSR animals were randomly assigned to 
receive a normal (0.6% NaCl) or high salt (8% NaCl) diet for a 21-day experimental 
period (N=6/group). 
2) Naïve Dahl Salt-Sensitive (DSS): Naïve DSS animals were randomly assigned to 
receive a normal (0.6% NaCl) or high salt (8% NaCl) diet for a 21-day experimental 
period (N=6/group). 
3) Dahl Salt-Sensitive + Propranolol ((β1/β2-adrenergic receptor antagonist) 
Infusion): DSS rats underwent implantation of an osmotic mini-pump delivering s.c. 
infusion of propranolol (Sigma, St. Louis, MO, USA; cat#P0884) dissolved in 
DMSO/isotonic saline (50:50 solution; propranolol 10mg/kg/day, flow rate 5µl/h) (King 
et al., 2013) prior to assignment to a high salt (8% NaCl) diet for a 21-day experimental 
period (N=6/group). 
4) Dahl Salt-Sensitive + Prazosin (α1-adrenergic receptor antagonist) Infusion: DSS 
rats were given prazosin (2.5mg/kg/day, orally; Sigma, St. Louis, MO, USA; cat#P7791) 
prior to assignment to a high salt (8% NaCl) diet for a 21-day experimental period 
(N=6/group). 
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 Renal Nerve Studies 
1) Chronic Renal-CAP in Sprague-Dawley Rats: Sprague-Dawley rats instrumented 
with a telemetry probe undergo Renal-CAP or sham surgery immediately prior to a high 
salt (8% NaCl) diet for a 21-day experimental period following a 5-day period of baseline 
telemetry measurements (N=6/group). 
2) Chronic Renal-CAP in Dahl Rats: DSR and DSS rats instrumented with a telemetry 
probe undergo Renal-CAP or sham surgery immediately prior to a high salt (8% NaCl) 
diet for a 21-day experimental period following a 5-day period of baseline telemetry 
measurements (N=6/group). 
3) Chronic RDNX in Dahl Rats: DSR and DSS rats instrumented with a telemetry probe 
undergo RDNX or sham surgery and are placed on a high salt (8% NaCl) diet for a 21-
day experimental period following a 5-day period of baseline telemetry measurements 
(N=6/group). 
4) Acute Renal-CAP in Sprague-Dawley Rats: Sprague-Dawley rats undergo Renal-
CAP or sham surgery and are placed on a high salt (8% NaCl) diet for a 14-day 
experimental period (N=6/group). 
 
Acute Experimental Protocols  
The following cardiovascular, renal sodium transporter activity, and autonomic function 
protocols were performed consecutively in a single experiment in each animal following 
14-days of NS or HS intake.   
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Cardiovascular Function:  Following a 2-h surgical recovery period, baseline MAP was 
recorded continuously over a 30-min period in conscious rats via the surgically implanted 
femoral artery cannula (N=6/group) (Kapusta et al., 2013; Wainford et al., 2015). The 
presented value for MAP represents the average obtained over the entire 30-min period in 
which baseline MAP was recorded. 
Renal Sodium Transporter Activity: Following the completion of the cardiovascular 
function protocol, a renal sodium transporter activity protocol was initiated. All animals 
received a control i.v. infusion of isotonic saline (flow rate 20m l/min) for 1-h, followed 
by an i.v. bolus of amiloride (2mg/kg) preceding a 1-h i.v. infusion of amiloride (ENaC 
antagonist; 2mg/kg, flow rate 20m l/min) (Ashek et al., 2012; Walsh et al., 2016), and an 
i.v. bolus of HCTZ (2mg/kg) preceding a 1-h i.v. infusion of amiloride (2mg/kg, flow 
rate 20m l/min) (Ashek et al., 2012; Walsh et al., 2016) in combination with HCTZ (NCC 
antagonist; 2mg/kg, flow rate 20m l/min) (Ashek et al., 2012). Throughout the 3-h 
protocol, HR and MAP were continually monitored and urine was collected in 10-min 
intervals to assess peak natriuresis to i.v. amiloride or HCTZ (N=6/group). The peak 
natriuretic response (ΔUNaV; µeq/min) was determined by subtracting the baseline 
UNaV value from the maximum natriuretic value observed during each h of drug 
infusion (i.e., i.v. amiloride or i.v. amiloride + HCTZ). Baseline UNaV values were 
determined by averaging the UNaV values from the last two 10-min time points during 
the previous h of the study (h 1: i.v. saline (40-50 min, 50-60 min) or h 2: i.v. amiloride 
(100-110 min, 110-120 min)). The maximum natriuretic response to amiloride and 
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amiloride + HCTZ occurred during the 10-20 min and 20-30 min time points post drug 
infusion, respectively.  
Autonomic Function Protocol: Following completion of the renal sodium transporter 
activity protocol, the peak change in MAP in response to an i.v. bolus of hexamethonium 
(30mg/kg) (Kapusta et al., 2013; Wainford et al., 2015) was assessed. Baseline MAP was 
determined as the average MAP recorded over a 10-min control period prior to 
hexamethonium injection. After baseline MAP measurement, animals received an i.v. 
bolus of hexamethonium and blood pressure was monitored for an additional 30-min 
period. The peak depressor response, assessed over a 60 second period, occurred within 
5-min post-injection.  
Adrenergic Receptor Stimulation: Following the completion of the renal sodium 
transporter protocol for animals receiving s.c. infusions of adrenergic antagonists only, 
peak change to MAP and HR in response to an i.v. bolus of phenylephrine (4µg) 
(Wainford et al., 2015) and isoproteronol (0.7µg) (Wainford et al., 2015) was assessed.  
Following the completion of the renal sodium transporter protocol or the adrenergic 
receptor stimulation protocol, depending on experimental treatment group, animals were 
sacrificed and both kidneys were collected and frozen at -80oC for the PCR array and 
western blot analysis. 
 
Metabolic Balance Studies 
Metabolic balance studies were conducted in all treatment groups on day-13 or day-20 of 
their respective dietary sodium intake period following a 48-h acclimatization to the 
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metabolic cages. Rats were individually housed in metabolic cages (model 18cv, Fenco, 
Cataumet, MA, USA) with external food containers and water bottles. Metabolic cages 
were equipped with a double-fine mesh screen that allowed separation of food and feces 
from urine that was collected into beakers that contained a layer of mineral oil to prevent 
evaporation. Rats were given ad libitum access to their respective assigned diet and tap 
water for 24-h. Measurements were made for food and water consumption and urine 
output during the 24-h period (Kapusta 2013; Wainford 2015; Walsh 2016). Daily water 
balance was determined by calculating the difference between water intake and urine 
output. Daily sodium balance was determined by calculating the difference between 
sodium intake (dietary sodium intake) and sodium output (urinary sodium excretion).  
 
Analytical Techniques 
 Urine volume was determined gravimetrically assuming 1g = 1ml. Urinary and plasma 
sodium concentration was measured by flame photometry (model 943, Instrumentation 
Laboratories, Bedford, MA, USA) (Kapusta et al., 2013; Wainford et al., 2013; Walsh et 
al., 2016). Plasma hematocrit (Hct) was determined using a micro-hematocrit centrifuge 
(Adams Readacrit, Clay Adams, NJ, USA). Hct was used to calculate estimated plasma 
volume (EPV) and estimated blood volume (EBV) using the following equations: EPV = 
(0.065 x body weight (kg)) x (100 – Hct), EBV = (EPV x 100)/(100-Hct) (Walsh et al., 
2016).  
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Plasma Renin Activity and Plasma and Renal Norepinephrine Measurement 
In separate groups of animals, naïve Sprague-Dawley and NE infused Sprague-Dawley 
rats were placed on a NS or HS diet for the 14-day experimental protocol. At the end of 
the 14-day experimental period, animals were decapitated while conscious and whole 
blood was collected. Plasma renin activity was determined via ELISA (Immuno-
Biological Labs America, Minneapolis, MN, USA; cat#IB59131). Plasma NE content 
was determined via ELISA (Immuno-Biological Labs America, Minneapolis, MN, USA; 
cat#IB89552). Renal NE content was determined via ELISA (Immuno-Biological Labs 
America, Minneapolis, MN, USA; cat#IB89537). 
 
Kidney Cortical Membrane Preparation   
Kidneys were harvested from animals following completion of acute experimental 
protocols (see above) and stored at -80oC. Kidney cortex tissue (~200mg) was 
homogenized on ice using a hand held pestle in a homogenizing buffer (10mM 
triethanolamine, 250mM sucrose, 100mM NaN3, 10mM PMSF, and 1mM Leupeptin). 
The resulting homogenate was centrifuged at 4000xg for 10-min at 4oC. The supernatant 
was collected and centrifuged at 17000xg for 60-min at 4oC. Following centrifugation, 
the membrane pellet was resuspended in 400µl of homogenizing buffer and protein 
content was quantified via the BCA assay. Membrane preparations were stored at -80oC 
prior to use in immunoblotting studies.   
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Determination of Renal Sodium Chloride Cotransporter (NCC) and 
Regulatory Protein Levels 
Protein extracted from membrane preparations of kidney cortex tissue were loaded at a 
concentration of 20µg of protein per lane. Membranes were blocked in 5% milk for 1-h 
and probed overnight at 4oC with anti-NCC (1:2000; Millipore, Billerica, MA, USA; cat# 
AB3553), anti-SPAK (1:1000; Abcam, Cambridge, MA, USA; cat#ab79045), anti-
OxSR1 (1:1000; Abcam, Cambridge, MA, USA; cat#ab125468), anti-WNK1 (1:200; 
Santa Cruz, Dallas, TX, USA; cat#sc-28897), or anti-β-actin (1:5000; Sigma, St. Louis, 
MO, USA; cat#A5316) antibodies in 0.1% PBS-T. Subsequently, membranes were 
exposed to either a secondary horseradish peroxidase donkey anti-rabbit IgG (H+L) 
(1:5000; Promega, Madison, WI, USA; cat#V7951) or anti-mouse IgG peroxidase 
antibody (1:10000; Sigma, St. Louis, MO, USA; cat#A9044) in 0.1% PBS-T for 1-h at 
room temperature. Bound antibodies were visualized using chemiluminescence (GE 
signal enhancer, Buckinghamshire, UK). Densitometric analysis was performed using 
Quantity One software (Bio-Rad, Hercules, CA, USA) and band densities were 
normalized to β-actin. 
 
Substance P Release from an Isolated Renal Pelvic Wall Preparation 
To study the mechanisms involved in the responsiveness of the afferent nerves to NE in 
animal models of salt-resistance and salt-sensitivity, we examined the mechanisms of the 
NE-mediated release of substance P in an isolated renal pelvic wall preparation (Kopp et 
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al., 1998; Kopp and Cicha, 2004). Naïve Sprague-Dawley rats, Sprague-Dawley rats 
receiving a s.c. infusion of NE (600ng/min), Dahl salt-resistant, and Dahl salt-sensitive 
rats were decapitated while conscious after 14- or 21-days, depending on the 
experimental protocol. The kidneys were immediately removed and the renal pelvises 
dissected from the kidneys were placed in wells containing 400µl HEPES buffer (Sigma, 
St. Louis, MO, USA; cat#83264) maintained at 37°C. Each well contained the pelvic wall 
from one kidney. The renal pelvises incubated in HEPES buffer, replacing the medium 
every 10-min. After a 2-h equilibration period, the experiment was started with four 5-
min control periods followed by one 5-min experimental period and four 5-min recovery 
periods. NE (1250pmol) was added to the incubation bath during the experimental period. 
The incubation medium, aspirated every 5-min, was placed in eppendorf tubes, and 
stored at -80oC for later analysis of substance P (Kopp and Cicha, 1999; Kopp et al., 
2003). Substance P content was determined via ELISA (Enzo Life Sciences, 
Farmingdale, NY, USA; cat#ADI-901-018).  
 
mRNA PCR Array 
Kidneys were harvested from animals following completion of acute experimental 
protocols (see above) and stored at -80oC. mRNA was extracted from kidney tissue using 
the Qiagen RNAeasy Plus Universal mini kit (Qiagen, Venlo, Netherlands; cat#73404) 
and the QIAcube as per manufacturer’s instructions. To test the quality of the mRNA, a  
nanodrop was used and samples with a low quality RNA (assessed as OD 260/280 ratio 
outside the range of 1.8 to 2.1) were excluded from further analysis. Reverse transcription 
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for cDNA synthesis was performed with RT first strand kit (Qiagen, Hilden, Germany; 
cat#330401) using 100ng of mRNA from the samples. A custom designed PCR plate, 
verified by Qiagen, was used to determine mRNA levels with 32 gene primers and 4 
housekeeping genes (Table 1) in a 384-well plate format. The PCR reaction mixture for 
the 384-well plate included 1µg of RNA with 2µl of genomic elimination buffer and 
RNase-free H2O (total 60µl) and 60ul RT2 SYBR Green master mix (Qiagen, Hilden, 
Germany; cat#330523). The PCR array was run on an Applied Biosystems ViiA7 Life 
Technologies PCR machine in the Whitaker Cardiovascular Institute at Boston University 
School of Medicine. Changes in mRNA levels were measured as fold change and 
normalized against 4 housekeeping genes: lactate dehydrogenase (LDHA), ribosomal 
protein large P1 (RPLP1), β-actin (ACTB), and hypoxanthine phosphoribosyltransferase 
1 (HPRT1). 
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Renal Rat Genes Gene 
Name 
Notes 
NKCC2/BSc-1 (Na-K-2Cl co-transporter) 
bumetanide-sensitive sodium-potassium- 
SLC12A1  
NKA-alpha1 (Na/K-ATPase alpha 1  
subunit) 
ATP1A1  
NKA-beta1 (Na/K-ATPase beta 1subunit) ATP1B  
NaPi-2 (Type 2 Na-phosphate cotransporter SLC34A1  
NHE3 (Type 3 Na/H exchanger) SLC9A3  
NCC (Na-Cl co-transporter) SLC12A3  
ENaC alpha (alpha-subunit of epithelial Na 
channel) 
SCNN1A  
ENaC beta (alpha-subunit of epithelial 
sodium channel) 
SCNN1B  
ENaC gamma (alpha-subunit of epithelial 
sodium channel) 
SCNN1G  
NBC-1 type 1 (Na-bicarbonate cotransporter) SLC4A4  
Oxidative Stress Response-1 OSR1  
STE20/SPS1-related Proline-Alanine-rich 
kinase 
SPAK  
With-No-Lysine 1 WNK1  
With-No-Lysine 2 WNK2  
With-No-Lysine 3 WNK3  
With-No-Lysine 4 WNK4  
Alpha 1a adrenergic receptor Adra1a  
Alpha 1b adrenergic receptor Adra1b  
Alpha 1d adrenergic receptor Adra1d  
Beta 1 adrenergic receptor Adrb1  
Beta 2 adrenergic receptor Adrb2  
β-actin ACTB Housekeeping Gene 
hypoxanthine phosphoribosyltransferase 1 HPRT1 Housekeeping Gene 
Lactate dehydrogenase LDHA Housekeeping Gene 
Ribosomal protein large P1 RPLP1 Housekeeping Gene 
Rat Genomic DNA Control RGDC Rat Genomic DNA Control 
RTC RTC RT Control 
RTC RTC RT Control 
RTC RTC RT Control 
PPC PPC Positive PCR Control 
PPC PPC Positive PCR Control 
PPC PPC Positive PCR Control 
Table 1: PCR array of renal rat genes tested in kidney cortex tissue. 
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Statistical Analysis 
Data are expressed as mean±SEM. Differences between treatment groups were assessed 
by a one-way ANOVA, followed by a Tukey post-hoc test, to compare variations among 
the groups. A two-tailed Student’s t-test was used to assess the difference between diet 
groups for the NCC, SPAK, OxSR1, and WNK1 expression quantification (GraphPad 
Prism version 6; GraphPad software, La Jolla, CA, USA). In each case, statistical 
significance is defined as p<0.05. 
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CHAPTER THREE: The development of salt-sensitive hypertension is evoked by a 
failure to downregulate renal sodium chloride cotransporter (NCC) activity through 
increased activity of the sympathetic nervous system 	
 
The majority of the data presented in this chapter has been published. 
 
Walsh KR, Kuwabara JT, Shim JW, Wainford RD (2016) Norepinephrine-evoked salt-
sensitive hypertension requires impaired renal sodium chloride cotransporter activity in 
Sprague-Dawley rats. American Journal of Physiology Regulatory, Integrative, and 
Comparative Physiology 310:R115-R124. 
 
Rationale 
Recently, there has been increased interest in delineating the interactions between 
the sympathetic nervous system and the kidney, which function to regulate sodium 
reabsorption. Increased dietary salt intake in salt-resistant phenotypes results in the 
suppression of neural, humoral, and renal sodium-retaining mechanisms (Lohmeier et al., 
1999; Brooks et al., 2005; Osborn et al., 2008). In contrast, increased activity of the 
sympathetic nervous system is thought to play a key role in the pathogenesis of salt-
sensitive hypertension by triggering an increase in renal sodium and water retention 
(DiBona, 2005; Rodriguez-Iturbe and Vaziri, 2007; May et al., 2010).  
Both ENaC and the NCC play important roles in the maintenance of sodium 
homeostasis and blood pressure. It has been demonstrated that increased dietary salt 
intake suppresses sympathetic outflow and circulating plasma NE levels (Kapusta et al., 
2012; Kapusta et al., 2013) as well as rapidly and persistently reducing the expression of 
the NCC in salt-resistant Sprague-Dawley rats (Yang et al., 2008). The physiological 
process of downregulating the NCC in response to increased dietary salt intake is 
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hypothesized to facilitate sodium homeostasis and normotension (Yang et al., 2008). 
However, investigations into the direct impact of increased NE levels on the expression 
of the NCC during normal dietary salt intake have produced conflicting evidence. In the 
Sprague-Dawley rat increased plasma NE content, achieved via a subcutaneous (s.c.) 
osmotic mini-pump infusion of NE, in animals maintained on a normal salt intake evoked 
hypertension without impacting the renal expression of the NCC (Sonalker et al., 2008). 
In contrast, studies conducted in C57BL/6J mice have reported that a chronic s.c. NE 
infusion results in the development of hypertension and the upregulation of both total and 
phosphorylated NCC expression during normal salt intake (Mu et al., 2011; Terker et al., 
2014). In addition to the recent focus of the actions of NE on the NCC, angiotensin II 
(AngII), a potent vasoconstrictor and sodium-retaining hormone (Mitchell et al., 1992), 
has been reported to alter both the activity and phosphorylation of the NCC via actions on 
the angiotensin type 1 receptor (AT1) (Sandberg et al., 2007; van der Lubbe et al., 2011; 
van der Lubbe et al., 2013).  
In this aim, we hypothesize that salt-sensitive hypertension is driven, in part, by a 
failure to downregulate renal NCC activity in the presence of excess circulating NE 
during high dietary salt intake. The following studies are designed to test this hypothesis 
by examining the impact of excess circulating NE and increased dietary salt intake, both 
individually and in combination, on sodium homeostasis, blood pressure regulation and 
NCC function and expression in conscious male Sprague-Dawley, Dahl salt-resistant, and 
Dahl salt-sensitive rats. Furthermore, chronic pharmacological antagonism of the AT1 
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receptor in Sprague-Dawley rats examined the potential role of the renin-angiotensin 
system (RAS) in the development of NE-evoked salt-sensitive hypertension.  
 
Results 
High salt intake exacerbates norepinephrine-induced hypertension in Sprague-Dawley 
Rats 
When naïve or s.c. infused saline treated Sprague-Dawley rats were challenged with a HS 
diet for 14-days, we did not detect any difference in baseline MAP compared to animals 
maintained on a NS diet (Figure 10). In contrast to a s.c. saline infusion, a 14-day s.c. 
infusion of NE at a rate of 600ng/min resulted in the development of hypertension in 
animals maintained on a NS diet (Figure 10; MAP [mmHg] Naïve+NS: 128±2; s.c. 
saline+NS: 125±2 vs. s.c. NE+NS: 151±3; p<0.05). The magnitude of hypertension 
evoked by a s.c. NE infusion was exacerbated when the animals were maintained on a HS 
diet (Figure 10; MAP [mmHg] s.c. NE+NS: 151±3 vs. s.c. NE+HS: 172±4; p<0.05). 
Illustrated as an index of the salt-sensitivity of blood pressure, both naïve and s.c. saline 
infused Sprague-Dawley rats exhibit a classical salt-resistant phenotype. The s.c. infusion 
of NE caused a significant reduction in the slope of the chronic pressure-natriuresis 
relationship in Sprague-Dawley rats (Figure 11), reflecting the increased salt-sensitivity 
of blood pressure.  
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Figure 10: Mean arterial pressure for naïve Sprague-Dawley rats and Sprague-Dawley rats receiving a s.c. 
saline or norepinephrine infusion. Mean arterial pressure (MAP; mmHg) in naïve conscious male Sprague-
Dawley rats and in Sprague-Dawley rats receiving either a s.c. isotonic saline infusion or a s.c. 
norepinephrine (NE; 600ng/min) infusion maintained on either a normal (0.6% NaCl) or high salt (8% 
NaCl) diet for 14-days. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; 
τp<0.05 vs. respective naive group value; ϕp<0.05 vs. respective saline group value. 
 
 
 
Figure 11: Index of salt-sensitivity for naïve Sprague-Dawley rats and Sprague-Dawley rats receiving a s.c. 
saline or norepinephrine infusion. Index of salt-sensitivity determined from 24-h sodium excretion and 
baseline MAP (mmHg) in naïve conscious male Sprague-Dawley rats and in Sprague-Dawley rats 
receiving either a s.c. isotonic saline infusion or a s.c. norepinephrine (NE; 600ng/min) infusion maintained 
on either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean±SEM (N=6/group).  
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Additionally, Sprague-Dawley rats placed on a HS diet or receiving a s.c. NE 
infusion showed no significant differences in 24-h sodium or water balance (Table 2). 
Further, the combination of a s.c. NE infusion and increased salt intake did not 
significantly alter 24-h sodium or water balance (Table 2). When estimated plasma (EPV) 
and blood volume (EBV) was calculated in these groups of animals we observed no 
significant effect of increased dietary sodium intake or NE infusion, alone or in 
combination, on EPV or EBV (Table 3).  
 
Treatment 24-h H2O Balance (ml) 24-h Sodium Balance (meq) 
 0.6% NaCl 8% NaCl 0.6% NaCl 8% NaCl 
Naïve 19.1±3.2 24.3±4.0 0.6±0.3 0.7±0.2 
Saline 26.2±2.6 33.2±4.2 0.5±0.2 0.8±0.2 
DMSO/Saline 21.5±4.2 34.1±6.0 1.0±0.3 0.9±0.2 
NE 13.7±2.6 19.5±2.5 0.5±0.2 0.5±0.3 
NE & HCTZ 16.3±4.3 13.8±2.3 0.2±0.6 032±0.6 
 
Table 2: 24-h water and sodium balance for naïve Sprague-Dawley rats and Sprague-Dawley rats receiving a s.c. 
saline, DMSO/saline, norepinephrine, or norepinephrine and hydrochlorothiazide infusion. 24-h water (ml) and 
sodium balance (meq) listed for naïve Sprague-Dawley rats and Sprague-Dawley rats receiving a s.c. 
isotonic saline, 50:50 solution of DMSO and isotonic saline, norepinephrine (NE; 600ng/min), or NE 
(600ng/min) and hydrochlorothiazide (HCTZ; 4mg/kg/day) infusion maintained on either a normal (0.6% 
NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=6/group). 
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Treatment EPV (ml) EBV (ml) 
Naïve 0.6% NaCl 12.2±0.4 21.0±0.2 
Naïve 8% NaCl 12.5±0.2 21.7±0.2 
Saline 0.6% NaCl 11.9±0.2 22.0±0.4 
Saline 8% NaCl 11.8±0.3 21.1±0.2 
NE 0.6% NaCl 12.2±0.4 21.8±0.7 
NE 8% NaCl 11.9±0.2 21.6±0.2 
 
Table 3: Estimated plasma volume and estimated blood volume naïve Sprague-Dawley rats and Sprague-
Dawley rats receiving a s.c. saline or norepinephrine infusion. Estimated plasma volume (EPV) and estimated 
blood volume (EBV) in milliliters (ml) listed for naive Sprague-Dawley rats and Sprague-Dawley rats 
receiving a s.c. infusion of isotonic saline or 600ng/min norepinephrine (NE), maintained on either a 
normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=6/group).  
 
Norepinephrine infusion prevents dietary sodium-evoked suppression of NCC activity in 
Sprague-Dawley rats 
To assess the impact of NE infusion on vascular tone, we challenged animals with the 
ganglionic blocker, hexamethonium, via an acute i.v. bolus injection. As illustrated 
(Figure 12), increased dietary sodium intake did not alter the peak depressor response 
following ganglionic blockade in naïve and s.c. saline infused Sprague-Dawley rats. 
However, NE infusion significantly increased the peak depressor response to 
hexamethonium, a response that was not altered following 14-days of HS intake (Figure 
12). Next, we assessed the impact of NE infusion on the activity of two key renal sodium 
transporters, ENaC and NCC. The peak natriuretic response to amiloride, an ENaC 
inhibitor, in naïve and saline treated groups was suppressed on a HS diet (Figure 13; Peak 
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ΔUNaV to i.v. amiloride [µeq/min] Naïve+NS: 7.7±0.5 vs. Naïve+HS: 4.2±1; p<0.05). 
NE infusion did not impact the dietary sodium-evoked suppression of the peak natriuretic 
response to amiloride (Figure 13; Peak ΔUNaV to i.v. amiloride [µeq/min] s.c NE+NS: 
9.4±1 vs. s.c. NE+HS: 3.7±1.6; p<0.05). Both naïve and s.c. saline infused rats exhibited 
dietary sodium-evoked suppression of the peak natriuretic response to HCTZ, a NCC 
antagonist (Figure 14; Peak ΔUNaV to i.v. HCTZ [µeq/min] Naïve+NS: 9.4±0.2 vs. 
Naïve+HS: 7±0.1; p<0.05; s.c. saline+NS: 8.8±0.3 vs. s.c. saline+HS: 7.2±0.7; p<0.05). 
Significantly, dietary sodium-evoked suppression of the peak natriuresis to HCTZ was 
not observed in NE infused animals (Figure 14; Peak ΔUNaV to i.v. HCTZ [µeq/min] s.c. 
NE+NS: 11.1±1 vs. NE+HS: 10.8±0.4). Both saline and NE infusion in Sprague-Dawley 
rats had no impact on plasma sodium content irrespective of dietary sodium intake 
(Plasma Na+ [mmol/L] s.c. saline+NS: 138±2; s.c. saline+HS: 138±1; s.c. NE+NS: 
137±1; s.c. NE+HS: 136±2). Additionally, plasma renin activity (PRA) and plasma NE 
content was determined in naïve and NE infused Sprague-Dawley rats. Naïve rats showed 
a significant decrease in PRA and plasma NE content when challenged with a HS diet 
(Table 4). Rats receiving a NE infusion maintained on either a NS or HS diet showed a 
significant decrease in PRA when compared to naïve Sprague-Dawley rats on NS (Table 
4). In NE infused rats, we observed increased plasma NE levels in animals maintained on 
both NS and HS compared to naïve Sprague-Dawley rats (Table 4). 
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Figure 12: Peak change in mean arterial pressure in response to hexamethonium in naïve Sprague-Dawley rats 
and Sprague-Dawley rats receiving a s.c. saline or norepinephrine infusion. Peak change in mean arterial 
pressure (MAP; mmHg) in response to an i.v. bolus of hexamethonium (30mg/kg) in naïve conscious male 
Sprague-Dawley rats and in Sprague-Dawley rats receiving either a s.c. isotonic saline infusion or a s.c. 
norepinephrine (NE; 600ng/min) infusion maintained on either a normal (0.6% NaCl) or high salt (8% 
NaCl) diet for 14-days. Data are mean ± SEM (N=6/group). τp<0.05 vs. respective naive group value; 
ϕp<0.05 vs. respective saline group value. 
 
 
 	
Figure 13: Peak natriuresis in response to an i.v. infusion of amiloride naïve Sprague-Dawley rats and Sprague-
Dawley rats receiving a s.c. saline or norepinephrine infusion. Peak natriuresis (UNaV; µeq/min) in response to an 
i.v. infusion of amiloride (2mg/kg) in naïve conscious male Sprague-Dawley rats and in Sprague-Dawley rats receiving 
either a s.c. isotonic saline infusion or a s.c. norepinephrine (NE; 600ng/min) infusion maintained on either a normal 
(0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% 
NaCl group value. 
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Figure 14: Peak natriuresis in response to an i.v. infusion of amiloride in combination with hydrochlorothiazide 
in naïve Sprague-Dawley rats and Sprague-Dawley rats receiving a s.c. saline or norepinephrine infusion. Peak 
natriuresis (UNaV; µeq/min) in response to an i.v. infusion of amiloride (2mg/kg) in combination with 
hydrochlorothiazide (HCTZ; 2mg/kg), in naïve conscious male Sprague-Dawley rats and in Sprague-
Dawley rats receiving either a s.c. isotonic saline infusion or a s.c. norepinephrine (NE; 600ng/min) 
infusion maintained on either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean 
± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective naive group 
value; ϕp<0.05 vs. respective saline group value. 
 
 
 
Treatment PRA expressed as AngI 
generation (ng/ml/h) 
Plasma NE (nmol/L) 
Naïve 0.6% NaCl 5.1±0.3 61.6±4.5 
Naïve 8% NaCl 1.8±0.3* 36.7±4.2* 
NE 0.6% NaCl 1.3±0.2* 104.3±8.2*τ 
NE 8% NaCl 0.8±0.1* 118.4±7.3*τ 
Table 4: Estimated plasma renin activity and plasma NE content listed for naïve Sprague-Dawley rats and 
Sprague-Dawley rats receiving a s.c. infusion of norepinephrine. Estimated plasma renin activity (PRA) 
expressed as angiotensin I (AngI) generation as ng/ml/h and plasma NE content (nmol/L) listed for naïve 
Sprague-Dawley rats and Sprague-Dawley rats receiving a s.c. infusion of 600ng/min NE maintained on a 
normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=5/group). *p<0.05 
vs. naïve + 0.6% NaCl group value; τp<0.05 vs. naïve + 8% NaCl group value. 
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Norepinephrine infusion prevents dietary sodium-evoked suppression of NCC expression 
in Sprague-Dawley rats 
A PCR array was completed examining mRNA expression of a variety of sodium 
transporters (Table 1) in kidney tissue from s.c. saline and NE infused Sprague-Dawley 
rats used in figures 10-14. Rats receiving a s.c. saline infusion demonstrated dietary 
sodium-evoked suppression of NCC mRNA expression (Figure 15; p<0.05). Further, rats 
receiving the s.c. NE infusion did not show dietary sodium-evoked suppression of NCC 
mRNA expression (Figure 15). Animals receiving a s.c. saline infusion demonstrated 
dietary sodium-evoked decreases in βENaC mRNA expression (Figure 15; p<0.05). 
βENaC mRNA expression was significantly decreased in rats receiving a s.c. NE infusion 
for rats maintained on a normal salt diet when compared against rats receiving a s.c. 
saline infusion on normal salt (Figure 15; p<0.05). The s.c. NE infusion showed dietary 
sodium-evoked suppression of βENaC mRNA expression (Figure 15; p<0.05). For all 
other sodium transporters analyzed in the PCR array, no significant differences in mRNA 
expression was observed between any diet or treatment groups.  
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Figure 15: Renal sodium transporter mRNA levels in male Sprague-Dawley rats receiving either a s.c. isotonic 
saline or a s.c. norepinephrine infusion. Renal sodium transporter mRNA levels in male Sprague-Dawley rats 
receiving either a s.c. isotonic saline infusion or a s.c. norepinephrine (NE; 600ng/min) infusion maintained 
on either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean ± SEM 
(N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; ϕp<0.05 vs. respective saline 0.6% NaCl 
group value; τp<0.05 vs. respective saline 8% NaCl group value.  
 
NCC protein expression was determined for saline and NE infused rats for which 
physiological data is presented in figures 10-14. When challenged with HS for 14-days, 
normotensive saline treated animals showed dietary sodium-evoked suppression of renal 
NCC expression (Figures 16A, 16B), mirroring our physiology results. Chronic NE 
infusion did not significantly change NCC expression in animals maintained on a NS 
intake. In contrast to the result obtained in saline infused rats, animals receiving a NE 
infusion and maintained on HS failed to show a dietary sodium-evoked decrease in NCC 
expression (Figures 16A, 16B).  
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Figure 16: Renal NCC protein expression in kidney cortex tissue from Sprague-Dawley rats receiving a s.c. 
saline or s.c. norepinephrine infusion. (A) Representative immunoblots illustrating NCC expression in kidney 
cortex tissue and (B) Quantification of renal NCC expression in male Sprague-Dawley rats receiving either 
a s.c. saline or norepinephrine (NE; 600ng/min) infusion maintained for 14-days on a normal (0.6% NaCl) 
or high salt (8% NaCl) diet. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group 
value.   
 
Chronic NCC antagonism abolishes the salt-sensitive component of norepinephrine-
evoked hypertension in Sprague-Dawley rats 
Following our observation that a NE infusion prevented the sodium-evoked suppression 
of NCC function and expression (Figures 14, 16), we elected to chronically antagonize 
the NCC with HCTZ during s.c. NE infusion. A s.c. DMSO/saline vehicle infusion did 
not alter the salt-resistant phenotype of the Sprague-Dawley rat (Figures 17, 18) or the 
sodium-evoked suppression of the peak natriuresis to HCTZ (Figure 20). The co-infusion 
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of HCTZ with NE did not prevent the development of hypertension in animals 
maintained on a NS diet. In these animals the magnitude of hypertension was comparable 
to that observed in NE infused animals (Figure 17; MAP [mmHg] s.c. NE+NS: 151±3; 
s.c. NE & HCTZ+NS: 145±1). Significantly, the co-infusion of NE with HCTZ during a 
HS intake abolished the salt-sensitive component of NE-evoked hypertension, reducing 
the MAP to a level similar to that observed in NE treated animals maintained on NS 
(Figure 18). When plotted as an index of the salt-sensitivity of blood pressure, co-
infusion of NE & HCTZ significantly increased the slope of the chronic pressure-
natriuresis relationship versus animals receiving a s.c. infusion of NE alone (Figure 18), 
indicating a reduction in the salt-sensitivity of blood pressure.  
 
 
Figure 17: Mean arterial pressure for Sprague-Dawley rats receiving s.c. DMSO/saline, s.c. norepinephrine, or 
s.c norepinephrine with hydrochlorothiazide infusion. Mean arterial pressure (MAP; mmHg) in conscious 
male Sprague-Dawley rats receiving either a s.c. 50:50 DMSO/isotonic vehicle saline infusion, a s.c. 
norepinephrine (NE; 600ng/min) infusion or a s.c. NE (600ng/min) and hydrochlorothiazide (HCTZ; 
4mg/kg/day) infusion maintained on either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. 
Data are mean ± SEM (N=6/group) *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective 
DMSO/saline group value; ϕp<0.05 vs. respective NE group value. Data for s.c. NE infusion reproduced 
from figure 10 for clarity. 
 
Figure 4B 
Figure 4A 
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Figure 18: Index of salt-sensitivity for Sprague-Dawley rats receiving a s.c. DMSO/saline, s.c. 
norepinephrine, and s.c norepinephrine with hydrochlorothiazide infusions. Index of salt-sensitivity 
determined from 24-h sodium excretion and baseline MAP in conscious male Sprague-Dawley rats 
receiving either a s.c. 50:50 DMSO/isotonic vehicle saline infusion, a s.c. norepinephrine (NE; 600ng/min) 
infusion or a s.c. NE (600ng/min) and hydrochlorothiazide (HCTZ; 4mg/kg/day) infusion maintained on 
either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=6/group).  
 
The NE & HCTZ co-infusion did not prevent dietary sodium-evoked suppression 
of the peak natriuretic response to amiloride, an ENaC inhibitor (Figure 19). 
Demonstrating the efficacy of our chronic antagonism of the NCC, an acute i.v. infusion 
of HCTZ, an NCC antagonist, did not evoke natriuresis in animals receiving a s.c. NE & 
HCTZ co-infusion (Figure 20). Additionally, DMSO/saline vehicle or co-infusion of NE 
& HCTZ did not significantly alter 24-h sodium or water balance regardless of salt intake 
(Table 2). When estimated plasma (EPV) and blood volume (EBV) was calculated in 
these groups of animals, we observed no significant effect of increased dietary sodium 
intake or drug infusion on EPV or EBV (Table 5). 
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Figure 19: Peak natriuresis in response to an i.v. infusion of amiloride for Sprague-Dawley rats receiving a s.c. 
DMSO/saline, norepinephrine, or s.c norepinephrine with hydrochlorothiazide infusion. Peak natriuresis 
(UNaV; µeq/min) in response to an i.v. amiloride infusion  (2mg/kg) in conscious male Sprague-Dawley 
rats receiving either a s.c. 50:50 DMSO/isotonic saline vehicle infusion, a s.c. norepinephrine (NE; 
600ng/min) infusion or a s.c. NE (600 ng/min) and HCTZ (4 mg/kg/day) infusion maintained on either a 
normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=6/group). *p<0.05 
vs. respective 0.6% NaCl group value. Data for s.c. NE infusion reproduced from figure 13 for clarity. 
 
 
Figure 20: Peak natriuresis in response to an i.v. infusion of amiloride in combination with hydrochlorothiazide 
in Sprague-Dawley rats receiving a s.c. DMSO/saline, norepinephrine, or s.c norepinephrine with 
hydrochlorothiazide infusion. Peak natriuresis (UNaV; µeq/min) in response to an i.v. infusion of  amiloride 
(2mg/kg) in combination with hydrochlorothiazide (HCTZ; 2mg/kg), in conscious male Sprague-Dawley 
rats receiving either a s.c. 50:50 DMSO/isotonic saline vehicle infusion, a s.c. norepinephrine (NE; 
600ng/min) infusion or a s.c. NE (600 ng/min) and HCTZ (4 mg/kg/day) infusion maintained on either a 
normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=6/group). *p<0.05 
vs. respective 0.6% NaCl group value; τp<0.05 vs. respective DMSO/Saline group value; ϕp<0.05 vs. 
respective NE group value. Data for s.c. NE infusion reproduced from figure 14 for clarity. 
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Treatment EPV (ml) EBV (ml) 
DMSO/Saline 0.6% NaCl 12.4±0.3 22.1±0.4 
DMSO/Saline 8% NaCl 11.9±0.4 21.2±0.4 
NE & HCTZ 0.6% NaCl 11.8±0.3 21.2±0.3 
NE & HCTZ 8% NaCl 12.5±0.3 22.4±0.6 
Table 5: Estimated plasma volume and estimated blood volume for Sprague-Dawley rats receiving a s.c. 
DMSO/saline or a s.c. co-infusion of NE and HCTZ infusion. Estimated plasma volume (EPV) and estimated 
blood volume (EBV) in milliliters (ml) listed for Sprague-Dawley rats receiving a s.c. infusion of a 50:50 
solution of DMSO and isotonic saline or 600ng/min NE in combination with 4mg/kg/day 
hydrochlorothiazide (HCTZ), maintained on either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 
14-days. Data are mean ± SEM (N=6/group).  
 
 
 
 
Chronic AT1 receptor antagonism prevents norepinephrine-evoked hypertension, but 
does not restore sodium-evoked NCC impairment in Sprague-Dawley rats 
To determine the contribution of the RAS to impaired NCC function during NE infusion 
and HS intake, we co-infused Sprague-Dawley rats with NE and losartan, an AT1 
receptor antagonist. A s.c. infusion of NE & losartan significantly reduced baseline MAP 
for animals on a NS diet when compared to NE infusion alone (Figure 21; MAP[mmHg] 
s.c. NE+NS: 151±3 vs. s.c. NE & losartan+NS: 135±3; p<0.05). A NE & losartan co-
infusion also prevented the development of salt-sensitivity (Figure 21; MAP[mmHg] s.c. 
NE+HS: 172±4 vs. s.c. NE & losartan+HS: 138±3; p<0.05). Dietary sodium-evoked 
suppression of peak natriuresis to amiloride, an ENaC inhibitor, was observed in animals 
receiving a s.c. infusion of NE & losartan (Figure 22; Peak ΔUNaV to i.v. amiloride 
[µeq/min] s.c. NE & losartan+NS: 7.8±1 vs. s.c. NE & losartan+HS: 4.15±1; p<0.05). 
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However, dietary sodium-evoked suppression of natriuresis to HCTZ, a NCC antagonist, 
was not observed following NE & losartan co-infusion (Figure 23; Peak ΔUNaV to i.v. 
HCTZ [µeq/min] s.c. NE & losartan+NS: 11.5±2;. s.c. NE & losartan+HS: 11.3±2).  
 
 
 
Figure 21: Mean arterial pressure in Sprague-Dawley rats receiving either a s.c. infusion of 50:50 
DMSO/isotonic saline vehicle, NE or a NE and losartan. Mean arterial pressure (MAP; mmHg) in conscious 
male Sprague-Dawley rats receiving either a s.c. 50:50 DMSO/isotonic saline vehicle infusion, a s.c. 
norepinephrine (NE; 600ng/min) infusion or a s.c. NE (600 ng/min) and losartan (3mg/kg/day) infusion 
maintained on either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean ± SEM 
(N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective DMSO/Saline group 
value; ϕp<0.05 vs. respective NE group value. Data for s.c. DMSO/saline and s.c. NE infusion reproduced 
from figures 17 for clarity. 
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Figure 22: Peak natriuresis in response to an i.v. infusion of amiloride in Sprague-Dawley rats receiving a s.c. 
infusion of DMSO/saline, norepinephrine, or norepinephrine with losartan. Peak natriuresis (UNaV; µeq/min) 
in response to an i.v. amiloride infusion  (2mg/kg), in conscious male Sprague-Dawley rats receiving either 
a s.c. 50:50 DMSO/isotonic saline vehicle infusion, a s.c. norepinephrine (NE; 600ng/min) infusion or a 
s.c. NE (600 ng/min) and losartan (3mg/kg/day) infusion maintained on either a normal (0.6% NaCl) or 
high salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% 
NaCl group value. Data for s.c. DMSO/saline and s.c. NE infusion reproduced from figure 19 for clarity. 
 
 
Figure 23: Peak natriuresis in response to an i.v. infusion of amiloride in combination with  
hydrochlorothiazide in Sprague-Dawley rats receiving a s.c. infusion of DMSO/saline, norepinephrine, or 
norepinephrine with losartan. Peak natriuresis (UNaV; µeq/min) in response to an i.v. infusion of amiloride 
(2mg/kg) in combination with hydrochlorothiazide (HCTZ; 2mg/kg), in conscious male Sprague-Dawley 
rats receiving either a s.c. 50:50 DMSO/isotonic saline vehicle infusion, a s.c. norepinephrine (NE; 
600ng/min) infusion or a s.c. NE (600 ng/min) and losartan (3mg/kg/day) infusion maintained on either a 
normal (0.6% NaCl) or high salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=6/group). *p<0.05 
vs. respective 0.6% NaCl group value; τp<0.05 vs. respective DMSO/Saline group value. Data for s.c. 
DMSO/saline and s.c. NE infusion reproduced from figure 20 for clarity. 
 
		 73 
A 21-day high salt diet evokes the development of hypertension in Dahl salt-sensitive rats 
When naïve DSR animals were placed on a 21-day normal or high salt diet, we observed 
no change in baseline MAP (Figure 24; MAP [mmHg] DSR+NS: 125±2; DSR+HS: 
129±3). In contrast, DSS rats showed a significant increase in MAP when maintained on 
a high salt diet (Figure 24; MAP [mmHg] DSS+HS: 166±6; p<0.05). Naïve DSR showed 
dietary sodium-evoked suppression of plasma NE levels (Figure 25; plasma NE [nmol/L] 
DSR+NS: 48±6; DSR+HS: 29±4). However, DSS animals show a significant increase in 
plasma NE levels when maintained on a high salt diet when compared to DSS animals 
maintained a normal salt diet (Figure 25; plasma NE [nmol/L] DSS+NS: 47±6; DSS+HS: 
76±4; p<0.05). 
 
 
Figure 24: Mean arterial pressure in naïve male Dahl salt-resistant and Dahl salt-sensitive rats. Mean arterial 
pressure (MAP; mmHg) in naïve conscious male Dahl salt-resistant and Dahl salt-sensitive rats maintained 
on either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 21-days. Data are mean ± SEM 
(N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; ϕp<0.05 vs. DSR + 8% NaCl group value. 
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Figure 25: Plasma norepinephrine concentrations in naïve male Dahl salt-resistant and Dahl salt-sensitive rats. 
Plasma norepinephrine (NE) concentrations (nmol/L) in naïve male Dahl salt-resistant and Dahl salt-sensitive rats 
maintained on either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 21-days. Data are mean ± SEM 
(N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; ϕp<0.05 vs. DSR + 8% NaCl group value. 
 
Dietary sodium-evoked suppression of NCC activity is prevented in the Dahl salt-
sensitive rat  
DSR rats demonstrated dietary sodium-evoked suppression of the peak natriuresis to 
amiloride, an ENaC inhibitor (Figure 26; Peak ΔUNaV to i.v. amiloride [µeq/min] 
DSR+NS: 8.8±0.6; DSR+HS: 6.5±0.5; p<0.05). A dietary sodium induced decrease of 
the peak natriuresis to amiloride was observed in the DSS rat as well (Figure 26; Peak 
ΔUNaV to i.v. amiloride [µeq/min] DSS+NS: 8.9±0.4; DSS+HS: 6.3±0.7; p<0.05). DSR 
rats showed dietary sodium-evoked suppression of the peak natriuresis to HCTZ, a NCC 
antagonist (Figure 27; Peak	 ΔUNaV to i.v. HCTZ [µeq/min] DSR+NS: 10.5±1.5; 
DSR+HS: 8.5±1.2; p<0.05). Significantly, dietary sodium-evoked suppression of the 
peak natriuresis to HCTZ was not observed in the DSS animals (Figure 27; Peak	 ΔUNaV 
to i.v. HCTZ [µeq/min] DSS+NS: 8.89±1.6; DSS+HS:  11.5±2). 
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Figure 26: Peak natriuresis in response to an i.v. infusion of amiloride in naïve Dahl salt-resistant and Dahl salt-
sensitive rats. Peak natriuresis (UNaV; µeq/µl) in response to an i.v. infusion of amiloride (2mg/kg) in naïve conscious 
Dahl salt-resistant and Dahl salt-sensitive rats maintained on a normal (0.6% NaCl) or high salt (8% NaCl) diet for 21-
days. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value. 
 
 
 
 
 
Figure 27: Peak natriuresis in response to an i.v. infusion of amiloride in combination with hydrochlorothiazide 
in conscious Dahl salt-resistant and Dahl salt-sensitive rats. Peak natriuresis (UNaV; µeq/µl) in response to an i.v. 
infusion of amiloride (2mg/kg) in combination with hydrochlorothiazide (HCTZ; 2mg/kg), in naïve conscious Dahl 
salt-resistant and Dahl salt-sensitive rats maintained on a normal (0.6% NaCl) or high salt (8% NaCl) diet for 21-days. 
Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value. 
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Dietary sodium-evoked suppression of NCC expression is prevented in the Dahl salt-
sensitive rat 
Following the completion of all acute experiments, kidney cortex tissue was harvested 
from the same DSR and DSS rats for which physiological data is presented in figures 24, 
26, & 27 for analysis of the expression of the NCC. When challenged with a high salt 
intake for 21-days, DSR animals, which remain normotensive and salt-resistant (Figure 
24) and exhibit reduced NCC activity (Figure 27), demonstrated dietary sodium-evoked 
suppression of NCC expression, similar to results observed in our saline infused Sprague-
Dawley rats (Figure 28A, 28B). No sodium-evoked suppression of NCC expression was 
observed in DSS animals maintained on a high salt diet for 21-days (Figure 28A, 28B). 
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Figure 28: Renal NCC protein expression in kidney cortex tissue from Dahl salt-resistant and Dahl salt-sensitive 
rats. (A) Representative immunoblots illustrating sodium chloride cotransporter (NCC) expression in kidney cortex 
tissue and (B) Quantification of renal NCC expression in male Dahl salt-resistant and Dahl salt-sensitive rats 
maintained for 21-days on a normal (0.6% NaCl) or high salt (8% NaCl) diet. Data are mean ± SEM (N=6/group). 
*p<0.05 vs. respective 0.6% NaCl group value τp<0.05 vs. DSR + 8% NaCl group value.  	
Discussion 
These studies demonstrate that excess plasma NE levels in combination with a 
high dietary salt intake results in the development of salt-sensitive hypertension in the 
Sprague-Dawley rat, which exhibits a salt-resistant phenotype (Wainford et al., 2015). 
We demonstrate that in our animal model, a s.c. NE infusion alone evoked hypertension, 
the magnitude of which was exacerbated when NE infused rats were placed on a HS diet, 
demonstrating the development of the salt-sensitivity of blood pressure. The 
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aforementioned results in our NE infusion model, mirror those found in the genetic model 
of salt-sensitivity, the DSS rat. Our study shows that naïve DSS rats maintained on a HS 
diet for 21-days develop hypertension, while naïve DSR rats maintained on a HS diet 
remain normotensive, like the Sprague-Dawley rat. In salt-sensitive animals, increased 
plasma NE content prevented dietary sodium-evoked suppression of NCC, but not ENaC 
activity, suggesting a role for the NCC in the observed development of salt-sensitive 
hypertension. In agreement with a prior report in rats (Sonalker et al., 2008), and in 
contrast to studies in mice (Mu et al., 2011; Terker et al., 2014), NE infusion alone did 
not increase NCC protein expression in animals maintained on a NS diet. Significantly, 
dietary sodium-evoked suppression of NCC expression was abolished in animals with 
elevated plasma NE levels and an elevated salt intake, a response correlating with 
impaired NCC activity and salt-sensitivity. Confirming a direct role of the NCC in the 
development of NE-evoked salt-sensitive hypertension, chronic NCC antagonism with 
HCTZ abolished the salt-sensitive component of NE-mediated hypertension. Chronic 
antagonism of AT1 receptors with losartan was unable to restore NCC function, however 
AT1 receptor blockade was able to significantly reduce NE-evoked increases in MAP in 
animals maintained on either a NS or HS diet. Collectively, these data show a critical 
interaction between dietary salt intake and circulating levels of NE that prevents the 
downregulation of NCC activity and expression to evoke the development of salt-
sensitive hypertension in the Sprague-Dawley rat.     
Our results demonstrating NE-mediated hypertension are substantiated by the 
findings of Sonalker et al. (2008), in which the same chronic infusion of NE (600ng/min) 
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resulted in the development of hypertension in Sprague-Dawley rats maintained on a NS 
diet. We demonstrate that salt-resistant phenotypes (naïve SD & DSR) show an expected 
decrease in plasma NE concentration when challenged with a high salt intake (Wainford 
et al.). Extending the studies of Sonalker et al. (2008), we show that both of our salt-
sensitive phenotypes (NE infusion SD & DSS) show an increase in plasma NE 
concentrations when challenged with a high salt diet, each animal model increasing 
plasma NE concentrations by approximately 25nmol/L. This data validates our model of 
NE infusion as an animal model of salt-sensitive hypertension showing striking 
similarities in physiological responses between our NE infusion animal model and the 
genetic DSS rat. The development of salt-sensitivity during chronic NE infusion is 
evidenced by a significant increase in MAP during HS intake and a rightward shift of the 
chronic pressure-natriuresis relationship, reflecting the long-term resetting of the chronic 
pressure-natriuresis relationship to a new higher set-point blood pressure, matching 
results in the DSS (Beard and Mescam, 2012). Notably, EPV and EBV was not impacted 
by 14-days of dietary sodium intake or NE infusion in these studies conducted in 
Sprague-Dawley rats. These data suggest that the observed increases in MAP after the 
14-day protocol are not dependent on a long-term increase in blood or plasma volume. 
However, these studies do not rule out the possibility that transient increases in EPV 
and/or EBV play a role in the induction and/or development of NE-evoked hypertension. 
To further investigate the mechanisms contributing to elevated MAP in these NE infused 
animals, we assessed the impact of hexamethonium-mediated ganglionic blockade on the 
peak depressor response. In these studies we observed no difference in the peak depressor 
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response following ganglionic blockade between NE infused animals maintained on 
either a NS or HS diet. In NE infused animals we observed a significantly greater drop in 
blood pressure versus that observed in saline infused rats, indicating that increased 
vasoconstriction contributes to the development of NE-evoked hypertension. As observed 
in control (naïve and saline infused) animals, a HS intake did not significantly affect the 
depressor response to ganglionic blockade in NE infused rats, suggesting that there is no 
impact of sodium intake to increase sympathetic outflow in NE infused animals. As such, 
we believe the difference in basal blood pressure observed following ganglionic blockade 
between NE infused animals on NS versus HS is reflective of the baseline blood pressure 
differences observed prior to hexamethonium administration versus intrinsic differences 
in sympathetic activity. The mechanism underlying our observation of an enhanced 
depressor response post-ganglionic blockade in NE infused animals remains to be 
determined and highlights the complexity of interpreting the results of ganglionic 
blockade in the setting of chronic hypertension. In the current experimental paradigm, it 
would be anticipated that NE infusion would not activate the SNS and may evoke 
reduced sympathetic outflow. Therefore, we speculate that vascular hypertrophy, as has 
been reported following AngII-evoked persistent increases in blood pressure (Moretti et 
al., 2009), may underlie the enhanced response to ganglionic blockade observed in these 
studies.  
  Previous studies have shown that the DSS rat fails to downregulate certain ENaC 
subunits during high salt intake (Weinberger et al., 2001; Amin et al., 2011), so we 
elected to examine the activity of the ENaC in hypertensive NE infused Sprague-Dawley 
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rats. Our physiological data, generated in conscious animals, indicates that the 
combination of a NE infusion and a HS intake does not prevent sodium-evoked 
downregulation of the activity of the ENaC. These data suggest that in the Sprague-
Dawley rat failure to suppress ENaC activity (assessed via peak natriuresis to amiloride) 
is not involved in the development of NE-evoked salt-sensitive hypertension, a finding in 
contrast to the ENaC dysregulation observed in the Dahl salt-sensitive rat phenotype (Aoi 
et al., 2006; Amin et al., 2011). Interestingly, mRNA expression of the βENaC subunit 
was decreased in rats receiving the s.c. NE infusion, however, this decrease in βENaC 
mRNA matched the physiological response to an acute challenge with amiloride (ENaC 
inhibitor). The differences between the previously reported impact of salt intake on ENaC 
in the Dahl salt-sensitive rat and our current report of a lack of effect during chronic NE 
infusion in the Sprague-Dawley rat may be attributed to 1) the genetic differences 
between the Dahl salt-sensitive and Sprague-Dawley rat and 2) the multifactorial nature 
of Dahl salt-sensitive hypertension featuring aberrations in central, vascular, cardiac, 
hormonal and renal mechanisms. We elected not to determine renal ENaC subunit 
expression or to examine the impact of chronic ENaC inhibition on the development of 
NE-evoked salt-sensitivity of blood pressure in the Sprague-Dawley rat for the following 
reasons: 1) we observed no significant physiological differences in our NE infusion 
model when compared to control animals in terms of the response of ENaC function 
during HS intake and 2) a prior report stating that chronic ENaC inhibition did not 
prevent the development of NE-evoked salt-sensitive hypertension in mice (Mu et al., 
2011). 
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Therefore, our next series of studies focused on the role of the NCC in the 
development of the salt-sensitivity of blood pressure. Our initial data demonstrate that on 
a NS intake, the infusion of NE, which evokes hypertension, does not alter the activity 
(assessed as peak natriuresis to HCTZ) or expression, both protein and mRNA level 
(assessed via immunoblotting and PCR array), of the NCC. These data support the prior 
findings that chronic NE exposure does not alter NCC expression in the Sprague-Dawley 
rat (Sonalker et al., 2008) or in mice (Uchida et al., 2012). However, these data are in 
direct contrast to data generated in mice reporting that total expression and 
phosphorylation of NCC is increased by both chronic (Mu et al., 2011) and acute 
increases in NE (Terker et al., 2014). We believe the discrepancy between our data and 
the data of other laboratories concerning the impact of NE on the expression of the NCC 
may reflect, in part, a potential species difference in the mechanistic effects of NE on 
NCC protein and mRNA expression. In support of previous studies demonstrating that a 
HS intake evokes downregulation of the NCC (Yang et al., 2008), we observed the 
downregulation of NCC activity (assessed as peak natriuresis to HCTZ) and protein and 
mRNA expression (assessed via immunoblotting and PCR array) in salt-resistant 
phenotypes challenged with a HS diet. In contrast, animals that received a NE infusion 
and a HS diet failed to downregulate the activity of the NCC during HS intake, 
suggesting a role of impaired NCC function in the pathophysiology of sympathetically-
mediated salt-sensitive hypertension, mirroring the findings in the DSS rat. These data 
suggest, that in the Sprague-Dawley and DSS rat, contrary to prior observations in mice, 
the NCC evokes the development of salt-sensitive hypertension through a failure to be 
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downregulated in response to an elevated salt intake versus a direct action of elevated NE 
levels to increase activity and expression of the NCC. We acknowledge that these studies 
cannot exclude a potential direct effect of increased blood pressure, occurring 
independently of an interaction between salt and NE, that is influencing the activity of the 
NCC. To confirm a direct role of the failure to downregulate the activity of the NCC in 
response to HS in the development of salt-sensitivity, we conducted additional studies in 
which the NCC was chronically antagonized by co-infusing Sprague-Dawley rats with 
NE & HCTZ for 14-days. The chronic antagonism of the NCC abolished the salt-
sensitive component of NE-mediated hypertension and significantly attenuated the 
reduction in the slope of the chronic pressure-natriuresis relationship. These data provide 
strong evidence that the NCC plays a key role in the sympathetically-mediated regulation 
of the kidney to drive the development of salt-sensitive hypertension.  
In order to determine the potential contribution of the RAAS in our NE infusion 
animal model of salt-sensitive hypertension, we co-infused Sprague-Dawley rats with NE 
& losartan, an AT1 receptor antagonist. The co-infusion of NE & losartan significantly 
decreased MAP in animals maintained on both NS and HS diets versus animals receiving 
a NE infusion. Our data, indicating the suppression of PRA activity during NE infusion, 
raises the paradoxical issue of how AT1 antagonism reduces blood pressure in the setting 
of low renin/AngII levels. These data are in line with prior studies that have demonstrated 
the efficacy of AT1 antagonism in multiple models of “low renin” hypertension and we 
believe that further studies, beyond the scope of the current aim, are required to 
determine the mechanism underlying the apparent counter-intuitive abolishment of 
		 84 
hypertension during NE infusion by AT1 antagonism. These data are similar to those 
conducted in the Dahl salt-sensitive rats, where an intracerebroventricular infusion of 
losartan blunts salt-induced increases in blood pressure (Huang and Leenen, 1998; 
Yamada et al., 2011). Additionally, Dahl salt-sensitive rats show increased SNS activity, 
an effect that can be attenuated in Dahl salt-sensitive rats on a high salt diet when treated 
with losartan (Huang and Leenen, 1998). The effectiveness of losartan to decrease the 
blood pressure and the pressor response in response to increased dietary salt intake in 
Dahl salt-sensitive rats suggests that AngII contributes to decreases in sympathoinhibition 
and increased sympathoexcitation in the development of salt-sensitive hypertension 
(Huang and Leenen, 1998, 1999; Gabor and Leenen, 2011; Yamada et al., 2011). 
However, when Sprague-Dawley rats receiving a NE & losartan co-infusion were acutely 
challenged with HCTZ, dietary sodium-evoked suppression of NCC activity was not 
observed. These data indicate that the failure of the NCC to be downregulated in response 
to increased dietary salt intake during NE infusion occurs independently of the actions of 
the RAAS. The effect of a losartan infusion on NCC activity in a Dahl salt-sensitive rat 
has yet to be determined. Previous studies have reported that AngII has direct effects on 
the abundance, activity, and regulation of the NCC (San-Cristobal et al., 2008; van der 
Lubbe et al., 2012; van der Lubbe et al., 2013). However, a recent study utilizing AngII 
receptor type 1a (AT1a) knockout mice reported that NE-induced effects on NCC 
expression and phosphorylation are not AT1a dependent (Terker et al., 2014). These data 
support our results, which also indicate that the effects of NE on the NCC are 
independent of AngIl. Further, the ability of losartan to prevent NE-evoked hypertension, 
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but not restore HS stimulated downregulation of NCC activity, suggests that NCC 
activity is regulated by NE via a mechanism that is independent of increased blood 
pressure. Low dose AngII infusion results in hyponatremia in Sprague-Dawley rats 
(Nguyen et al., 2013), in the current studies plasma Na+ levels in NE infused rats 
remained within the normal range (135-145mmol/L) suggesting that in our NE infusion 
model we are not evoking systemic increases in AngII, at least not to a level that evokes 
hyponatremia, a hypothesis supported by the NE-evoked suppression of PRA. Our data 
on the suppression of PRA activity during NE infusion and HS intake substantiates a lack 
of activation of the RAS in our experimental paradigm. The actions of NE to impact the 
NCC have been suggested to be dependent on the actions of the β-adrenergic receptor 
(βAR) (Mu et al., 2011; Terker et al., 2014). Mu et al. (2011) reported that stimulation of 
the β2AR increased NCC activity and sodium retention during the development of salt-
sensitive hypertension in mice. However, a recent study has suggested that the β1AR is 
primarily responsible for mediating the effects of NE on the NCC due to the fact that 
β1ARs are highly enriched in the DCT (Terker et al., 2014). Currently, the β-adrenergic 
receptor subtype responsible for mediating the effects of NE on the NCC remains to be 
definitively established, as does the impact of dietary salt intake and NE on the renal 
expression of β-adrenergic receptors. 
  
Overall Conclusion for Aim 1 
In conclusion, our results highlight the importance of the interaction between NE 
and salt, and not just NE alone, to influence the function and expression of the NCC 
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during the pathophysiology of salt-sensitive hypertension. Although we believe our 
results are based on an action of elevated levels of NE directly on NCC regulation, we 
cannot exclude a direct effect of blood pressure preventing the downregulation of the 
NCC independently of an interaction between salt and NE. In our Sprague-Dawley rat 
studies, NE is being increased systemically, not just locally at the level of the kidney, as 
such, we are unable to rule out extra-renal effects and acknowledge that circulating NE 
may not penetrate the kidney to the same extent as local release of NE from sympathetic 
nerve terminals. However, given that in salt-sensitive human and rat (DSS) subjects there 
is global sympathoexcitation (Campese et al., 1982; Gill et al., 1988), and that our model 
of s.c. NE infusion is directly comparable with prior studies published in rats (Sonalker et 
al., 2008) and mice (Mu et al., 2011; Uchida et al., 2012), we believe we have developed 
a suitable model to investigate the actions of both salt and NE on sodium homeostasis 
and blood pressure regulation. Despite the clinical use and well-defined transporter 
specific diuretic actions of both HCTZ and amiloride, we recognize this series of studies 
relies on their selectivity and that off-target effects must be considered when interpreting 
the results. Due to the short-term infusion of amiloride and HCTZ during the acute 
experimental protocol, we speculate the off-targets actions of these drugs are likely 
limited. In regard to the 14-day infusion of HCTZ or losartan, we observed no overt signs 
of potential hypokalemia or hyperkalemia, respectively, that could have impacted our 
studies. Our data suggest there is a crucial impact of NE in preventing dietary sodium-
evoked suppression of NCC activity and expression and support a key role of the NCC in 
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the pathophysiology of salt-sensitive hypertension as demonstrated in both of our animal 
models of salt-sensitivity, the NE infusion model and the DSS rat.  
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CHAPTER FOUR: The development of salt-sensitive hypertension is evoked by the 
actions of norepinephrine on a renal α-adrenergic receptor-gated WNK1-OxSR1 
signal transduction pathway that drives NCC-mediated sodium reabsorption  	
Rationale 	
Salt-sensitive hypertension has been associated with increased SNS activity and 
increased sodium retention (Fujita et al.; Campese et al.; Gill et al.; Fujita and Sato). We 
demonstrate in Aim 1 that animals with increased plasma NE levels develop hypertension 
and show a failure for the NCC to be appropriately downregulated following a high salt 
challenge (Walsh et al., 2016). These studies highlight an interaction between dietary salt 
intake and increased NE levels on the activity and expression of the NCC (Walsh et al., 
2016). To further examine the role of the NCC in the development of salt-sensitive 
hypertension, we assessed the regulatory network of the NCC. Several studies have 
elucidated the intracellular signaling cascade that regulates NCC activity, which consists 
of a multi-kinase network including WNK (with-no-lysine), SPAK (STE20/SPS1-related 
Proline-Alanine-rich kinase), and OxSR1 (oxidative stress response-1). These kinases 
have the ability to phosphorylate and activate the NCC. More specifically, the WNK4 
isoform has been suggested to activate the NCC in salt-induced hypertension (Mu et al., 
2011). A recent study showed that WNK1 has the ability to stimulate NCC activity and 
expression in a SPAK-dependent manner, demonstrating the importance of WNK1 in 
NCC regulation (Chavez-Canales et al., 2014). Additionally, SPAK and OxSR1 have 
been shown to have complementary, yet distinct, roles in NCC regulation. During basal 
conditions, SPAK appears to be more dominant in activating the NCC, while OxSR1 is 
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predominant in the kidney during periods of acute adrenergic stimulation (Terker et al., 
2014).  
Mu et al. (2011) suggested a mechanism in which renal β2-adrenergic receptors 
stimulate increases in tubular sodium reabsorption that is caused by NCC activation 
mediated by WNK4 downregulation (Mu et al., 2011). Since WNK4 is a negative 
regulator of NCC activity, it can be suggested that WNK4 suppression by β2-adrenergic 
receptor activation, induces increased sodium reabsorption through NCC activation in the 
DCT (Ando and Fujita, 2012). Recently, a study demonstrated the effects of acute 
adrenergic stimulation using NE that resulted in increases in total and phosphorylated 
NCC expression, an effect mediated by β1-adrenergic receptors (Terker et al., 2014). 
While both of these studies claim that the β-adrenergic receptors are responsible for 
mediating adrenergic effects on NCC function and expression, they failed to examine the 
role of the α-adrenergic receptors as a potential activator of the NCC signaling pathway. 
Previous studies have shown that α-adrenergic receptors facilitate sodium retention by 
either increasing renin release or directly stimulating sodium reabsorption in the proximal 
tubules, demonstrating their importance in facilitating sodium homoeostasis (DiBona, 
1985b; Mu et al., 2011; Vieira-Coelho and Moura, 2012). These studies suggest that the 
α-adrenergic receptors could potentially play a role in the development of salt-sensitive 
hypertension due to their key role in facilitating sodium reabsorption.  
In this study, we hypothesize that salt-sensitive hypertension is evoked, in part by 
the actions of NE on a renal α1-adrenergic receptor-gated WNK1-OxSR1 signal 
transduction pathway that drives renal NCC-mediated sodium reabsorption. The 
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following aim is designed to examine the impact of excess circulating NE and increased 
dietary salt intake, both individually and together, on the expression of OxSR1, SPAK, 
and WNK1. Furthermore, chronic antagonism of either the α- or β-adrenergic receptors in 
Sprague-Dawley rats will examine the contribution of the α- and/or β-adrenergic 
receptors in development of NE-evoked salt-sensitive hypertension in Sprague-Dawley 
and DSS rats. 
 
Results 
Norepinephrine infusion prevents dietary sodium-evoked suppression of OxSR1, SPAK, 
and WNK1 expression in Sprague-Dawley rats  
Following the completion of all acute physiological experiments in Aim 1, kidney cortex 
tissue was harvested from the same saline and NE infused Sprague-Dawley rats for which 
physiological data is presented in Chapter 3 for analysis of the expression of OxSR1, 
SPAK and WNK1. When challenged with a high salt diet for 14-days, saline treated 
animals, which remain normotensive and salt-resistant (Chp 3: Figure 10, 11) and exhibit 
reduced NCC activity and expression (Chp 3: Figure 14, 16), also showed dietary 
sodium-evoked suppression of OxSR1, SPAK, and WNK1 expression (Figures 29-31). 
However, NE infused rats maintained on a high salt diet for 14-days did not exhibit 
dietary sodium-evoked suppression of OxSR1, SPAK, and WNK1 expression (Figures 
29-31). NE infused rats also showed significantly higher endogenous levels of OxSR1 
expression when compared to saline infused rats (Figure 30). 
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Figure 29: Renal SPAK protein expression in kidney cortex tissue from Sprague-Dawley rats receiving either a 
s.c. saline or norepinephrine infusion. (A) Representative immunoblots illustrating SPAK expression in kidney 
cortex tissue and (B) Quantification of renal SPAK expression in male Sprague-Dawley rats receiving either a s.c. 
isotonic saline or norepinephrine (NE; 600ng/min) infusion maintained for 14-days on a normal (0.6% NaCl) or high 
salt (8% NaCl) diet. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. 
saline + 8% NaCl group value. 
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Figure 30: Renal OxSR1 protein expression in kidney cortex tissue from Sprague-Dawley rats receiving either a 
s.c. saline or norepinephrine infusion. (A) Representative immunoblots illustrating OxSR1 expression in kidney 
cortex tissue and (B) Quantification of renal OxSR1 expression in male Sprague-Dawley rats receiving either a s.c. 
isotonic saline or norepinephrine (NE; 600ng/min) infusion maintained for 14-days on a normal (0.6% NaCl) or high 
salt (8% NaCl) diet. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. 
saline + 8% NaCl.   
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Figure 31: Renal WNK1 protein expression in kidney cortex tissue from Sprague-Dawley rats receiving either a 
s.c. saline or norepinephrine infusion. (A) Representative immunoblots illustrating WNK1 expression in kidney 
cortex tissue and (B) Quantification of renal WNK1 expression in male Sprague-Dawley rats receiving either a s.c. 
isotonic saline or norepinephrine (NE; 600ng/min) infusion maintained for 14-days on a normal (0.6% NaCl) or high 
salt (8% NaCl) diet. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. 
saline + 8% NaCl group value. WNK1 immunoblot cropped for presentation. 
 
  
Dietary sodium-evoked suppression of OxSR1, SPAK, and WNK1 expression is prevented 
in the Dahl salt-sensitive rat  
Following the completion of all acute experiments, kidney cortex tissue was harvested 
from the same DSR and DSS rats for which physiological data is presented in Chapter 3 
for analysis of the expression of OxSR1, SPAK, and WNK1. When challenged with a 
high salt intake for 21-days, DSR animals, which remain normotensive (Chp 3: Figure 
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24) and exhibit reduced NCC activity and expression (Chp 3: Figure 28), demonstrated 
dietary sodium-evoked suppression of OxSR1, SPAK, and WNK1 expression (Figures 
32-34). There was no sodium evoked suppression of OxSR1, SPAK or WNK1 expression 
in DSS animals maintained on a high salt diet for 21-days (Figures 32-34). Lower 
endogenous levels of OxSR1 and WNK1 were observed in DSR animals when compared 
against the DSS animals (Figure 33, 34).  
 
Figure 32: SPAK expression from Dahl salt-resistant and Dahl salt-sensitive rats. (A) Representative immunoblots 
illustrating SPAK expression in kidney cortex tissue and (B) Quantification of renal SPAK expression in male Dahl 
salt-resistant and Dahl salt-sensitive rats maintained for 21-days on a normal (0.6% NaCl) or high salt (8% NaCl) diet. 
Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value τp<0.05 vs. DSR + 8% NaCl group 
value.  
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Figure 33: OxSR1 expression from Dahl salt-resistant and Dahl salt-sensitive rats. (A) Representative 
immunoblots illustrating OxSR1 expression in kidney cortex tissue and (B) Quantification of renal OxSR1 expression 
in male Dahl salt-resistant and Dahl salt-sensitive rats maintained for 21-days on a normal (0.6% NaCl) or high salt 
(8% NaCl) diet. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value τp<0.05 vs. DSR + 
8% NaCl group value.  
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Figure 34: WNK1 expression from Dahl salt-resistant and Dahl salt-sensitive rats. (A) Representative 
immunoblots illustrating WNK1 expression in kidney cortex tissue and (B) Quantification of renal WNK1 expression 
in male Dahl salt-resistant and Dahl salt-sensitive rats maintained for 21-days on a normal (0.6% NaCl) or high salt 
(8% NaCl) diet. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value τp<0.05 vs. DSR + 
8% NaCl group value. WNK1 immunoblot cropped for presentation. 
α1D-adrenergic receptor subtype mRNA expression is significantly increased in NE-
evoked hypertension 
Recent studies have implicated β-adrenergic receptors as the primary pathway mediating 
NCC activation, but the adrenergic receptors mediating this response remain to be fully 
elucidated. A PCR array was completed examining the mRNA expression of α- and β-
adrenergic receptor subtypes (Table 2) in kidney tissue from s.c. saline and NE infused 
Sprague-Dawley rats. Rats receiving a s.c. saline infusion demonstrated dietary sodium-
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evoked suppression of α2B1, α2B2 and β2- adrenergic receptor mRNA expression 
(Figure 35). When Sprague-Dawley rats receive a s.c. NE infusion α1D- adrenergic 
receptor subtype is significantly increased regardless of sodium intake (Figure 35). The 
β2- adrenergic receptor subtype is significantly decreased with the NE infusion in rats 
maintained on both NS and HS diets (Figure 35). 
 
 
Figure 35: Renal adrenergic receptor subtype mRNA levels in male Sprague-Dawley rats receiving either a s.c. 
isotonic saline or a s.c. norepinephrine infusion. Renal adrenergic receptor subtype mRNA levels in male Sprague-
Dawley rats receiving either a s.c. isotonic saline infusion or a s.c. norepinephrine (NE; 600ng/min) infusion 
maintained on either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 14 days. Data are mean ± SEM 
(N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; ϕp<0.05 vs. respective saline 0.6% NaCl group value; 
τp<0.05 vs. respective saline 8% NaCl group value.  
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Propranolol and norepinephrine co-infusion attenuates the development of hypertension  
To test the impact of the β-adrenergic receptors in the development of salt-sensitive 
hypertension, we chronically antagonized the β1/ β2-adrenergic receptors with 
propranolol (pro), alone and in combination with the s.c. 600ng/min NE dose. A s.c. 
propranolol infusion did not alter the salt-resistant phenotype of the Sprague-Dawley rat 
(Figure 36). The NE and propranolol co-infusion dramatically attenuated baseline MAP, 
regardless of sodium intake (Figure 36; MAP [mmHg] s.c. NE & Pro+NS: 136±4; s.c. 
NE & Pro+HS 136±4; p<0.05), when compared to animals receiving the NE infusion 
alone (Figure 36; MAP [mmHg] s.c. NE+NS: 151±3; s.c. NE+HS: 171±4). To investigate 
the effect of the NE and propranolol co-infusion on NCC activity, rats were acutely 
challenged with an i.v. bolus of HCTZ, a NCC antagonist. Rats receiving a s.c. infusion 
of NE and propranolol did not show dietary sodium evoked suppression of natriuresis to 
HCTZ (Figure 37; Peak ΔUNaV to HCTZ [µeq/min] s.c. NE & Pro+NS: 8.49±1; s.c. NE 
& Pro+HS: 10.04±1.8). Additionally, a s.c. propranolol infusion prevented the sodium-
evoked suppression of the peak natriuresis to HCTZ (Figure 37). β-blockade in Sprague-
Dawley rats receiving a s.c. NE and propranolol co-infusion was confirmed with an acute 
i.v. bolus of isoproterenol (β-adrenergic receptor agonist) by a lack of change observed in 
HR and MAP (Figure 36B, 36C). 
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Figure 36: Mean arterial pressure in Sprague-Dawley rats receiving either a s.c. infusion of 50:50 
DMSO/isotonic saline vehicle, propranolol, or norepinephrine and propranolol and the cardiovascular response 
to isoproterenol for Sprague-Dawley rats receiving s.c. norepinephrine and propranolol infusion. (A) Mean 
arterial pressure (MAP; mmHg) in conscious male Sprague-Dawley rats receiving either a s.c. 50:50 DMSO/isotonic 
vehicle saline infusion, s.c. propranolol (10mg/kg/d), a s.c. norepinephrine (NE; 600ng/min) infusion, or a s.c. NE 
(600ng/min) and propranolol (10mg/kg/d) infusion maintained on either a normal (0.6% NaCl) or high salt (8% NaCl) 
diet for 14-days (B) Change in heart rate (ΔHR) and (C) Change in mean arterial pressure (ΔMAP) to an i.v. bolus of 
isoproterenol (0.7µg) for Sprague-Dawley rats receiving a s.c.  NE and propranolol infusion. Data are mean±SEM 
(N=6/group) *p<0.05 vs. respective DMSO/saline group; τp<0.05 vs. respective 0.6% NaCl group; ϕp<0.05 vs. 
respective NE group. 
 
Figure 36A 
Figure 36C Figure 36B 
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Figure 37: Peak natriuresis  in response to an i.v. infusion of amiloride in combination with  hydrochlorothiazide 
in Sprague-Dawley rats receiving a s.c. infusion of DMSO/saline, propranolol, or norepinephrine and 
propranolol. Peak natriuresis (UNaV; µeq/min) in response to an i.v. infusion of  amiloride (2mg/kg) in combination 
with hydrochlorothiazide (HCTZ; 2mg/kg), in conscious male Sprague-Dawley rats receiving either a s.c. 50:50 
DMSO/isotonic saline vehicle infusion, a s.c. propranolol (10mg/kg/d), a s.c. norepinephrine (NE; 600ng/min) infusion 
or a s.c. NE (600 ng/min) and propranolol (10mg/kg/day) infusion maintained on either a normal (0.6% NaCl) or high 
salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; 
τp<0.05 vs. respective DMSO/saline group value.  
 
Propranolol and norepinephrine co-infusion prevents sodium-evoked suppression of 
NCC expression  
As previously observed, Sprague-Dawley rats receiving a s.c. infusion of NE did not 
show dietary sodium-evoked suppression of NCC expression (Chp 3: Figure 16). The co-
infusion of NE with propranolol did not restore dietary sodium-evoked suppression of 
NCC expression as well (Figure 38). Dietary sodium-evoked suppression of SPAK 
expression was observed in animals given the NE and propranolol co-infusion (Figure 
39). Overall, OxSR1 expression was significantly increased when given the NE and 
propranolol co-infusion when compared to saline infused Sprague-Dawley rats (Figure 
40). No significant difference in OxSR1 expression was observed between NS and HS 
groups given the NE and propranolol co-infusion (Figure 40). WNK1 expression was 
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significantly decreased in rats receiving a s.c. infusion of NE and propranolol when 
compared to their respective rat group receiving a s.c. infusion of NE alone (Figure 41).  
 
Figure 38: Renal NCC protein expression in kidney cortex tissue from Sprague-Dawley rats receiving a s.c. 
infusion of DMSO/saline, propranolol, or norepinephrine and propranolol. (A) Representative immunoblots 
illustrating NCC expression in kidney cortex tissue and (B) Quantification of renal NCC expression in male Sprague-
Dawley rats receiving either a s.c. isotonic saline, norepinephrine (NE; 600ng/min) or a s.c. NE (600 ng/min) and 
propranolol (10mg/kg/day) infusion maintained for 14-days on a normal (0.6% NaCl) or high salt (8% NaCl) diet. Data 
are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. saline + 8% NaCl.   
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Figure 39: Renal SPAK protein expression in kidney cortex tissue from Sprague-Dawley rats receiving a s.c. 
infusion of DMSO/saline, propranolol, or norepinephrine and propranolol. (A) Representative immunoblots 
illustrating SPAK expression in kidney cortex tissue and (B) Quantification of renal SPAK expression in male Sprague-
Dawley rats receiving either a s.c. isotonic saline, norepinephrine (NE; 600ng/min) or a s.c. NE (600 ng/min) and 
propranolol (10mg/kg/day) infusion maintained for 14-days on a normal (0.6% NaCl) or high salt (8% NaCl) diet. Data 
are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective NE group value; 
ϕp<0.05 vs. respective saline group.   
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Figure 40: Renal OxSR1 protein expression in kidney cortex tissue from Sprague-Dawley rats receiving a s.c. 
infusion of DMSO/saline, propranolol, or norepinephrine and propranolol. (A) Representative immunoblots 
illustrating OxSR1 expression in kidney cortex tissue and (B) Quantification of renal OxSR1 expression in male 
Sprague-Dawley rats receiving either a s.c. isotonic saline, norepinephrine (NE; 600ng/min) or a s.c. NE (600 ng/min) 
and propranolol (10mg/kg/day) infusion maintained for 14-days on a normal (0.6% NaCl) or high salt (8% NaCl) diet. 
Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; ϕp<0.05 vs. respective saline 
group.   
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Figure 41: Renal WNK1 protein expression in kidney cortex tissue from Sprague-Dawley rats receiving a s.c. 
infusion of DMSO/saline, propranolol, or norepinephrine and propranolol. (A) Representative immunoblots 
illustrating WNK1 expression in kidney cortex tissue and (B) Quantification of renal WNK1 expression in male 
Sprague-Dawley rats receiving either a s.c. isotonic saline, norepinephrine (NE; 600ng/min) or a s.c. NE (600 ng/min) 
and propranolol (10mg/kg/day) infusion maintained for 14-days on a normal (0.6% NaCl) or high salt (8% NaCl) diet. 
Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective NE group 
value; ϕp<0.05 vs. respective saline group.   
 
 
Prazosin and norepinephrine co-infusion abolishes the salt-sensitive component of 
norepinephrine-evoked hypertension and restores dietary sodium-evoked suppression of 
NCC activity 
To examine the role of the α-adrenergic receptor in NE-mediated hypertension, we 
chronically inhibited the α1-adrenergic receptor with prazosin (praz) for 14-days. The co-
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infusion of NE and prazosin did not prevent the development of hypertension, but the 
salt-sensitive component of NE-induced hypertension was abolished (Figure 42A; MAP 
[mmHg] s.c. NE & Praz+NS: 159±4; s.c. NE & Praz+HS: 156±5). To investigate the 
effect of the NE and prazosin co-infusion on NCC activity, rats were acutely challenged 
with an i.v. bolus of HCTZ, a NCC antagonist. Rats receiving a s.c. infusion of NE and 
prazosin showed dietary sodium-evoked suppression of NCC activity (Figure 43; Peak 
ΔUNaV to HCTZ [µeq/min] s.c. NE & Praz+NS: 10.7±1.5; s.c. NE & Praz+HS: 
6.14±1.2; p<0.05). α-blockade in Sprague-Dawley rats receiving a s.c. NE infusion with 
prazosin was confirmed with an acute i.v. bolus of phenylephrine (α-adrenergic receptor 
agonist) by a lack of change observed in HR and MAP (Figure 42B, 42C). 
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Figure 42: Mean arterial pressure in Sprague-Dawley rats receiving either a s.c. infusion of 50:50 
DMSO/isotonic saline vehicle, prazosin, or norepinephrine and prazosin and the cardiovascular response to 
phenylephrine for Sprague-Dawley rats receiving a s.c. infusion of norepinephrine and prazosin. (A) Mean 
arterial pressure (MAP; mmHg) in conscious male Sprague-Dawley rats receiving either a s.c. 50:50 DMSO/isotonic 
vehicle saline infusion, prazosin (2.5mg/kg/d, orally), a s.c. norepinephrine (NE; 600ng/min) infusion, or a s.c. NE 
(600ng/min) and prazosin (2.5mg/kg/d, orally) infusion maintained on either a normal (0.6% NaCl) or high salt (8% 
NaCl) diet for 14-days. (B) Change in heart rate (ΔHR) and (C) Change in mean arterial pressure (ΔMAP) to an i.v. 
bolus of phenylephrine (4µg)for Sprague-Dawley rats receiving a s.c.  NE and prazosin infusion. Data are mean±SEM 
(N=6/group) *p<0.05 vs. respective control group; τp<0.05 vs. respective 0.6% NaCl group. 
 
 
 
 
Figure 42A 
Figure 42C Figure 42B 
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Figure 43: Peak natriuresis in response to an i.v. infusion of amiloride in combination with  hydrochlorothiazide 
in Sprague-Dawley rats receiving a s.c. infusion of DMSO/saline, prazosin, or norepinephrine and prazosin. Peak 
natriuresis (UNaV; µeq/min) in response to an i.v. infusion of  amiloride (2mg/kg) in combination with 
hydrochlorothiazide (HCTZ; 2mg/kg), in conscious male Sprague-Dawley rats receiving either a s.c. 50:50 
DMSO/isotonic saline vehicle infusion, prazosin (2.5mg/kg/d, orally), a s.c. norepinephrine (NE; 600ng/min) infusion, 
or a s.c. NE (600ng/min) and prazosin (2.5mg/kg/d, orally) infusion maintained on either a normal (0.6% NaCl) or high 
salt (8% NaCl) diet for 14-days. Data are mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; 
τp<0.05 vs. respective DMSO/Saline group value.  
 
 
Prazosin and norepinephrine co-infusion restores sodium evoked-suppression of NCC 
expression  
As previously observed, Sprague-Dawley rats receiving a s.c. infusion of NE did not 
show dietary sodium-evoked suppression of NCC expression (Figure 16). The co-
infusion of NE with prazosin showed dietary sodium-evoked suppression of NCC 
expression (Figure 44). The s.c. infusion of NE and prazosin demonstrated sodium-
evoked suppression of SPAK expression as well  (Figure 45). Decreases in OxSR1 
expression were observed in rats given the NE and prazosin co-infusion when compared 
to their respective s.c. NE groups (Figure 46). No significant difference in OxSR1 
expression was observed between diet groups for rats given the co-infusion of NE and 
prazosin. The NE and prazosin co-infusion animals had overall decreased WNK1 
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expression levels when compared to animals given the NE infusion alone (Figure 47). No 
significant differences in WNK1 expression was observed between diet groups for rats 
given the co-infusion of NE and prazosin. 
 
Figure 44: Renal NCC protein expression in kidney cortex tissue from Sprague-Dawley rats receiving a s.c. 
infusion of DMSO/saline, prazosin, or norepinephrine and prazosin. (A) Representative immunoblots illustrating 
NCC expression in kidney cortex tissue and (B) Quantification of renal NCC expression in male Sprague-Dawley rats 
receiving either a s.c. isotonic saline, norepinephrine (NE; 600ng/min) or a s.c. NE (600 ng/min) and prazosin 
(2.5mg/kg/day, orally) infusion maintained for 14-days on a normal (0.6% NaCl) or high salt (8% NaCl) diet. Data are 
mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. saline + 8% NaCl; ϕp<0.05 vs. 
respective saline group.    
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Figure 45: Renal SPAK protein expression in kidney cortex tissue from Sprague-Dawley rats receiving a s.c. 
infusion of DMSO/saline, prazosin, or norepinephrine and prazosin. (A) Representative immunoblots illustrating 
SPAK expression in kidney cortex tissue and (B) Quantification of renal SPAK expression in male Sprague-Dawley 
rats receiving either a s.c. isotonic saline, norepinephrine (NE; 600ng/min) or a s.c. NE (600 ng/min) and prazosin 
(2.5mg/kg/day, orally) infusion maintained for 14-days on a normal (0.6% NaCl) or high salt (8% NaCl) diet. Data are 
mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. saline + 8% NaCl; ϕp<0.05 vs. 
respective saline group.    
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Figure 46: Renal OxSR1 protein expression in kidney cortex tissue from Sprague-Dawley rats receiving a s.c. 
infusion of DMSO/saline, prazosin, or norepinephrine and prazosin. (A) Representative immunoblots illustrating 
OxSR1 expression in kidney cortex tissue and (B) Quantification of renal OxSR1 expression in male Sprague-Dawley 
rats receiving either a s.c. isotonic saline, norepinephrine (NE; 600ng/min) or a s.c. NE (600 ng/min) and prazosin 
(2.5mg/kg/day, orally) infusion maintained for 14-days on a normal (0.6% NaCl) or high salt (8% NaCl) diet. Data are 
mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. saline + 8% NaCl; ϕp<0.05 vs. 
respective saline group.   
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Figure 47: Renal WNK1 protein expression in kidney cortex tissue from Sprague-Dawley rats receiving a s.c. 
infusion of DMSO/saline, prazosin, or norepinephrine and prazosin. (A) Representative immunoblots illustrating 
WNK1 expression in kidney cortex tissue and (B) Quantification of renal WNK1 expression in male Sprague-Dawley 
rats receiving either a s.c. isotonic saline, norepinephrine (NE; 600ng/min) or a s.c. NE (600 ng/min) and prazosin 
(2.5mg/kg/day, orally) infusion maintained for 14-days on a normal (0.6% NaCl) or high salt (8% NaCl) diet. Data are 
mean ± SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. saline + 8% NaCl; ϕp<0.05 vs. 
respective saline group.    
 
 
Propranolol and prazosin each significantly reduce MAP in Dahl salt-sensitive rats  
DSS rats showed a significant increase in MAP when maintained on a high salt diet 
(Figure 48; MAP [mmHg] DSS+NS: 138±5; DSS+HS: 166±6; p<0.05). When DSS rats 
received a s.c. infusion of propranolol a significant decrease in MAP was observed 
(Figure 48; MAP [mmHg] DSS+HS: 166±6 vs. DSS+Pro: 151±4; p<0.05). Additionally, 
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DSS rats given prazosin while on a high salt diet showed significantly decreased MAP 
(Figure 48; MAP [mmHg] DSS+HS: 166±6 vs. DSS+Praz: 149±5; p<0.05). To assess the 
impact of the propranolol or prazosin on the NCC we assessed the peak natriuretic 
response to an acute HCTZ challenge, a NCC antagonist. The dietary sodium-evoked 
suppression to peak natriuretic response to HCTZ was prevented in DSS rats receiving 
the propranolol and the prazosin (Figure 49; Peak ΔUNaV to HCTZ [µeq/min] DSS+NS: 
8.89±1.6; DSS+HS: 11.5±2; DSS+Pro: 11.1±1.1; DSS+Praz: 14±1.5). β-blockade and α-
blockade in DSS rats was confirmed with an acute i.v. bolus of isoproterenol (β-
adrenergic receptor agonist) or phenylephrine (α-adrenergic receptor agonist), 
respectively, by a lack of change observed in HR and MAP (Figure 50). 
 
 
 
 
 
Figure 48: Mean arterial pressure in naive Dahl salt-sensitive and Dahl salt-sensitive rats receiving either a s.c. 
infusion of propranolol or prazosin. Mean arterial pressure (MAP; mmHg) in naive Dahl salt-sensitive and Dahl salt-
sensitive rats receiving either a s.c. infusion of propranolol (10mg/kg/d) or prazosin (2.5mg/kg/d, orally) maintained on 
either a normal (0.6% NaCl) or high salt (8% NaCl) diet for 21-days. Data are mean±SEM (N=4-6/group). *p<0.05 vs. 
respective normal salt group value; τp<0.05 vs. DSS + 8% NaCl group value. 
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Figure 49: Peak natriuresis in response to an i.v. infusion of amiloride in combination with  hydrochlorothiazide 
in Dahl salt-sensitive and Dahl salt-sensitive rats receiving either a s.c. infusion of propranolol or prazosin. Peak 
natriuresis (UNaV; µeq/min) in response to an i.v. infusion of  amiloride (2mg/kg) in combination with 
hydrochlorothiazide (HCTZ; 2mg/kg), in conscious male Dahl salt-sensitive and Dahl salt-sensitive rats receiving 
either a s.c. infusion of propranolol (10mg/kg/d) or prazosin (2.5mg/kg/d, orally) maintained on either a normal (0.6% 
NaCl) or high salt (8% NaCl) diet for 21-days. Data are mean ± SEM (N=6/group).  
 
Figure 50: Peak change in heart rate and mean arterial pressure in Dahl salt-sensitive rats receiving either a s.c. 
infusion of propranolol or prazosin to isoproterenol or phenylephrine, respectively. (A) Peak change in heart rate 
(HR; beats per minute, BPM) and (B) mean arterial pressure (MAP; mmHg) in Dahl salt-sensitive rats receiving a s.c. 
infusion of propranolol (10mg/kg/d) to an acute i.v. bolus of isoproterenol (0.7µg) maintained on a high salt (8% NaCl) 
diet for 21-days. (C) Peak change in heart rate (BPM) and (D) MAP in Dahl salt-sensitive rats receiving prazosin 
(2.5mg/kg/d , orally) to an acute i.v. bolus of phenylephrine (4µg) maintained on a high salt (8% NaCl) diet for 21-
days. Data are mean±SEM (N=6/group). 
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Discussion 
To further examine the role of the NCC in the development of salt-sensitive 
hypertension, we assessed the following NCC regulatory kinases, OxSR1, SPAK and 
WNK1 using kidney cortex tissue from the same animals for which physiology data is 
presented in aim 1. We show that saline infused Sprague-Dawley rats maintained on a 
high salt diet for 14-days demonstrate dietary sodium-evoked suppression of SPAK 
expression, mirroring the results in NCC expression for saline treated Sprague-Dawley as 
well as DSR rats maintained on high salt. However, dietary sodium-evoked suppression 
of SPAK expression was prevented in our salt-sensitive phenotypes (SD-NE infusion & 
DSS), mirroring the NCC expression found in the same animals. Interestingly, acute 
studies conducted in mice, measuring changes in total and phosphorylated NCC thirty 
minutes after NE administration showed no change in the localization or expression of 
SPAK (Terker et al., 2014). This data generated in mice supports the data we observed in 
our chronic experiments with Sprague-Dawley rats where no significant difference in 
SPAK expression was detected between saline and NE treated Sprague-Dawley rats 
maintained on a normal salt diet (Terker et al., 2014). These data suggest SPAK as a 
potential upstream regulator contributing to aberrant NCC expression in the development 
of salt-sensitive hypertension.  
Dietary sodium-evoked suppression of OxSR1 expression was observed in our 
salt-resistant phenotypes, an effect prevented in our salt-sensitive phenotypes. We also 
observed lower endogenous baseline levels of OxSR1 in our salt-resistant phenotypes 
when compared against our salt-sensitive phenotypes. Again, the OxSR1 expression 
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coincides with NCC expression in both our salt-resistant and salt-sensitive phenotypes, 
suggesting that OxSR1 plays a role in the upstream regulation of the NCC. A recent study 
showed that acute adrenergic stimulation with NE increases OxSR1 translocation to the 
membrane aiding in the phosphorylation of the NCC (Terker et al., 2014), supporting our 
data showing an increase of OxSR1 expression in our animal model of salt-sensitivity 
featuring NE-mediated adrenergic activation. These data suggest that excess plasma NE 
results in increased OxSR1 expression, possibly contributing to the failure to 
downregulate the NCC in the development of salt-sensitive hypertension. Together, salt-
sensitive phenotypes show increased SPAK and OxSR1 expression and consequently 
NCC expression resulting in increased renal sodium reabsorption contributing to the 
development of salt-sensitive hypertension in these animal models of salt-sensitive 
hypertension.   
The roles of the WNK kinases have been firmly established in blood pressure 
regulation from the discovery of mutations in WNK1 and WNK4 in the disease 
psudeohyperaldosteronism type II (PHAII), which results in hypertension and 
hyperkalemia (Yang et al., 2003; Chiga et al., 2008; San-Cristobal et al., 2008). We 
investigated the expression of WNK1 in our animal models of salt-resistance and salt-
sensitivity. Ideally, we would investigate the contribution of WNK4 in the development 
of salt-sensitive hypertension, but there are no reliable WNK4 antibodies available on the 
market today. Additionally, our requests for access to WNK4 antibodies from other 
laboratories have been unsuccessful. In examining WNK1 expression, we show dietary 
sodium-evoked suppression of WNK1 expression in both of our salt-resistant phenotypes 
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(SD-saline infusion & DSR), while dietary-sodium evoked-suppression was prevented in 
our salt-sensitive phenotypes (SD-NE infusion & DSS). Again, these data coincide with 
the expression of NCC, OxSR1, and SPAK, showing a failure for NCC and its regulatory 
proteins to be appropriately downregulated in the development of salt-sensitive 
hypertension. WNK1 has the ability to phosphorylate and activate both OxSR1 and 
SPAK directly (Vitari et al., 2005), which is evident in our results showing sodium 
dependent decreases in OxSR1, SPAK and consequently NCC expression in our salt-
resistant phenotypes. These data show that WNK1 plays a key role in determining 
downstream NCC activation and expression in the development of salt-sensitive 
hypertension. While both WNK1 and WNK4 can directly and indirectly affect the actions 
of the NCC, the WNK isoform that plays the most central role in the development of 
hypertension remains to be firmly established. In a study from Mu et al. (2011) 
examining the effects of salt and NE on NCC expression, they showed in the DSS rat, 
increased dietary salt intake suppressed renal WNK4 expression, activating the NCC, 
implicating WNK4 in the development of salt-sensitive hypertension (Mu et al., 2011). 
While, Uchida et al. (2012) were able to confirm the blood pressure effects of NE and 
increased dietary salt intake on blood pressure, they did not detect effects on both NCC 
and WNK4 expression (Uchida et al., 2012). Additionally, no change in WNK4 
expression was observed upon acute NE stimulation in mice, suggesting that WNK4 is 
not involved in the development of salt-sensitive hypertension (Terker et al., 2014). 
Interestingly, these studies did not examine the impact of WNK1 in the development of 
NE-mediated hypertension. Since WNK1 expression correlates with the expression of 
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SPAK and OxSR1, we can infer that actions of WNK1 on SPAK and OxSR1 influence 
the activation of the NCC. The importance of WNK1 on NCC activity can be 
substantiated by a study that compared the contribution of WNK1 and WNK4 to the 
activity of the NCC (Chavez-Canales et al., 2014). This study found that WNK1 
stimulates NCC expression and activity in a SPAK-dependent manner and not through 
modulation of an inhibitory effect of WNK4 (Chavez-Canales et al., 2014). Additionally, 
they concluded that the presence of WNK4 decreases the WNK1 and WNK3-mediated 
activation of the NCC (Chavez-Canales et al., 2014). Despite the fact that we cannot 
attest to the contribution of WNK4, we believe that our study shows that WNK1 
expression in both our NE infusion model and in the genetic model of salt-sensitivity, the 
DSS rat, showcases the importance of WNK1 in NCC-mediated sodium reabsorption 
driving the development of salt-sensitive hypertension. 
Using our kidney cortex tissue from our saline infused and NE infused Sprague-
Dawley rats, we conducted an analysis of α- and β-adrenergic receptor subtypes via 
mRNA expression in a PCR array (Table 1). We show dietary sodium-evoked 
suppression of α2B1, α2B2, and β2-adrenergic receptors mRNA expression in saline 
infused Sprague-Dawley rats. A s.c. NE infusion in Sprague-Dawley rats showed a 
significant decrease in the β2-adrenergic receptor subtype for rats maintained on both a 
NS and HS diet. Interestingly, NE infused rats showed increased α1D-adrenergic receptor 
subtype mRNA expression. These data indicate that the α1D-adrenergic receptor may 
play a significant role in mediating the effects of NE on the NCC signal transduction 
pathway in the development of hypertension in our NE infusion Sprague-Dawley rat 
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model of salt-sensitivity. The β-adrenergic receptor has been considered to be the renal 
adrenergic receptor responsible for mediating the effects of NE on NCC activation, but 
the specific subtype has yet to be definitively defined. Mu et al. (2011) argue that the β2-
adrenergic receptor is primarily responsible for aberrant NCC activation in NE-mediated 
salt-sensitivity of blood pressure, while another study shows an increased abundance of 
renal β1-adrenergic receptors in response to an acute stimulation with NE (Mu et al., 
2011; Terker et al., 2014). Interestingly, Terker et al. (2014) argue the existence of a 
synergistic interaction between α-and β-adrenergic receptors to stimulate the NCC, 
concluding that the NCC can be modulated in an acute setting directly via β-adrenergic 
receptors, an effect enhanced by concomitant α-adrenergic stimulation (Terker et al., 
2014). These data show an interaction between the α- and β-adrenergic receptors 
suggesting a role for the α-adrenergic receptor, substantiating our renal mRNA results 
showing increased α1-adrenergic receptor mRNA expression, in the development of salt-
sensitive hypertension. 
To investigate the role the β-adrenergic receptors play in NCC activation in salt-
sensitive hypertension, we co-infused NE with propranolol, a β1-/β2-adrenergic receptor 
antagonist. When Sprague-Dawley rats were co-infused with NE and propranolol, the 
development of hypertension was abolished for Sprague-Dawley rats maintained on a NS 
or HS diet for 14-days. Despite this reduction in MAP in Sprague-Dawley rats receiving 
the NE and propranolol co-infusion, dietary sodium-evoked suppression of NCC function 
and expression was still prevented. Chronically antagonizing the β-adrenergic receptors 
in our NE infusion model did not restore NCC function or expression, suggesting that this 
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failure to appropriately downregulate the NCC is not exclusively mediated through the β-
adrenergic receptors, contrary to the studies conducted by Mu et al. (2011) and Terker et 
al. (2014), which proposed that adrenergic stimulation of β-adrenergic receptors primarily 
stimulates NCC activity contributing to the development of salt-sensitive hypertension 
(Mu et al., 2011; Terker et al., 2014).  
To further investigate the effects of propranolol on NE-evoked hypertension, we 
examined protein expression of NCC, SPAK, OxSR1, and WNK1. The NE and 
propranolol co-infusion did not show significant dietary sodium-evoked suppression of 
total NCC expression. This data reflects our physiological data showing that the NE and 
propranolol co-infusion did not show dietary sodium-evoked suppression of NCC 
activity. SPAK expression in our NE and propranolol co-infused Sprague-Dawley rats 
shows dietary sodium-evoked suppression. Due to the fact that SPAK expression was 
able to be appropriately downregulated in response to a high salt challenge during the 
chronic β-adrenergic receptor blockade, suggests that SPAK may not be the primary 
regulator of the NCC in NE-evoked hypertension. However, OxSR1 expression was 
significantly increased with the NE and propranolol co-infusion when compared to salt-
resistant phenotypes. Since, no significant difference in OxSR1 expression was observed 
between NS and HS groups given the NE and propranolol co-infusion, chronic β-
blockade does not appear to have any effect on OxSR1 expression. The OxSR1 
expression observed with the chronic β-blockade is similar to OxSR1 expression 
observed to Sprague-Dawley rats given the NE infusion alone. This suggests that OxSR1 
expression is not mediated by β-adrenergic receptors in NE-mediated hypertension, 
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highlighting the importance of OxSR1 in the regulation of the NCC in salt-sensitivity. 
Chronic antagonism of the β-adrenergic receptors in our NE infusion model shows an 
overall decrease in WNK1 expression when compared to NE infusion alone. These data 
suggest that WNK1 expression is partially mediated through β-adrenergic receptors. 
Despite the decrease in WNK1 expression in animals receiving the NE and propranolol 
co-infusion, restoration of NCC function and expression was not observed. Since WNK1 
has an activating effect on the NCC, the failure for the NCC to be appropriately 
downregulated in response to a high salt challenge during a chronic β-blockade may 
possibly be attributed to WNK4’s affect on NCC activation. Due to our inability to 
measure renal WNK4 expression, its effects on NCC activation in our animal model 
cannot be discounted. In our analysis of NCC expression, we are unable to differentiate 
between total and phosphorylated NCC expression. Due to this fact, our data could 
suggest that SD rats given the NE and propranolol co-infusion have increased 
phosphorylation of NCC, possibly explaining the NCC dysfunction observed when these 
animals were acutely challenged with HCTZ where no dietary sodium-evoked 
suppression of NCC activity was observed. Overall, these data show that chronic 
antagonism of the β-adrenergic receptors in the presence of excess NE does not restore 
the dietary sodium-evoked suppression of NCC activity and expression. While dietary 
sodium-evoked suppression of SPAK expression remained intact with concomitant 
increases in overall OxSR1 expression suggesting that OxSR1 plays a more crucial role 
in regulating the NCC during chronic adrenergic stimulation. Further, this data shows 
excess NE alone may not solely rely on the β-adrenergic receptors to perpetuate a failure 
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of the NCC to be downregulated in response to increased dietary salt intake during the 
development of salt-sensitive hypertension.  
Mu et al. (2011) did not examine the role of the α-adrenergic receptors in the 
regulation of the NCC. Previous studies have shown that α-adrenergic receptors can 
facilitate sodium retention by either increasing renin release or by directly stimulating 
sodium reabsorption in the proximal tubules, demonstrating their importance in sodium 
homoeostasis (DiBona, 1985b, a; Mu et al., 2011; Vieira-Coelho and Moura, 2012). 
Terker et al. (2014) investigated the β-adrenergic receptors in an acute experimental 
setting, giving either an α- or β-agonist and measuring NCC phosphorylation thirty 
minutes later (Terker et al., 2014). Mice given the β-agonist demonstrated a significant 
increase in NCC phosphorylation, while no increase was observed in mice when acutely 
challenged with an α-agonist. However, when mice were given both the α- and β-agonists 
simultaneously, they exhibited the greatest elevation in NCC phosphorylation, suggesting 
a synergistic interaction between the α- or β-adrenergic receptors on NCC activation 
(Terker et al., 2014). These data show a potential role for the α-adrenergic receptor in the 
regulation and activation of the NCC in the development of NE-evoked salt-sensitive 
hypertension. In order to investigate the role of the α-adrenergic receptors, we elected to 
chronically antagonize the α1-adrenergic receptor using prazosin. While the addition of 
prazosin to the NE infusion abolished the salt-sensitive component of NE-mediated 
hypertension, but it did not lower blood pressure. These data show that renal α1-
adrenergic receptors help mediate the salt-sensitive component of NE-evoked 
hypertension in our NE infusion Sprague-Dawley rat model. Interestingly, when animals 
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given the NE and prazosin co-infusion are acutely challenged with HCTZ, a NCC 
antagonist, they showed dietary sodium-evoked suppression of NCC activity. These data 
are similar to the effects of an acute HCTZ challenge in our salt-resistant phenotypes. 
This physiological data suggest that the α1-adrenergic receptors, not the β-adrenergic 
receptors, are responsible for the failure of the NCC to be appropriately downregulated in 
NE-mediated salt-sensitive hypertension. When NCC expression was evaluated, the NE 
and prazosin co-infusion showed dietary sodium-evoked suppression of NCC expression, 
matching our physiology results. When examining the regulatory proteins, we observed 
sodium-dependent decreases in SPAK expression in rats given the NE and prazosin co-
infusion. Since dietary sodium-evoked suppression is restored when both the α1- and β-
adrenergic receptors are chronically inhibited, this suggests that SPAK is not exclusively 
regulated by α- or β-adrenergic receptors and that SPAK is not responsible for the 
aberrant NCC activity and/or expression observed in NE-evoked hypertension. OxSR1 
expression levels in Sprague-Dawley rats given NE and prazosin mirror those observed in 
saline infused Sprague-Dawley rats, suggesting that α1-adrenergic receptors are 
mediating the effects on OxSR1 in NE-evoked hypertension. These data suggest that α1-
adrenergic receptors are mediating the effects on the NCC through an OxSR1-dependent 
mechanism. Similar to the results observed with the co-infusion of NE and propranolol, 
the chronic α-blockade with NE and prazosin showed an overall decrease in renal WNK1 
expression. No significant differences were observed between the NS and HS diet groups 
as well. These data suggest that when α1-adrenergic receptors are chronically 
antagonized, sodium-dependent decreases in WNK1 expression are restored when 
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compared to salt-resistant phenotypes. These data indicate that WNK1 expression is 
impacted by chronic α1-adrenergic receptor antagonism. These data show that α1-
adrenergic receptors are responsible for mediating the salt-sensitive component of NE-
evoked hypertension and for the failure of the NCC to be appropriately downregulated by 
OxSR1 in NE-mediated salt-sensitive hypertension. 	 DSS rats showed expected decreases in MAP when given an α- or β-adrenergic 
receptor blocker. Despite these decreases in blood pressure, the antagonism of α- or β-
adrenergic receptors did not restore dietary sodium-evoked suppression of the NCC. 
Based on our previous results regarding propranolol and the NCC, we did not expect the 
chronic antagonism of the β-adrenergic receptors to restore NCC activity. Surprisingly, 
prazosin did not restore NCC function in DSS rats on a high salt diet. The difference 
between results observed from Sprague-Dawley rats given the NE and prazosin co-
infusion and DSS rats given prazosin may be attributed to the genetic differences 
between the DSS rat and the Sprague-Dawley rat and the multifactorial nature of the DSS 
hypertension featuring aberrations in central, vascular, cardiac, hormonal, and renal 
mechanisms. Due to the complex nature of the DSS rat, the potential chronic antagonism 
of both the α- or β-adrenergic receptors at the same time may have the ability to restore 
NCC function.  
 
Overall Conclusion from Aim 2 
 In conclusion, our results highlight the interaction between NE and salt to 
influence NCC-mediated sodium reabsorption via an α1-adrenergic receptor-gated 
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WNK1-OxSR1 signal transduction pathway driving the pathophysiology of salt-sensitive 
hypertension. We show that chronic β-blockade can significantly decrease the MAP in 
NE-mediated hypertension, most likely through actions of propranolol on the vasculature 
and cardiac output. Notably, these results highlight a previously unappreciated role for 
the α1-adrenergic receptor in the development of salt-sensitive hypertension. Showcasing 
the importance of the α1-adrenergic receptor in NCC-mediated sodium reabsorption in 
salt-sensitivity highlights an alternative strategy to treat an underlying cause of salt-
sensitive hypertension, possibly using a low dose α1-adrenergic receptor antagonist. 
Despite the clinical use and well-defined actions of both propranolol and prazosin, we 
recognize this series of studies relies on their selectivity and that off-target effects must 
be considered when interpreting results. In regard to the 14-day infusion of propranolol or 
prazosin, we observed no overt signs of hyponatriemia or impacts on baroreflex, 
respectively, that could have impacted our studies. Overall, our data suggests a key role 
for the renal α1-adrenergic receptors to drive a WNK1-OxSR1 signal transduction 
pathway to facilitate NCC-mediated sodium reabsorption in salt-sensitive hypertension.  		
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CHAPTER FIVE: Afferent renal nerves are a crucial sodium responsive mechanism 
that mediates the regulation of the renal NCC to prevent the development of salt-
sensitive hypertension 
 
 
Rationale 
 
Recent interest has grown in understanding the role of the SNS, specifically the 
role of the renal sympathetic nerves, in the development and pathogenesis of salt-
sensitive hypertension. In aim 1, we are able to demonstrate that animals with increased 
plasma NE levels develop hypertension and show a failure for the NCC to be 
appropriately downregulated following a high salt challenge, highlighting an interaction 
between dietary sodium intake and increased levels of NE on the activity and expression 
of the NCC (Walsh et al., 2016). Aim 2 showed how the interaction between NE and salt 
influenced NCC-mediated sodium reabsorption via an α1-adrenergic receptor-gated 
WNK1-OxSR1 signal transduction pathway drives the pathophysiology of salt-sensitive 
hypertension. To further examine the sodium responsive mechanism(s) responsible for 
NCC-mediated sodium reabsorption in salt-sensitivity, we explored the contribution of 
the afferent renal sympathetic nerves in the development of salt-sensitive hypertension.  
Several studies have examined the role of the renal nerves by using a variety of 
animal models. The efferent and afferent renal nerves interact with one another where an 
increase in efferent renal sympathetic nerve activity increases afferent renal nerve 
activity, and through a renorenal negative feedback loop, decreases efferent renal 
sympathetic nerve activity (Chp 1: Figure 6). Recently, numerous clinical trials have 
highlighted catheter-based renal nerve ablation as a possible treatment for drug-resistant 
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hypertensive patients (Esler et al., 2012; Krum et al., 2014; Mahfoud et al., 2014). 
However, the Symplicity HTN-3 clinical trials failed to show a significant anti-
hypertensive effect after removal of the renal sympathetic nerves (Krum et al., 2014; 
Bakris et al., 2015). Despite the conflicting clinical trial results, bilateral renal 
denervation has been consistently shown to decrease MAP in a variety of animal models 
of hypertension, suggesting that renal denervation can have an effective anti-hypertensive 
effect in certain forms of hypertension (DiBona and Kopp, 1997). The conflicting results 
of these recent clinical trials demonstrates a need to further investigate the mechanisms 
underlying the anti-hypertensive effects of renal denervation and how the afferent and 
efferent renal nerves contribute to these effects, specifically to renal excretory function 
and the regulation of the NCC. Currently, the integrated sodium-sensitive mechanisms 
that operate between the brain and the kidney to facilitate sodium homeostasis and 
normotension in salt-resistant phenotypes remain to be definitively established (Fujita 
and Fujita; Noda and Sakuta; Stocker et al.). This aim will investigate the impact of the 
afferent renal (sensory input to CNS) sympathetic nerves on long-term sodium 
homeostasis, NCC regulation, and blood pressure in response to increased dietary salt 
intake.  
In this study, we hypothesize that the afferent renal nerves are a critical 
sympathetic nervous system sodium responsive mechanism that mediates the regulation 
of the renal NCC to prevent the development of salt-sensitive hypertension. The 
following aim is designed to examine the role of the afferent renal nerves on the impact 
of elevated NE levels and increased dietary salt intake on blood pressure regulation, and 
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NCC activity and expression in both salt-resistant and salt-sensitive rat phenotypes. 
Collectively, these studies will provide important mechanistic information regarding a 
novel role of the afferent renal nerves as a critical sodium responsive mechanism acting 
to facilitate sodium homeostasis and normotension via an α1-adrenergic receptor-gated 
WNK1-OxSR1 pathway.  
 
Results 
In salt-resistant rat phenotypes, a high dietary salt intake increases afferent renal nerve 
sensitivity 
Mean arterial pressure was measured using telemetry probes implanted in 
Sprague-Dawley, Dahl salt-resistant, and Dahl salt-sensitive rats. Rats were implanted 
with the telemetry probe and remained on a normal salt diet for 5-days. On day-5, the rats 
were placed on a high salt diet for 21-days. Both the Sprague-Dawley and Dahl salt-
resistant rats show no change in blood pressure after being placed on a high salt diet, 
demonstrating their salt-resistance (Figure 51). However, Dahl salt-sensitive rats show a 
significantly elevated MAP when compared to Sprague-Dawley and Dahl salt-resistant 
MAP at baseline (Figure 51). MAP significantly increases when Dahl salt-sensitive rats 
increase their dietary sodium intake, with MAP steadily increasing over the 21-day high 
salt intake period (Figure 51). Sprague-Dawley and Dahl salt-resistant rats demonstrate 
dietary sodium-evoked suppression of both plasma and renal NE content, while dietary 
sodium-evoked suppression of plasma and renal NE content was prevented in Dahl salt-
sensitive rats (Figure 52, 53). 
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 To evaluate the responsiveness of the afferent renal nerves to NE in animals of 
salt-resistance and salt-sensitivity, we examined the mechanisms of the NE-mediated 
release of substance P in a renal pelvis preparation (Kopp et al., 1998; Kopp et al., 2003; 
Kopp and Cicha, 2004). In our salt-resistant phenotypes (Sprague-Dawley & Dahl salt-
resistant), a high salt intake resulted in a significant increase in NE-mediated substance P 
release (Figure 54). In our salt-sensitive phenotype (Dahl salt-sensitive), a high salt intake 
did not evoke an increase in NE-mediated substance P release (Figure 54).   
 
Figure 51: Effect of elevated dietary sodium intake on daily MAP for male Sprague-Dawley, Dahl salt-resistant 
and Dahl salt-sensitive rats. Daily MAP (mmHg) for male Sprague-Dawley, Dahl salt-resistant and Dahl salt-
sensitive rats maintained on a high salt (8% NaCl) diet for 21-days. *p<0.05 vs. respective normal salt intake group 
value; τp<0.05 vs. respective DSR high salt intake group value. 
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Figure 52: Plasma norepinephrine concentrations in naïve Sprague-Dawley, Dahl salt-resistant, and Dahl salt-
sensitive rats. Plasma norepinephrine (NE) concentrations (nmol/L) in naïve Sprague-Dawley, Dahl salt-resistant, and 
Dahl salt-sensitive rats maintained on either a normal (0.6% NaCl; NS) or high salt (8% NaCl; HS) diet for 14- or 21-
days. Data are mean±SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective DSR + 
8% NaCl group value. 
 
 
 
 
 
 
 
 
 
Figure 53: Renal norepinephrine concentrations in naïve Sprague-Dawley, Dahl salt-resistant, and Dahl salt-
sensitive rats. Renal norepinephrine (NE) concentrations (pg/mg) in naïve Sprague-Dawley, Dahl salt-resistant, and 
Dahl salt-sensitive rats maintained on either a normal (0.6% NaCl; NS) or high salt (8% NaCl; HS) diet for 14- or 21-
days. Data are mean±SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective DSR + 
8% NaCl group value. 
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Figure 54: NE-evoked substance P release concentrations in naïve Sprague-Dawley, Dahl salt-resistant, and 
Dahl salt-sensitive rats. NE-evoked substance P release concentrations (pg/min) in naïve Sprague-Dawley, Dahl salt-
resistant, and Dahl salt-sensitive rats maintained on either a normal (0.6% NaCl; NS) or high salt (8% NaCl; HS) diet 
for 14- or 21-days. Data are mean±SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. 
respective DSR + 8% NaCl group value. 
 
 
Selective afferent renal denervation immediately prior to high salt intake suppresses 
MAP, NE release, and renal NE content in Sprague-Dawley rats 
 Sprague-Dawley rats were implanted with a telemetry probe, which allows for the 
recording of blood pressure, heart rate, etc. in a low stress environment (i.e., home cage). 
Initial baseline blood pressure was measured via telemetry for 10-days while the animals 
were maintained on a normal salt diet. All Sprague-Dawley rats remained normotensive 
during this 10-day baseline measurement period (Figure 55). On day-10, either sham 
Renal-CAP or Renal-CAP surgeries were performed and the rats were immediately 
placed on a high salt diet for 21-days. The sham renal-CAP animals remained 
normotensive when challenged with high salt, exhibiting a salt-resistant phenotype 
(Figure 55). Sprague-Dawley rats that underwent the renal-CAP surgery show a 
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significant and sustained increase in blood pressure when maintained on a high salt diet 
(Figure 55). Illustrated as an index of the salt-sensitivity of blood pressure, Sham renal-
CAP Sprague-Dawley rats exhibit a classical salt-resistant phenotype. The renal-CAP 
surgical procedure caused a significant reduction in the slope of the chronic pressure-
natriuresis relationship in Sprague-Dawley rats (Figure 56), reflecting the increased salt-
sensitivity of blood pressure. Additionally, the sham renal-CAP rats demonstrated dietary 
sodium-evoked suppression of plasma and renal NE content (Figure 57, 58). Dietary 
sodium-evoked decreases in plasma NE content were prevented in renal-CAP Sprague-
Dawley rats (Figure 55). However, the renal-CAP Sprague-Dawley rat showed dietary 
sodium-dependent decreases in renal NE content, but the dietary sodium-evoked decrease 
in renal NE content in the renal-CAP was significantly higher than in the sham renal-
CAP rats (Figure 58). 
 
Figure 55: Effect of elevated dietary sodium intake on daily MAP for sham renal-CAP or renal-CAP Sprague-
Dawley rats. Daily MAP (mmHg) for sham renal-CAP or renal-CAP Sprague-Dawley rats maintained on a high salt 
(8% NaCl) diet for 21-days. *p<0.05 vs. respective normal salt intake group value; τp<0.05 vs. respective sham renal-
CAP group value. 
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Figure 56: Index of salt-sensitivity for sham renal-CAP and renal-CAP Sprague-Dawley rats. Index of salt-
sensitivity determined from 24-h sodium excretion and baseline MAP in Sprague-Dawley rats that underwent either 
sham renal-CAP or renal-CAP surgeries maintained on a normal (0.6% NaCl) or high salt (8% NaCl) diet for 21-days. 
Data are mean±SEM (N=6/group). 
 
 
Figure 57: Plasma norepinephrine concentrations for sham renal-CAP or renal-CAP Sprague-Dawley rats. 
Plasma norepinephrine (NE) concentrations (nmol/L) in Sprague-Dawley rats that underwent either sham renal-CAP or 
renal-CAP (ADNX) surgeries maintained on a high salt (8% NaCl) diet for 21-days. Data are mean±SEM (N=6/group). 
*p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective sham + 8% NaCl group value. 
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Figure 58: Renal norepinephrine content for sham renal-CAP or renal-CAP Sprague-Dawley rats. Renal 
norepinephrine (NE) content (pg/mg) in naïve Sprague-Dawley rats that underwent either sham renal-CAP or renal-
CAP (ADNX) surgeries maintained on a high salt (8% NaCl) diet for 21-days. Data are mean±SEM (N=6/group). 
*p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective sham + 8% NaCl group value. 
 
Selective afferent renal denervation prior to high salt intake exacerbates the development 
of hypertension in Dahl salt-sensitive rats 
Dahl salt-sensitive rats were implanted with a telemetry probe allowing for the 
recording of blood pressure, heart rate, etc. in a low stress environment (i.e., home cage). 
Initial baseline blood pressure was measured via telemetry for 5-days while the animals 
were maintained on a normal salt diet. On day-5, either sham Renal-CAP or Renal-CAP 
surgeries were performed and the rats were immediately placed on a high salt diet for 21-
days. DSS rats that underwent the sham renal-CAP surgery developed hypertension after 
being maintained on a high salt diet for 21-days (Figure 59). The development of 
hypertension was exacerbated in DSS rats where the afferent renal nerves were 
selectively removed (Figure 59). Plasma and renal NE content significantly increased in 
DSS sham renal-CAP rats maintained on a high salt diet when compared to their 
		 Sham Renal-CAP 
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respective normal salt group (Figure 60, 61). Selective afferent renal denervation in the 
DSS rat exacerbated dietary sodium-dependent increases in plasma or renal NE content 
(Figure 60, 61).  
 
Figure 59: Effect of elevated dietary sodium intake on daily MAP for sham renal-CAP or renal-CAP Dahl salt-
sensitive rats. Daily MAP (mmHg) for sham renal-CAP or renal-CAP Dahl salt-sensitive rats maintained on a high salt 
(8% NaCl) diet for 21-days. *p<0.05 vs. respective normal salt intake group value; τp<0.05 vs. respective sham renal-
CAP group value. 
 
Figure 60: Plasma norepinephrine content for sham renal-CAP or renal-CAP Dahl salt-sensitive rats. Plasma 
norepinephrine (NE) concentrations (nmol/L) in Dahl salt-sensitive rats that underwent either sham renal-CAP or renal-
CAP (ADNX) surgeries maintained on a normal (0.6% NaCl) or high salt (8% NaCl) diet for 21-days. Data are 
mean±SEM (N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective sham + 8% NaCl 
group value. 
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Figure 61: Renal norepinephrine content for sham renal-CAP or renal-CAP Dahl salt-sensitive rats. Renal 
norepinephrine (NE) content (pg/mg) in Dahl salt-sensitive rats that underwent either sham renal-CAP or renal-CAP 
(ADNX) surgeries maintained on a normal (0.6% NaCl) or high salt (8% NaCl) diet for 21-days. Data are mean±SEM 
(N=6/group). *p<0.05 vs. respective 0.6% NaCl group value; τp<0.05 vs. respective sham + 8% NaCl group value. 
 
Selective afferent renal denervation does not impact established Dahl salt-sensitive 
hypertension 
In a chronic telemetry experiment using the DSS rat, rats were maintained on a normal 
salt diet for 5-days to establish baseline blood pressure. On day-5, all DSS rats were 
maintained on a high salt diet for 35-days. On day-25, either sham renal-CAP or renal-
CAP surgeries were performed to gauge any changes a Renal-CAP surgery would have 
on established hypertension in DSS rats. All DSS rats develop hypertension after being 
maintained on a high salt diet (Figure 62). No significant differences in MAP for sham or 
renal-CAP DSS rats were observed from day-25 to day-40 (Figure 62). 
 In an additional chronic telemetry experiment using DSS rats, baseline MAP was 
measured for 5-days prior to a sham DNX, bilateral RDNX, or ADNX surgery, removing 
either none, both the afferent and efferent or just the afferent renal nerves. On day-5, all 
	
		 136 
groups were maintained on a high salt diet for 21-days. DSS bilateral RDNX rats 
demonstrate that the removal of both the efferent and afferent renal nerves results in a 
significant decrease in blood pressure at the end of the 21-day high salt intake period by 
about 10mmHg when compared to DSS sham DNX rats (Figure 63). DSS ADNX rats’ 
development of hypertension is exacerbated by the selective removal of the afferent renal 
nerves, an increase that was prevented in the DSS bilateral RDNX rat (Figure 63). 
 
 
Figure 62: Effect of elevated dietary sodium intake and selective afferent renal denervation on daily MAP Dahl 
salt-sensitive rats. Daily MAP (mmHg) for sham renal-CAP or renal-CAP Dahl salt-sensitive rats maintained on a 
high salt (8% NaCl) diet for 21-days. *p<0.05 vs. respective normal salt intake group value. 
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Figure 63: Effect of elevated dietary sodium intake on daily MAP  sham denervated, bilateral renal denervated, 
and selective afferent renal denervated Dahl salt-sensitive rats. Daily MAP (mmHg) for sham denervated (DNX), 
bilateral renal denervated (RDNX), and selective afferent renal denervated (ADNX) Dahl salt-sensitive rats maintained 
on a high salt (8% NaCl) diet for 21-days. *p<0.05 vs. respective normal salt intake group value. 
 
Selective afferent renal denervation results in the development of hypertension and 
prevents dietary sodium-evoked suppression of NCC activity in Sprague-Dawley rats 
In an acute setting, Sprague-Dawley rats underwent either a sham renal-CAP or 
renal-CAP surgery and maintained on a high salt diet for 14-days. On day-14, our acute 
cardiovascular and renal sodium transporter protocol was performed measuring MAP and 
the peak natriuresis to HCTZ, a NCC antagonist. Sham renal-CAP Sprague-Dawley rats 
remained normotensive during this acute protocol, as previously observed during our 
chronic telemetry sham renal-CAP experiments in Sprague-Dawley rats (Figure 64; MAP 
[mmHg] sham renal-CAP+HS: 124±1). In contrast to the sham renal-CAP surgery, the 
selective removal of the afferent renal nerves resulted in the development of hypertension 
(Figure 64; MAP [mmHg] sham renal-CAP+HS: 124±1; renal-CAP+HS: 142±2; 
0.6 
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p<0.05). To assess the impact of selective removal of the afferent renal nerves on the 
NCC, we measured the natriuretic response to HCTZ, a NCC antagonist. Sham renal-
CAP Sprague-Dawley rats demonstrated dietary sodium-evoked suppression of the peak 
natriuresis to HCTZ, with results similar to other salt-resistant phenotypes (Figure 65; 
Peak ΔUNaV to i.v. HCTZ [µeq/min] sham Renal-CAP: 7.2±0.7). Dietary sodium-
evoked suppression of the peak natriuresis to HCTZ was prevented in renal-CAP 
Sprague-Dawley rats, similar to results observed in other salt-sensitive phenotypes 
(Figure 65; Peak ΔUNaV to i.v. HCTZ [µeq/min] Renal-CAP+HS: 10.3±0.8). 
 
Figure 63: Mean arterial pressure for sham renal-CAP or renal-CAP Sprague-Dawley rats. Mean arterial 
pressure (MAP; mmHg) in Sprague-Dawley that underwent either a sham renal-CAP or renal-CAP surgery maintained 
on a high salt (8% NaCl) for 14-days. Data are mean±SEM (N=4/group). *p<0.05 vs. sham renal-CAP group value. 
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Figure 64: Peak natriuresis in response to an i.v. infusion of amiloride in combination with hydrochlorothiazide 
in sham renal-CAP or renal-CAP Sprague-Dawley rats. Peak natriuresis (UNaV; µeq/min) in response to an i.v. 
infusion of amiloride (2mg/kg) in combination with hydrochlorothiazide (HCTZ; 2mg/kg) in Sprague-Dawley that 
underwent either a sham renal-CAP or renal-CAP surgery maintained on a high salt (8% NaCl) for 14-days. Data are 
mean±SEM (N=4/group). *p<0.05 vs. sham renal-CAP group value. 
 
 
 
Selective afferent renal denervation prevents dietary sodium-evoked suppression of NCC 
expression in Sprague-Dawley rats 
Protein expression for NCC, SPAK, OxSR1, and WNK1 was determined for 
sham renal-CAP and renal-CAP Sprague-Dawley rats for which physiological data is 
presented in figures 63-64. When challenged with HS for 14-days, renal-CAP animals 
showed significantly increased NCC expression when compared to sham renal-CAP 
animals (Figures 65), mirroring our physiology results. Significantly increased SPAK and 
WNK1 expression was observed in sham renal-CAP Sprague-Dawley rats when 
compared to renal-CAP rats (Figures 66 & 68). Additionally, OxSR1 expression was 
significantly increased in renal-CAP rats when compared to sham renal-CAP animals 
(Figure 67).  
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Figure 66: Renal NCC protein expression in kidney cortex tissue from sham renal-CAP and renal-CAP 
Sprague-Dawley rats. (A) Representative immumoblots illustrating NCC expression in kidney cortex tissue and (B) 
Quantification of renal NCC expression in sham renal-CAP and renal-CAP male Sprague-Dawley rats maintained on 
high salt (8% NaCl) diet for 14-days. Data are mean±SEM (N=4/group). *p<0.05 vs. sham renal-CAP group value. 
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Figure 67: Renal SPAK protein expression in kidney cortex tissue from sham renal-CAP and renal-CAP 
Sprague-Dawley rats. (A) Representative immumoblots illustrating SPAK expression in kidney cortex tissue and (B) 
Quantification of renal SPAK expression in sham renal-CAP and renal-CAP male Sprague-Dawley rats maintained on 
high salt (8% NaCl) diet for 14-days. Data are mean±SEM (N=4/group). *p<0.05 vs. sham renal-CAP group value. 
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Figure 68: Renal OxSR1 protein expression in kidney cortex tissue from sham renal-CAP and renal-CAP 
Sprague-Dawley rats. (A) Representative immumoblots illustrating OxSR1 expression in kidney cortex tissue and (B) 
Quantification of renal OxSR1 expression in sham renal-CAP and renal-CAP male Sprague-Dawley rats maintained on 
high salt (8% NaCl) diet for 14-days. Data are mean±SEM (N=4/group). *p<0.05 vs. sham renal-CAP group value. 
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Figure 69: Renal WNK1 protein expression in kidney cortex tissue from sham renal-CAP and renal-CAP 
Sprague-Dawley rats. (A) Representative immumoblots illustrating WNK1 expression in kidney cortex tissue and (B) 
Quantification of renal WNK1 expression in sham renal-CAP and renal-CAP male Sprague-Dawley rats maintained on 
high salt (8% NaCl) diet for 14-days. Data are mean±SEM (N=4/group). *p<0.05 vs. sham renal-CAP group value. 
 
Discussion 
To further examine the mechanism(s) that contribute to the development of salt-
sensitive hypertension, we assessed the contribution of the sympathetic afferent renal 
nerves in the regulation of the renal NCC to prevent the development of salt-sensitive 
hypertension. Using a renal pelvic wall preparation, where the majority of afferent renal 
nerve fibers are localized (Kopp et al., 2002, 2007), we demonstrate that salt-resistant 
phenotypes (Sprague-Dawley & DSR) show increased afferent renal nerve release of 
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substance P when stimulated with NE. In contrast, salt-sensitive phenotypes (NE-infusion 
& DSS) show no change in NE-evoked substance P release. These data indicate that 
afferent renal nerve sensitivity is blunted in animal models of salt-sensitive hypertension, 
suggesting impairment in the afferent renal nerves. Previous studies have showed 
impaired substance P release from afferent renal nerves in the spontaneously 
hypertensive rat (Lu et al.) (Lu et al., 2010) (Kopp et al., 1996; Kopp et al., 1998). The 
SHR is a neurogenic model of hypertension that is characterized by increased efferent 
renal nerve activity and sodium retention (DiBona and Kopp, 1997). Together, these data 
suggest that impaired sensitivity of the afferent renal nerves contributes to the 
development of hypertension, supporting our results in our animal models of 
hypertension. Interestingly, the interaction between the efferent and afferent renal nerve 
activity is modulated by NE, which can increase and decrease the activation of the renal 
sensory nerves via α1- and α2-adrenergic receptors located on the renal pelvis (Kopp et 
al., 2009). Increases in afferent renal sympathetic nerve activity decrease efferent renal 
sympathetic nerve activity, resulting in natriuresis (i.e. renorenal reflex response) (Kopp 
1984; 2009). Kopp et al. (2008) determined that during low dietary sodium intake, the 
efferent-afferent renal sympathetic nerve interaction gets suppressed, ultimately leading 
to sodium retention, with the converse occurring during high salt intake to facilitate in 
natriuresis (Kopp et al., 2008). Our data is substantiated by these studies showing 
increased sensitivity of the afferent renal sympathetic nerves during high salt intake to aid 
in natriuresis. These data highlight the critical role the afferent renal sympathetic nerves 
play in long-term blood pressure regulation and sodium homeostasis. 
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 Recent interest has grown in understanding the role of the renal sympathetic 
nerves in the development and pathogenesis of salt-sensitive hypertension. In Sprague-
Dawley rats, the afferent renal nerves were selectively removed and the rats were 
maintained on a high salt diet for 21-days. Afferent renal denervation resulted in salt-
sensitive hypertension in the salt-resistant Sprague-Dawley rat. The development of salt-
sensitivity after renal-CAP is evidenced by a significant increase in MAP during high salt 
intake and a rightward shift of the pressure-natriuresis relationship, reflecting the long-
term resetting of the chronic pressure-natriuresis relationship to a new higher set-point 
blood pressure. As observed in additional animal models of salt-sensitive hypertension 
(SD-NE infusion & DSS), dietary sodium-evoked suppression of plasma and renal NE 
content is prevented in renal-CAP Sprague-Dawley rats. Similarly, selective afferent 
renal denervation exacerbates DSS hypertension. These data further suggest that the 
afferent renal nerves play a crucial role in the development of salt-sensitive hypertension. 
While selective afferent renal denervation exacerbates increases in MAP in DSS rats, 
removal of both the efferent and afferent renal nerves results in no significant effect on 
MAP when compared to sham. Interestingly, when afferent renal nerves are removed 
after a DSS rat is already hypertensive, no change in MAP is observed. These data 
suggest that the afferent renal nerves play an important role in initiating salt-sensitive 
hypertension and their importance as a sodium-sensing mechanism. Conversely, a recent 
study demonstrated that the anti-hypertensive effect of bilateral renal denervation 
(RDNX) in the DSS rat is not due to the removal of the afferent renal nerves (Foss et al., 
2016). Our data, as well as other studies, have demonstrated the importance of the 
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afferent renal nerves in the development of salt-sensitive hypertension. However, in a 
previous study from the same lab (Foss et al., 2015), they show that selective removal of 
the afferent renal nerves attenuates the development of DOCA-salt hypertension to a 
similar extent as RDNX (Foss et al., 2015). 1 These results are important because they 
suggest that the mechanisms underlying the effects of renal denervation on blood 
pressure will most likely vary from patient to patient in a clinical setting.  
 Since we determined that the afferent renal sympathetic nerves play a key role in 
the development of salt-sensitivity, we wanted to see how the removal of the afferent 
renal nerves would affect NCC function. Renal-CAP Sprague-Dawley rats develop 
hypertension after 14-days of high salt intake when compared to sham Sprague-Dawley 
rats. When acutely challenged with HCTZ, a NCC antagonist, renal-CAP Sprague-
Dawley rats showed significantly increased NCC activity when compared to sham 
Sprague-Dawley rats. These data show that in an acute setting, removal of the afferent 
renal nerves results in the development of hypertension and a failure for the NCC to be 
appropriately downregulated in response to increased salt intake. This suggests that the 
renal afferent nerves facilitate the aberrant function of the NCC in animal models of salt-
sensitive hypertension. Additionally, NCC expression in renal-CAP Sprague-Dawley rats 
mirrors out physiology results, showing a failure of the NCC to be appropriately 
downregulated in response to increased dietary salt intake. These results are similar to 																																																								1	DOCA-salt hypertension: chronic administration of deoxycorticosterone acetate results in the development of 
hypertension via neurohumoral activation and volume expansion (Schenk J, McNeill JH (1992) The pathogenesis of 
DOCA-salt hypertension. Journal of pharmacological and toxicological methods 27:161-170. DOCA is a 
mineralocorticoids that causes an imbalances in renal sodium handling by increasing sodium and water reabsorption 
(Guyton AC, Coleman TG, Cowley AV, Jr., Scheel KW, Manning RD, Jr., Norman RA, Jr. (1972) Arterial pressure 
regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. The American journal of 
medicine 52:584-594. 
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those presented in Chapter 3 regarding our other animal models of salt-sensitive 
hypertension (SD-NE infusion & DSS) showing a failure of the NCC to be appropriately 
downregulated in response to a high salt challenge. While no significant differences in 
expression for SPAK and OxSR1 were observed, WNK1 expression was significantly 
lower in renal-CAP Sprague-Dawley rats when compared to sham. These data suggest 
that WNK1 is more strongly influenced by renal sympathetic nerve activity than SPAK 
or OxSR1. In contrast, dietary sodium-evoked suppression to WNK1 expression was 
prevented in our other salt-sensitive phenotypes (SD-NE infusion & DSS). While a 
limitation to this acute series of renal-CAP experiments is the lack of a normal salt 
control group, that does not negate the differences observed between the sham and renal-
CAP Sprague-Dawley rats in these studies. WNK1 has the ability to phosphorylate and 
activate both OxSR1 and SPAK directly (Vitari et al., 2005), but the decreased 
expression of WNK1 does not correlate with the lack of change observed in SPAK and 
OxSR1 expression in sham vs. renal-CAP rats. These data indicate that another WNK, 
like WNK4, could be responsible for mediating the effects of afferent renal nerves on 
SPAK and OxSR1 expression in this animal model of salt-sensitive hypertension. The 
increased NCC expression in renal-CAP rats when compared to sham may be attributed 
to a potential direct action of WNK4 or WNK3 on the NCC. One study demonstrated that 
the presence of WNK4 decreases the WNK1 and WNK3-mediated activation of the NCC 
(Chavez-Canales et al., 2014). This effect of WNK4 could possibly be responsible for the 
observed WNK1 and NCC expression in the renal-CAP Sprague-Dawley rat. Potentially, 
the removal of the afferent renal nerves could enhance WNK3-mediated activation of the 
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NCC, suggesting another alternative mechanism explaining our observed increase in 
NCC expression in renal-CAP rats. In the renal-CAP animals, the prevention of NCC 
downregulation appears to act through a WNK1-independent mechanism. The differences 
in WNK1 expression between our NE infusion model compared to the renal-CAP model 
of salt-sensitivity may also be attributed to the fact that in one model we are artificially 
increasing NE levels, while the other model is producing endogenous increases in NE 
content. The difference in the source of the NE could alter the mechanism contributing to 
the increase in NCC expression. Overall, the removal the afferent renal nerves results in 
the development of salt-sensitive hypertension and a failure to appropriately 
downregulate the NCC in response to increased salt intake.   
 
Overall Conclusions from Aim 3 
 In conclusion, our results demonstrate that the afferent renal nerves are a critical 
sympathetic nervous system sodium responsive mechanism that mediates the regulation 
of the renal NCC to prevent the development of salt-sensitive hypertension. These studies 
are the first to show how the selective afferent renal denervation affects NCC-mediate 
sodium reabsorption in the development of hypertension. Additionally, these data are the 
first to examine NCC function and expression and NCC’s regulatory network during 
selective afferent renal denervation, highlighting the importance of the afferent renal 
nerves in hypertension. Overall, these data show that the afferent renal nerves play a 
crucial role as a sodium sensing mechanism in the initiation of the development of salt-
sensitive hypertension. 
		 149 
CHAPTER 6: Overall Summary, Significance, and Perspectives 
 
Overall Summary  
 
The objective of these studies was to determine that the development of salt-
sensitive hypertension is evoked by a failure to downregulate the NCC acting through a 
predominant α1-adrenergic receptor-gated WNK1-OxSR1 signal transduction pathway 
mediated by the afferent renal sympathetic nerves. We were able to demonstrate that 
excess plasma NE levels in combination with a high dietary sodium intake result in the 
development of salt-sensitive hypertension in the salt-resistant Sprague-Dawley rat. Our 
NE infusion model demonstrated increases in MAP, an increase exacerbated by a high 
salt diet, shifting the pressure-natriuresis relationship to a new, higher set point blood 
pressure in order to maintain sodium homeostasis. Further, these results demonstrate that 
the combination of increased dietary salt intake and plasma NE levels show a failure of 
the NCC to be appropriately downregulated in our salt-resistant phenotypes via an 
angiotensin II-independent mechanism. Additionally, we show that our model of NE 
infusion in the Sprague-Dawley rat is comparable to the genetic Dahl salt-sensitive rat, 
providing an alternative animal model to demonstrate salt-sensitivity. Next, we examined 
the regulation of the NCC in the observed development of salt-sensitive hypertension by 
assessing the NCC regulatory kinases: OxSR1, SPAK, and WNK1. We show that NCC 
activity is maintained by a failure of a high salt intake to suppress renal OxSR1, SPAK, 
and WNK1 expression in salt-sensitive hypertension suggesting a potential underlying 
mechanism contributing to the development of salt-sensitive hypertension. Chronic 
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antagonism of the α- or β-adrenergic receptors helped evaluate the contribution of these 
receptors in the development of NE-evoked salt-sensitive hypertension. We demonstrate 
that the α1-adrenergic receptors are responsible for mediating the salt-sensitive 
component of hypertension and restored dietary sodium-evoked suppression of the NCC 
via a predominant OxSR1 pathway, suggesting that impaired function of the NCC is 
mediated through an α1-adrenergic receptor pathway. Furthermore, chronic β-adrenergic 
receptor blockade can significantly decrease MAP in NE-mediated hypertension. These 
results highlight distinct functions of the α- and β-adrenergic receptors on blood pressure 
and sodium homeostasis in the development of salt-sensitive hypertension. Finally, our 
data shows that the removal of the afferent renal nerves highlights the importance of the 
interaction between the SNS and the kidney on NCC function during the development of 
salt-sensitive hypertension. Overall, these support our hypothesis that attenuated afferent 
renal nerve feedback drive renal efferent nerve release of NE to prevent the 
downregulation of the NCC via a predominant α1-adrenergic receptor-gated WNK1-
OxSR1 signal transduction pathway to evoke the development of salt-sensitive 
hypertension. 
 
Significance and Perspectives 
This study helps elucidate the interaction of the sympathetic nervous system and 
the kidney to facilitate sodium homeostasis and the long-term regulation of blood 
pressure in the development of salt-sensitivity and hypertension. We have found that the 
NCC, a sodium transporter located in the distal convoluted tubule responsible for the fine 
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tuning of sodium reabsorption, fails to be appropriately downregulated in the presented 
animal models of salt-sensitive hypertension (SD-NE infusion, DSS, & SD-Renal-CAP). 
Using the NCC as a marker of salt-sensitivity could help distinguish between salt-
resistant and salt-sensitive hypertensive patients. One non-invasive way to determine salt-
sensitivity may be to develop a urinary exosome profile of the NCC and other sodium 
transporters as potential biomarkers in human patients. Currently, a definitive and easy 
test to prove whether a patient is salt-resistant or salt-sensitive does not exist. If 
physicians were able to easily distinguish between the two phenotypes, this could lead to 
more efficacious treatments of hypertension. Based on these studies, we show that the α1-
adrenergic receptor is responsible for NCC-mediated sodium reabsorption in NE-evoked 
hypertension, highlighting an alternative strategy to treat the underlying cause of salt-
sensitive hypertension. A low dose α1-adrenergic receptor antagonist may help treat the 
impaired NCC function found in salt-sensitive phenotypes.  
All the presented physiological data was determined from conscious rat models, 
which we believe gives this data greater credibility and a translational quality, but it was 
all done in rat models and not in humans or with human tissue. To increase the 
translational properties of this data, additional studies should be conducted using human 
kidney tissue, serum, and urine. NCC, OxSR1, SPAK, and WNK1 renal protein 
expression as well as renal NE content could be assessed in the human kidney tissue. 
Additionally, NE content could be measured in human serum to assess differences in NE 
content between hypertensive and normotensive patients. If the data found in human 
tissue mirrored our results from rat models of salt-sensitivity and salt-resistance, it would 
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allow researchers to move forward to curate a biomarker profile, potentially using urinary 
exosomes, to distinguish between these two phenotypes. Collection of human urine could 
enable the development of a urinary exosome biomarker profile. The use of human tissue 
in these studies would amplify the impact this data would have on human health and the 
treatment of hypertension. The importance of investigating the neural and renal 
mechanisms underlying the pathophysiology of hypertension and establishing new 
methodologies to distinguish between salt-sensitive and salt-resistant phenotypes is 
highlighted by the excess consumption of dietary salt, the lack of hypertension 
biomarkers and ability to determine the salt-sensitivity of blood pressure. Recently, the 
results of two clinical trials were published: SPRINT and PATHWAY-2. The SPRINT 
trial demonstrated that significantly reducing MAP resulted in lower rates of fatal and 
nonfatal cardiovascular events and death (Wright et al., 2015). The PATHWAY-2 trial 
highlighted the primary role that sodium retention plays in treatment-resistant 
hypertension (Williams et al., 2015). Both of these clinical trials illustrate the importance 
of reducing blood pressure and the crucial role the kidney plays in the pathogenesis of 
hypertension and highlighting the relevance of this research.   
We observed dietary sodium-evoked suppression of NCC activity (assessed as 
peak natriuresis to HCTZ) in salt-resistant phenotypes, but not in salt-sensitive 
phenotypes. While we were able to assess the protein and mRNA expression of the NCC 
in the kidney cortex tissue, we cannot conclusively state that there is increased movement 
of sodium/chloride ions through the transporter. A future experiment using radiolabeled 
sodium ions in the DCT would allow you to track the movement of sodium ions through 
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the NCC, definitively giving you a measurement of NCC activity in these animal models 
of salt-sensitive hypertension. Despite the fact that we are using a kidney cortical 
membrane preparation, we cannot definitively state that the NCC expression we observe 
is exclusively phosphorylated (activated) NCC, so potential use of a phosphoNCC 
antibody would useful to distinguish between total and phosphorylated forms of NCC 
expression in the kidney. On another note, if we had the means to assess the expression of 
WNK4 in this signal transduction pathway, that would further elucidate the regulation of 
the NCC in NE-evoked hypertension. 
Typically, the prevalence of hypertension increases with age, making this 
hypertension an age-related disease. Most of these experiments occur in young adult-to-
adult aged rats, but none occur in aged rats. Conducting future studies in an older cohort 
of Sprague-Dawley and Dahl rats would provide a model of the disease that is more 
closely related to the actual observed development of hypertension in human patients, 
making these future results more translational and clinically relevant. Additionally, we 
have conducted the majority of the experiments presented in the previous chapters on 
day-14 or day-21, but we cannot say exactly when these end-point effects are taking 
place. Future studies could examine the interaction of NE and salt intake on day-1, 2, 3, 5 
or 7 to evaluate how rapidly or slowly these physiological changes will occur. Further, 
our NE infusion model gives a constant s.c. infusion of NE, increasing the global NE 
content, but not directly at the level of the kidney. An interesting experiment would be to 
directly infuse NE into the renal artery to measure the effects of a local renal increase of 
NE on NCC function and blood pressure regulation.  
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Recently, the increased interest in the afferent renal nerves has resulted in several 
clinical trials evaluating renal nerve ablation in treatment-resistant hypertension. The 
recent Symplicity HTN-1 and HTN-2 renal denervation trials (Esler et al., 2012; Krum et 
al., 2014; Bakris et al., 2015) initially demonstrated a significant sustained decrease in 
MAP following catheter-based renal denervation (Esler et al., 2012). However, when a 
larger, randomized clinical trial was conducted (Symplicity HTN-3), no significant 
differences in blood pressure were observed following renal denervation (Bakris et al., 
2015; Kario et al., 2015). While the final conclusion of these clinical trials showed that 
renal denervation had no effect on blood pressure that does not devalue the potential use 
of renal denervation for treatment-resistant hypertensive patients. Ideally, stratifying 
patients based on salt-resistance or salt-sensitive may help determine patients who would 
benefit from this surgical approach to treat their hypertension. Additionally, the 
development of selective ablation techniques, targeting a subset of renal nerves, would 
help improve efficacy and reduce adverse effects.  
 
Conclusion 
 In summary, our data support the hypothesis that attenuated afferent renal nerve 
feedback drives renal efferent nerve release of NE to prevent the downregulation of the 
NCC via a predominant α1-adrenergic receptor-gated WNK1-OxSR1 signal transduction 
pathway to evoke the development of salt-sensitive hypertension. We demonstrate a 
mechanism that contributes the development of salt-sensitive hypertension and provide 
additional insight into the development of salt-sensitivity.  
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